BENZIMIDAZOLE MODULATORS OF VR1

CROSS REFERENCE TO RELATED APPLICATIONS

This present application claims benefit of U.S. Provisional Patent Application Serial No. 60/797504, filed May 3, 2006, which is incorporated herein by reference in its entirety and for all purposes.

BACKGROUND OF THE INVENTION

Noxious chemical, thermal and mechanical stimuli excite peripheral nerve endings of small diameter sensory neurons (nociceptors) deriving from sensory ganglia (e. g., dorsal root, nodose and trigeminal ganglia) and initiate signals that are perceived as pain. Such nociceptive neurons (i.e., nociceptors) are crucial for the detection of harmful or potentially harmful stimuli (e.g., noxious thermal, chemical, and/or mechanical) that arise from changes in the extracellular environment during inflammatory, ischemic or otherwise traumatic conditions and that cause or have the potential to cause tissue damage (Wall, P. D., and Melzack, R., Textbook of Pain, 1994, New York: Churchill Livingstone).

Nociceptors transduce noxious stimuli into membrane depolarization that leads to an action potential, its subsequent conduction to the CNS, and ultimately to the perception of pain, discomfort, etc. as well as to certain responses thereto. At the molecular level, nociception is carried out by ion channels and/or receptors. Plant-derived vanilloid compounds (e.g., capsaicin and resiniferatoxin) are known to selectively depolarize nociceptors and elicit sensations of burning pain: the sensation that is typically evoked by capsaicin-containing hot chili peppers. Therefore, capsaicin mimics the action of physiological/endogenous stimuli that activate the "nociceptive pathway". Recent advances in pain biology have identified a receptor, called VR1 (a.k.a. capsaicin receptor or TRPV1) for vanilloids, protons and noxious heat. Because nociceptors are drivers of unwanted pain and inflammatory conditions in human beings and animals,

modulation of their function is a validated strategy for palliative and other analgesic therapies.

Compounds that are modulators (competitive and non-competitive agonists or antagonists [with respect to capsaicin and/or its recognition site] and allosteric modulators) at VR1 have broad therapeutic potential, as demonstrated by the clinical usefulness of marketed, VR1-targeted pharmaceutical agents or the efficacy of VR1 modulators in animal models of disease. Furthermore, it is recognized that agonist modulators of VR1 may possess clinical utility deriving from their agonist properties, per se, and/or from their ability to produce an agonist-mediated desensitization, which would indirectly manifest as a functional antagonism. Similarly, antagonist modulators could exhibit direct antagonist (competitive or non-competitive) properties and/or indirect antagonist properties via the aforementioned desensitization mechanism. It is further recognized that positive and negative allosteric modulators may produce any or all of the aforementioned functional consequences and, as such, may also have clinical utility. Accordingly, this invention is directed to each of these types of modulators.

The effective use of VR1 agonists has been demonstrated in inflammatory, neuropathic, and visceral pain states. In an experimental human pain model, dermal capsaicin pretreatment reduced the pain caused by intradermal injection of an acidic solution (Bianco, E. D.; Geppetti, P.; Zippi, P.; Isolani, D.; Magini, B.; Cappugi, P. Brit J of Clin Pharmacol 1996, 41, 1-6), suggesting the benefit of VR1 agonists in the treatment of inflammatory pain. A particular role for VR1 agonists has been shown in inflammation and inflammatory pain: for example, resiniferatoxin prevented inflammatory hypersensitivity and edema induction by carrageenan (Kissin, I.; Bright, C. A.; Bradley, E. L., Jr. Anesth Analg 2002, 94, 1253-1258).

Additionally, capsaicin-containing creams (for example, Axcain® and Lidocare®) are marketed for dermal relief of pain related to diabetic neuropathy and postherpetic neuralgia, indicative of the usefulness of VR1 agonists in the

treatment of neuropathic pain states. Furthermore, such creams have been shown to reduce postsurgical neuropathic pain (Ellison, N., Loprinzi, C.L., Kugler, J., Hatfield, A.K., Miser, A., Sloan, J.A., Wender, D.B., Rowland, K.M., Molina, R., Cascino, T.L., Vukov, A.M., Dhaliwal, H.S. and Ghosh, C. J. Clin. Oncol. 15:2974-2980, 1997). In cancer patients, capsaicin contained in a taffy vehicle, was shown to substantially reduce oral mucositis pain caused by chemotherapy and radiation therapy (Berger, A., Henderson, M., Naadoolman, W., Duffy, V., Cooper, D., Saberski, L. and Bartoshuk, L. J. Pain Sympt. Mgmt 10:243-248, 1995.

VR1 also plays a role in the physiology of bladder emptying. VR1 is expressed by bladder sensory neurons, where it modulates bladder responsivity to liquid filling. The VR1 agonist resiniferatoxin desensitized bladder afferents in a dose-dependent manner (Avelino, A.; Cruz, F.; Coimbra, A. Eur. J Pharmacol. 1999, 378, 17-22), supporting its usefulness for the treatment of overactive bladder (Chancellor, M. B.; De Groat, W. C. J. Urol. (Baltimore) 1999, 162, 3-11). Indeed, intravesicular administration of capsaicin or resiniferatoxin inhibited bladder contraction in both normal and spinal cord injured rats (Komiyama, I.; Igawa, Y.; Ishizuka, O.; Nishizawa, O.; Andersson, K.-E. J. Urol. (Baltimore) 1999, 161, 314-319), indicative of the usefulness of VR1 agonists in nerve-injured incontinent patients. The effectiveness of capsaicin or resiniferatoxin treatment on incontinence in spinal cord injured patients was confirmed in a clinical study (de Seze, M.; Wiart, L.; de Seze, M.-P.; Soyeur, L.; Dosque, J.-P.; Blajezewski, S.; Moore, N.; Brochet, B.; Mazaux, J.-M.; Barat, M.; Joseph, P.-A. Journal of Urology (Hagerstown, MD, United States) 2003, 171, 251-255).

The effectiveness of VR1 agonists in the reduction of elevated blood pressure is suggested by capsaicin reduction in blood pressure in SHR and WKY rats (Li, J.; Kaminski, N. E.; Wang, D. H. Hypertension 2003, 41, 757-762.). Capsaicin was also gastroprotective with respect to gastric antral ulcers (Yamamoto, H.; Horie, S.; Uchida, M.; Tsuchiya, S.; Murayama, T.; Watanabe, K. Eur. J. Pharmacol. 2001, 432, 203-210).

VR1 antagonists also may be useful in the treatment of inflammatory, neuropathic and visceral pain. For example, the therapeutic utility of VR1 antagonists has been demonstrated in visceral inflammatory conditions. VR1 is elevated in colonic nerve fibers in patients with inflammatory bowel disease, and VR1 antagonists relieved pain and dysmotility (Yiangou, Y.; Facer, P.; Dyer, N. H.; Chan, C. L.; Knowles, C.; Williams, N. S.; Anand, P. Lancet 2001, 357, 1338-1339). Intestinal inflammation induced by toxin A or dextran sulfate sodium in rodents was attenuated by VR1 antagonists (McVey, D. C.; Schmid, P. C.; Schmid, H. H. O.; Vigna, S. R. J. Pharmacol. Exp. Ther. 2003, 304, 713-722). In addition, a synthetic VR1 antagonist reduced colitis disease scores at several important endpoints, including macroscopic damage, microscopic epithelial damage, myeloperoxidase levels, and diarrhea scores, strongly supporting the therapeutic use of VR1 antagonists in inflammatory bowel diseases (Kimball, E. S.; Wallace, N. H.; Schneider, C. R.; D'Andrea, M. R.; Hornby, P. J. Neurogasteroenterology 2004, 16, 811-818). The VR1 antagonists capsazepine and BCTC reversed mechanical hyperalgesia in models of inflammatory and neuropathic pain in guinea pigs (Walker, K. M.; Urban, L.; Medhurst, S. J.; Patel, S.; Panesar, M.; Fox, A. J.; McIntyre, P. J. Pharmacol. Exp. Ther. 2003, 304, 56-62) and rats (Pomonis, J. D.; Harrison, J. E.; Mark, L.; Bristol, D. R.; Valenzano, K. J.; Walker, K. J. Pharmacol. Exp. Ther. 2003, 306, 387-393).

LPS-induced fever was attenuated in VR1 knock out mice (Lida, T.; Shimizu, I.; Nealen, M. L.; Campbell, A.; Caterina, M. Neurosci. Lett. 2005, 378, 28-33). VR1 agonist-induced rises in core body temperature were suppressed by capsazepine, indicative of the usefulness of VR1 antagonists in the treatment of pyresis (Ohnluki, K.; Haramizu, S.; Watanabe, T.; Yazawa, S.; Fushiki, T. J. Nutr. Sci. Vitaminol. (Tokyo) 2001, 47, 295-298).


VR1 agonists also modulate body temperature and fever. In ferret, rat and mouse, administration of resiniferatoxin-induced hypothermia (Woods, A. J.; Stock, M. J.; Gupta, A. N.; Wong, T. T. L.; Andrews, P. L. R. Eur. J. Pharmacol. 1994, 264, 125-133). Additionally, phase I of LPS (lipopolysaccharide)-induced

fever did not occur in animals desensitized with low intraperitoneal doses of capsaicin (Romanovsky, A. A. Frontiers in Bioscience 2004, 9, 494-504).

The therapeutic potential of VR1 antagonists in inflammatory bronchial conditions is demonstrated by the finding that they antagonize capsaicin- and acid-induced bronchoconstriction (Nault, M. A.; Vincent, S. G.; Fisher, J. T. J. Physiol. 1999, 515, 567-578). Related findings demonstrate that the VR1 antagonist capsazepine attenuates anandamide-induced cough in guinea pigs (Jia, Y.; McLeod, R. L.; Wang, X.; Parra, L. E.; Egan, R. W.; Hey, J. A. Brit. J. Pharmacol. 2002, 137, 831-836).

The VR1 antagonist capsazepine was demonstrated to significantly reduce anxiety-like behaviors in rats using the elevated plus maze (Kasckow, J.W.; Mulchahey, J.J.; Geracioti, T.D. Jr. Progress in Neuro-Psychopharmacol. and Biological Psychiatry 2004, 28, 291-295). Thus, VR1 antagonists may have utility in the treatment of anxiety, panic disorders, phobias or other non-adaptive stress responses.


United States Patent 6,299,796B1 discloses electroluminescent elements comprising units of the formula:



Thus, there is a need for potent modulators of VR1, and in particular, for novel benzimidazole compounds that exhibit potent binding affinity for the human and rat VR1 ion channel. There is also a need for novel benzimidazole compounds that act as potent functional antagonists and/or agonists of the human and rat VR1 ion channel. Finally, there is a need for novel benzimidazoles that bind with high affinity to VR1 and also act as potent functional antagonists of the human and rat VR1 ion channel.

SUMMARY OF THE INVENTION

The present invention is directed to a compound of Formula (I):




(I)

and a form thereof, wherein R_1, R_2, R_{3a}, R_{3b}, R_4, p, q, r, L and A_1 are as defined herein, and their use as potent modulators of VR1.

The present invention is also directed to a method for treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I). The present invention is further directed to a process for making a compound of Formula (I) and salts thereof.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to compounds of Formula (I):



(I)

and a form thereof, wherein:

the dashed lines between positions 1, 2 and 3 in Formula (I) indicate the positions of a tautomeric double bond,

wherein when a double bond is formed between positions 1 and 2, then R_{3b} is present, and

wherein, when a double bond is formed between positions 2 and 3, then R_{3a} is present;

p is 1 or 2;

q is 0 or 1;

r is 0, 1, 2 or 3;

L is C_{1-3}alkyl, C_{2-3}alkenyl, C_{2-3}alkynyl or cyclopropyl;

A_1 is selected from the group consisting of phenyl, biphenyl, naphthyl, pyridinyl, quinolinyl and indole;

R_1 is each selected from the group consisting of hydroxy, cyano, halogen, formyl, carboxy, C_{1-6}alkyl, haloC_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, C_{1-6}alkylcarbonyl, C_{1-6}alkoxycarbonyl, C_{1-6}alkylthio, C_{1-6}alkylsulfonyl, C_{3-8}cycloalkyl, C_{3-8}cycloalkyl-C_{1-4}alkyl, C_{3-8}cycloalkyl-C_{1-4}alkoxy, C_{3-8}cycloalkyl-oxy, amino, $(C_{1-6}alkyl)_{1-2}$amino, $(C_{3-8}cycloalkyl)_{1-2}$amino, $(C_{3-8}cycloalkyl\text{-}C_{1-4}alkyl)_{1-2}$amino, aminocarbonyl, $(C_{1-6}alkyl)_{1-2}$aminocarbonyl, C_{1-6}alkylcarbonylamino, C_{1-6}alkoxycarbonylamino, aminocarbonylamino, $(C_{1-6}alkyl)_{1-2}$aminocarbonylamino, C_{1-6}alkylsulfonylamino, C_{1-6}alkylsulfinylamino, aminosulfonyl, $(C_{1-4}alkyl)_{1-2}$aminosulfonyl, aminosulfonylamino and $(C_{1-6}alkyl)_{1-2}$aminosulfonylamino,

wherein alkyl is optionally substituted with C_{1-8}alkoxy, amino, $(C_{1-4}alkyl)_{1-2}$amino, C_{1-6}alkylcarbonylamino, C_{1-6}alkoxycarbonylamino, aminocarbonylamino, $(C_{1-6}alkyl)_{1-2}$aminocarbonylamino, C_{1-6}alkylsulfonylamino, aminosulfonylamino, $(C_{1-6}alkyl)_{1-2}$aminosulfonylamino hydroxy and phenyl,

wherein phenyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, cyano, nitro, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-6}alkylthio and C_{1-6}alkylsulfonyl, and

wherein, each instance of alkyl and alkoxy is optionally perfluorinated;

R_2 is selected from the group consisting of halogen, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}alkylsulfonyl, nitro, amino, $(C_{1-4}alkyl)_{1-2}$amino and cyano,

wherein each instance of alkyl and alkoxy is optionally perfluorinated;

R_{3a} and R_{3b} are each selected from the group consisting of hydrogen and optionally perfluorinated C_{1-4}alkyl; and

R_4 is each selected from the group consisting of halogen, nitro, cyano, carboxy, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkyl, haloC_{1-6}alkoxy, C_{1-6}alkoxy-C_{1-6}alkyl, C_{1-6}alkylcarbonyl, C_{1-6}alkylthio, haloC_{1-6}alkylthio, C_{1-6}alkylsulfonyl, haloC_{1-6}alkylsulfonyl, C_{3-8}cycloalkyl, C_{3-8}cycloalkyl-C_{1-4}alkyl, C_{3-8}cycloalkyl-C_{1-4}alkoxy, C_{3-8}cycloalkyl-oxy, amino, $(C_{1-6}alkyl)_{1-2}$amino, $(C_{3-8}cycloalkyl)_{1-2}$amino, $(C_{3-8}cycloalkyl\text{-}C_{1-4}alkyl)_{1-2}$amino, aminocarbonyl, $(C_{1-6}alkyl)_{1-2}$aminocarbonyl, C_{1-6}alkylcarbonylamino, C_{1-6}alkoxycarbonylamino, aminocarbonylamino, $(C_{1-6}alkyl)_{1-2}$aminocarbonylamino, C_{1-6}alkylsulfonylamino, haloC_{1-6}alkylsulfonylamino, C_{1-6}alkylsulfinylamino, aminosulfonyl and $(C_{1-4}alkyl)_{1-2}$aminosulfonyl,

wherein each instance of alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C_{1-8}alkoxy, amino, $(C_{1-4}alkyl)_{1-2}$amino, C_{1-6}alkylcarbonylamino, C_{1-6}alkoxycarbonylamino, aminocarbonylamino, $(C_{1-6}alkyl)_{1-2}$aminocarbonylamino, C_{1-6}alkylsulfonylamino, oxo and hydroxy, and

wherein, each instance of alkyl and alkoxy is optionally perfluorinated.

An example of the present invention includes a compound of Formula (I) or a form thereof, wherein q is 0.

An example of the present invention includes a compound of Formula (I) or a form thereof, wherein A_1 is selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole.

An example of the present invention includes a compound of Formula (I) or a form thereof, wherein

R_1 is each selected from the group consisting of hydroxy, halogen, formyl, C_{1-6}alkyl, haloC_{1-6}alkyl, haloC_{1-6}alkoxy, C_{1-6}alkylcarbonyl, C_{1-6}alkoxycarbonyl, C_{1-6}alkylthio, C_{1-6}alkylsulfonyl, amino, aminocarbonyl, C_{1-6}alkylcarbonylamino, C_{1-6}alkoxycarbonylamino, C_{1-6}alkylsulfonylamino, aminosulfonyl, $(C_{1-4}alkyl)_{1-2}$aminosulfonyl and aminosulfonylamino,

wherein alkyl is optionally substituted with amino, $(C_{1-4}alkyl)_{1-2}$amino, aminosulfonylamino or hydroxy, and wherein, alkyl is optionally perfluorinated.

An example of the present invention includes a compound of Formula (I) or a form thereof, wherein R_2 is selected from the group consisting of halogen and C_{1-4}alkyl, wherein alkyl is optionally perfluorinated.

An example of the present invention includes a compound of Formula (I) or a form thereof, wherein R_{3a} and R_{3b} are each selected from the group consisting of hydrogen and C_{1-4}alkyl.

An example of the present invention includes a compound of Formula (I) or a form thereof, wherein R_4 is each selected from the group consisting of halogen, carboxy, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkyl, haloC_{1-6}alkoxy, C_{1-6}alkylcarbonyl, haloC_{1-6}alkylthio, C_{1-6}alkylsulfonyl, haloC_{1-6}alkylsulfonyl, $(C_{1-6}alkyl)_{1-2}$amino, $(C_{1-6}alkyl)_{1-2}$aminocarbonyl, C_{1-6}alkylcarbonylamino, C_{1-6}alkylsulfonylamino and haloC_{1-6}alkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.

An example of the present invention includes a compound of Formula (I) or a form thereof, wherein

p is 1 or 2;

q is 0;

r is 0, 1, 2 or 3;

L is C_{1-3}alkyl, C_{2-3}alkenyl, C_{2-3}alkynyl or cyclopropyl;

A_1 is selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole;

R_1 is each selected from the group consisting of hydroxy, halogen, formyl, C_{1-6}alkyl, haloC_{1-6}alkyl, haloC_{1-6}alkoxy, C_{1-6}alkylcarbonyl, C_{1-6}alkoxycarbonyl, C_{1-6}alkylthio, C_{1-6}alkylsulfonyl, amino, aminocarbonyl, C_{1-6}alkylcarbonylamino, C_{1-6}alkoxycarbonylamino, C_{1-6}alkylsulfonylamino, aminosulfonyl, $(C_{1-4}alkyl)_{1-2}$aminosulfonyl and aminosulfonylamino,


wherein alkyl is optionally substituted with amino, $(C_{1-4}alkyl)_{1-2}$amino, aminosulfonylamino or hydroxy, and wherein, alkyl is optionally perfluorinated;

R_2 is selected from the group consisting of halogen and C_{1-4}alkyl, wherein alkyl is optionally perfluorinated;


R_{3a} and R_{3b} are each selected from the group consisting of hydrogen and C_{1-4}alkyl; and

R_4 is each selected from the group consisting of halogen, carboxy, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkyl, haloC_{1-6}alkoxy, C_{1-6}alkylcarbonyl, haloC_{1-6}alkylthio, C_{1-6}alkylsulfonyl, haloC_{1-6}alkylsulfonyl, $(C_{1-6}alkyl)_{1-2}$amino, $(C_{1-6}alkyl)_{1-2}$aminocarbonyl, C_{1-6}alkylcarbonylamino, C_{1-6}alkylsulfonylamino and haloC_{1-6}alkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.

The present invention is further directed to compounds of Formula Ia or Ib:



Ia



Ib

wherein:

R_1 is independently hydroxyl; halogen, C_{1-6}alkanyl; fluorinated C_{1-6}alkanyl; C_{1-6}alkanyloxy; fluorinated C_{1-6}alkanyloxy; C_{1-6}alkanylthio; fluorinated C_{1-6}alkanylthio; C_{1-6}alkanylsulfonyl; fluorinated C_{1-6}alkanylsulfonyl; C_{3-8}cycloalkanyl; C_{3-8}cycloalkanyl; C_{1-4}alkanyl; C_{3-8}cycloalkanyloxy; C_{3-8}cycloalkanyl; C_{1-4}alkanyloxy; amino; $(C_{1-6}$alkanyl$)_{1-2}$amino; $(C_{3-8}$cycloalkanyl$)_{1-2}$amino; $(C_{3-8}$cycloalkanyl; C_{1-4}alkanyl$)_{1-2}$amino; cyano; aminocarbonyl; $(C_{1-6}$alkanyl$)_{1-2}$aminocarbonyl; C_{1-6}alkanylcarbonylamino; fluorinated C_{1-6}alkanylcarbonylamino; C_{1-6}alkanyloxycarbonylamino; C_{0-6}alkanylaminocarbonylamino; C_{1-6}alkanylsulfonylamino; fluorinated C_{1-6}alkanylsulfonylamino; aminosulfonyl; $(C_{1-8}$alkanyl$)_{1-2}$aminosulfonyl; fluorinated $(C_{1-8}$alkanyl$)_{1-2}$aminosulfonyl; wherein the alkanyl in any alkanyl-containing substituent of R_1 is optionally substituted with 1 to 3 substituents independently selected from the group consisting of amino, $(C_{1-8}$alkanyl$)_{1-2}$amino, C_{1-6}alkanylcarbonylamino; fluorinated C_{1-6}alkanylcarbonylamino; C_{1-6}alkanyloxycarbonylamino; C_{0-6}alkanylaminocarbonylamino; C_{1-6}alkanylsulfonylamino; fluorinated C_{1-6}alkanylsulfonylamino; halogen, oxo, hydroxyl, fluorinated alkanyl, and C_{1-8}alkanyloxy;

p is 1 or 2;

R_2 is independently selected from the group consisting of halogen; C_{1-4}alkanyl; fluorinated C_{1-4}alkanyl; C_{1-4}alkanyloxy; fluorinated C_{1-6}alkanyloxy; C_{1-4}alkanylsulfonyl; fluorinated C_{1-4}alkanylsulfonyl; nitro; $(C_{1-4}$alkanyl$)_{1-2}$amino; cyano;

n is 0, or 1;

R_3 is independently selected from the group consisting of hydrogen, C_{1-4}alkanyl, and fluorinated C_{1-4}alkanyl;

L is C_{2-3}alkyldiyl,


A_1 is selected from the group consisting of phenyl and naphthyl;

R_4 is independently halogen, C_{1-6}alkanyl; fluorinated C_{1-6}alkanyl; C_{1-6}alkanyloxy; fluorinated C_{1-6}alkanyloxy; C_{1-6}alkanylthio; fluorinated C_{1-6}alkanylthio; C_{1-6}alkanylsulfonyl; fluorinated C_{1-6}alkanylsulfonyl; C_{3-8}cycloalkanyl; C_{3-8}cycloalkanyl; C_{1-4}alkanyl; C_{3-8}cycloalkanyloxy; C_{3-8}cycloalkanyl; C_{1-4}alkanyloxy; amino; $(C_{1-6}$alkanyl$)_{1-2}$amino; $(C_{3-8}$cycloalkanyl$)_{1-2}$amino; $(C_{3-8}$cycloalkanyl; C_{1-4}alkanyl$)_{1-2}$amino; cyano; aminocarbonyl; $(C_{1-6}$alkanyl$)_{1-2}$aminocarbonyl; C_{0-6}alkanylcarbonylamino; fluorinated C_{1-6}alkanylcarbonylamino; C_{1-6}alkanyloxycarbonylamino; C_{0-6}alkanylaminocarbonylamino; C_{1-6}alkanylsulfonylamino; fluorinated C_{1-6}alkanylsulfonylamino; aminosulfonyl; $(C_{1-8}$alkanyl$)_{1-2}$aminosulfonyl; fluorinated $(C_{1-8}$alkanyl$)_{1-2}$aminosulfonyl; wherein the alkanyl in any alkanyl-containing substituent of R1 is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, oxo, hydroxyl, fluorinated alkanyl, and C_{1-8}alkanyloxy; phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen; C_{1-4}alkanyl; fluorinated C_{1-4}alkanyl; C_{1-4}alkanyloxy; fluorinated C_{1-4}alkanyloxy; C_{1-4}alkanylsulfonyl; fluorinated C_{1-4}alkanylsulfonyl; nitro; cyano;


r is 0, 1 or 2; and

enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.


An example of the present invention includes compounds and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof selected from the group consisting of:




Cpd 1




Cpd 2




Cpd 3




Cpd 4




Cpd 5




Cpd 6




Cpd 7




Cpd 8




Cpd 9




Cpd 10




Cpd 11




Cpd 12




Cpd 13




Cpd 14




Cpd 15




Cpd 16




Cpd 17




Cpd 18




Cpd 19




Cpd 20




Cpd 21




Cpd 22




Cpd 23




Cpd 24




Cpd 25




Cpd 26




Cpd 27




Cpd 28




Cpd 29




Cpd 30




Cpd 31




Cpd 32




Cpd 33




Cpd 34




Cpd 35




Cpd 36




Cpd 37




Cpd 38




Cpd 39




Cpd 40




Cpd 41




Cpd 42




Cpd 43




Cpd 44




Cpd 45




Cpd 46




Cpd 47




Cpd 48




Cpd 49




Cpd 50




Cpd 51




Cpd 52




Cpd 53




Cpd 54




Cpd 55




Cpd 56




Cpd 57




Cpd 58




Cpd 59




Cpd 60




Cpd 61




Cpd 62




Cpd 63




Cpd 64




Cpd 65




Cpd 66




Cpd 67




Cpd 68




Cpd 69




Cpd 70




Cpd 71




Cpd 72




Cpd 73




Cpd 74




Cpd 75




Cpd 76




Cpd 77




Cpd 78




Cpd 79




Cpd 80




Cpd 81




Cpd 82




Cpd 83




Cpd 84




Cpd 85




Cpd 86




Cpd 87




Cpd 88




Cpd 89




Cpd 90




Cpd 91




Cpd 92




Cpd 93




Cpd 94




Cpd 95




Cpd 96




Cpd 97




Cpd 98




Cpd 99




Cpd 100




Cpd 101




Cpd 102




Cpd 103




Cpd 104




Cpd 105




Cpd 106




Cpd 107




Cpd 108




Cpd 109




Cpd 110




Cpd 111




Cpd 112




Cpd 113




Cpd 114




Cpd 115




Cpd 116




Cpd 117




Cpd 118




Cpd 119




Cpd 120




Cpd 121




Cpd 122




Cpd 123




Cpd 124




Cpd 125




Cpd 126




Cpd 127




Cpd 128




Cpd 129




Cpd 130




Cpd 131




Cpd 132




Cpd 133




Cpd 134




Cpd 135




Cpd 136




Cpd 137




Cpd 138




Cpd 139




Cpd 140




Cpd 141




Cpd 142




Cpd 143




Cpd 144




Cpd 145




Cpd 146




Cpd 147




Cpd 148




Cpd 149




Cpd 150




Cpd 151




Cpd 152




Cpd 153




Cpd 154




Cpd 155




Cpd 156




Cpd 157




Cpd 158




Cpd 159




Cpd 160




Cpd 161




Cpd 162




Cpd 163




Cpd 164




Cpd 165




Cpd 166




Cpd 167




Cpd 168




Cpd 169




Cpd 170




Cpd 171




Cpd 172




Cpd 173




Cpd 174




Cpd 175




Cpd 176




Cpd 177




Cpd 178




Cpd 179




Cpd 180




Cpd 181




Cpd 182




Cpd 183




Cpd 184




Cpd 185




Cpd 186




Cpd 187




Cpd 188




Cpd 189




Cpd 190




Cpd 191




Cpd 192




Cpd 193




Cpd 194




Cpd 195




Cpd 196




Cpd 197




Cpd 198




Cpd 199




Cpd 200




Cpd 201




Cpd 202




Cpd 203




Cpd 204




Cpd 205




Cpd 206




Cpd 207




Cpd 208




Cpd 209




Cpd 210




Cpd 211




Cpd 212




Cpd 213




Cpd 214




Cpd 215




Cpd 216




Cpd 217




Cpd 218




Cpd 219




Cpd 220




Cpd 221




Cpd 222




Cpd 223




Cpd 224




Cpd 225




Cpd 226




Cpd 227




Cpd 228




Cpd 229




Cpd 230




Cpd 231




Cpd 232




Cpd 233




Cpd 234




Cpd 235




Cpd 236




Cpd 237




Cpd 238




Cpd 239




Cpd 240




Cpd 241




Cpd 242




Cpd 243




Cpd 244




Cpd 245




Cpd 246




Cpd 247




Cpd 248




Cpd 249




Cpd 250




Cpd 251




Cpd 252




Cpd 253




Cpd 254




Cpd 255




Cpd 256




Cpd 257




Cpd 258




Cpd 259




Cpd 260




Cpd 261




Cpd 262




Cpd 263




Cpd 264




Cpd 265




Cpd 266




Cpd 267




Cpd 268




Cpd 269




Cpd 270




Cpd 271




Cpd 272




Cpd 273




Cpd 274




Cpd 275




Cpd 276




Cpd 277




Cpd 278




Cpd 279




Cpd 280




Cpd 281




Cpd 282




Cpd 283




Cpd 284




Cpd 285




Cpd 286




Cpd 287




Cpd 288




Cpd 289




Cpd 290




Cpd 291




Cpd 292




Cpd 293




Cpd 294




Cpd 295




Cpd 296




Cpd 297




Cpd 298




Cpd 299




Cpd 300




Cpd 301




Cpd 302




Cpd 303




Cpd 304




Cpd 305




Cpd 306




Cpd 307




Cpd 308




Cpd 309




Cpd 310




Cpd 311




Cpd 312




Cpd 314




Cpd 315




Cpd 316




Cpd 317




Cpd 318




Cpd 319




Cpd 320




Cpd 321




Cpd 322




Cpd 323




Cpd 324




Cpd 325




Cpd 326




Cpd 327




Cpd 328




Cpd 329




Cpd 330




Cpd 331




Cpd 332




Cpd 333




Cpd 334




Cpd 335




Cpd 336




Cpd 337




Cpd 338




Cpd 339




Cpd 340




Cpd 341




Cpd 342




Cpd 343




Cpd 344




Cpd 345




Cpd 346




Cpd 347




Cpd 348




Cpd 349




Cpd 350




Cpd 351




Cpd 357




Cpd 358




Cpd 359




Cpd 360




Cpd 361




Cpd 362




Cpd 363




Cpd 364




Cpd 365




Cpd 366




Cpd 367




Cpd 368




Cpd 369




Cpd 370




Cpd 371




Cpd 372




Cpd 373




Cpd 374




Cpd 375




Cpd 376




Cpd 378




Cpd 379




Cpd 380




Cpd 383




Cpd 384




Cpd 385




Cpd 386




Cpd 387




Cpd 388




Cpd 389




Cpd 390




Cpd 391




Cpd 392




Cpd 393




Cpd 394




Cpd 395




Cpd 396




Cpd 397




Cpd 398




Cpd 399




Cpd 400




Cpd 402




Cpd 404




Cpd 405




Cpd 406




Cpd 407




Cpd 408




Cpd 409




Cpd 410




Cpd 411




Cpd 412




Cpd 413




Cpd 414




Cpd 415




Cpd 416




Cpd 417




Cpd 418




Cpd 419




Cpd 420




Cpd 421




Cpd 422




Cpd 423




Cpd 424




Cpd 425




Cpd 426




Cpd 427




Cpd 428




Cpd 429




Cpd 430




Cpd 431




Cpd 432




Cpd 433




Cpd 434




Cpd 435




Cpd 436




Cpd 437




Cpd 438




Cpd 439




Cpd 440




Cpd 441




Cpd 442




Cpd 443




Cpd 444




Cpd 445




Cpd 446




Cpd 447




Cpd 448




Cpd 449




Cpd 450




Cpd 451




Cpd 452




Cpd 453




Cpd 454




Cpd 455




Cpd 456




Cpd 457




Cpd 458




Cpd 459




Cpd 460




Cpd 461




Cpd 462




Cpd 463




Cpd 464




Cpd 465




Cpd 466




Cpd 467




Cpd 468




Cpd 469




Cpd 470




Cpd 471




Cpd 472




Cpd 473




Cpd 474




Cpd 475




Cpd 476




Cpd 477




Cpd 478




Cpd 479




Cpd 480




Cpd 481




Cpd 482




Cpd 483




Cpd 484




Cpd 485




Cpd 486




Cpd 487




Cpd 488




Cpd 489




Cpd 490




Cpd 491




Cpd 492




Cpd 494




Cpd 497




Cpd 498




Cpd 499




Cpd 500




Cpd 501




Cpd 502




Cpd 503




Cpd 504




Cpd 505



Cpd 506



Cpd 507



Cpd 508

As modulators of the vanilloid VR1 ion channel, the compounds of Formula (I) are useful in methods for treating a VR1 ion channel mediated disease in a subject which disease is affected by the modulation of one or more vanilloid receptors.

Accordingly, the present invention is directed to a method of treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) or a salt or solvate thereof.

Compound Forms

The term "form" means, in reference to compounds of the present invention, such may exist as, without limitation, a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form. The present invention encompasses all such compound forms and mixtures thereof.

The term "isolated form" means, in reference to compounds of the present invention, that such may exist in an essentially pure state such as, without limitation, an enantiomer, a racemic mixture, a geometric isomer (such as a *cis* or *trans* stereoisomer), a mixture of geometric isomers, and the like. The present invention encompasses all such isolated forms and mixtures thereof.

Certain compounds of Formula (I) may exist in various stereoisomeric or tautomeric forms and mixtures thereof. The invention encompasses all such compounds and mixtures thereof.

The compounds of the present invention may be present in the form of pharmaceutically acceptable salts. For use in medicines, the "pharmaceutically acceptable salts" of the compounds of this invention refer to non-toxic acidic/anionic or basic/cationic salt forms.

Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.

Furthermore when the compounds of the present invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.

Thus, representative pharmaceutically acceptable salts include the following: acetate, adipate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate (or camphosulphonate), carbonate, chloride, choline, clavulanate, citrate, dihydrochloride, disodium, edetate, fumarate, gluconate, glutamate, hydrabamine, hydrobromine, hydrochloride, iodide, isothionate, lactate, malate, maleate, mandelate, mesylate, nitrate, oleate, pamoate, palmitate, phosphate/diphosphate, salicylate, sodium, stearate, sulfate, succinate, tartrate, tromethane, tosylate, trichloroacetate, trifluoroacetate and the like.

An example of the present invention includes compounds of Formula (I) and a salt form thereof wherein the salt is selected from the group consisting of disodium, hydrochloride and sodium.

The invention includes compounds of various isomers and mixtures thereof. The term "isomer" refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. Such substances have the same number and kind of atoms but differ in structure. The structural difference may be in constitution (geometric isomers) or in an ability to rotate the plane of polarized light (stereoisomers).

The term "optical isomer" means isomers of identical constitution that differ only in the spatial arrangement of their groups. Optical isomers rotate the plane of polarized light in different directions. The term "optical activity" means the degree to which an optical isomer rotates the plane of polarized light.

The term "racemate" or "racemic mixture" means an equimolar mixture of two enantiomeric species, wherein each of the isolated species rotates the plane of polarized light in the opposite direction such that the mixture is devoid of optical activity.

The term "enantiomer" means an isomer having a nonsuperimposable mirror image. The term "diastereomer" means stereoisomers that are not enantiomers.

The term "chiral" means a molecule, which in a given configuration, cannot be superimposed on its mirror image. This is in contrast to achiral molecules, which can be superimposed on their mirror images.

The invention is considered to include the tautomeric forms of all compounds of Formula (I). In addition, for chiral embodiments of the invention, the invention is considered to include pure enantiomers, racemic mixtures, as well as mixtures of enantiomers having 0.001% to 99.99% enantiomeric excess. In addition, some of the compounds represented by Formula (I) may be prodrugs,

i.e., derivatives of a drug that possess superior delivery capabilities and therapeutic value as compared to the active drug. Prodrugs are transformed into active drugs by *in vivo* enzymatic or chemical processes.

The two distinct mirror image versions of the chiral molecule are also known as levo (left-handed), abbreviated L, or dextro (right handed), abbreviated D, depending on which way they rotate polarized light. The symbols "R" and "S" represent the configuration of groups around a stereogenic carbon atom(s).

An example of an enantiomerically enriched form isolated from a racemic mixture includes a dextrorotatory enantiomer, wherein the mixture is substantially free of the levorotatory isomer. In this context, substantially free means the levorotatory isomer may, in a range, comprise less than 25 % of the mixture, less than 10 %, less than 5 %, less than 2 % or less than 1 % of the mixture according to the formula:

$$\%levorotatory = \frac{(mass\,levorotatory)}{(mass\,dextrorotatory) + (mass\,levorotatory)} \times 100$$

Similarly, an example of an enantiomerically enriched form isolated from a racemic mixture includes a levorotatory enantiomer, wherein the mixture is substantially free of the dextrorotatory isomer. In this context, substantially free means the dextrorotatory isomer may, in a range, comprise less than 25% of the mixture, less than 10 %, less than 5 %, less than 2 % or less than 1 % of the mixture according to the formula:

$$\%dextrorotatory = \frac{(mass\,dextrorotatory)}{(mass\,dextrorotatory) + (mass\,levorotatory)} \times 100$$

"Geometric isomer" means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Substituent atoms (other than hydrogen) on each side of a carbon-carbon double bond may be in an E or Z configuration. In the "E" configuration, the substituents are on opposite sides in relationship to the carbon- carbon double bond. In the "Z" configuration, the substituents are oriented

on the same side in relationship to the carbon-carbon double bond. The scope of the present invention is intended to include all such "E" and "Z" isomers.

Substituent atoms (other than hydrogen) attached to a ring system may be in a cis or trans configuration. In the "cis" configuration, the substituents are on the same side in relationship to the plane of the ring; in the "trans" configuration, the substituents are on opposite sides in relationship to the plane of the ring. Compounds having a mixture of "cis" and "trans" species are designated "cis/trans". The scope of the present invention is intended to include all such "cis" and "trans" isomers.

The isomeric descriptors ("R," "S," "E," and "Z") indicate atom configurations relative to a core molecule and are intended to be used as defined in the literature.

Furthermore, compounds of the present invention may have at least one crystalline, polymorph or amorphous form. The plurality of such forms is included in the scope of the invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents (e.g., organic esters such as ethanolate and the like). The plurality of such solvates is also intended to be encompassed within the scope of this invention.

Chemical Nomenclature and Definitions

Bond lines drawn into a ring system from a substituent variable indicate that the substituent may be attached to any of the substitutable ring atoms.

As used herein, the following terms are intended to have the following meanings (additional definitions are provided where prophetic throughout the Specification). The definitions herein may specify that a chemical term has an indicated formula. The particular formula provided is not intended to limit the scope of the invention, but is provided as an illustration of the term and is intended to include the plurality of variations expected to be included by one of ordinary skill in the art.

Definitions

The term "C_{1-6}alkyl" or "alkyl" means a straight or branched chain hydrocarbon alkyl radical, comprising from 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, tertiary butyl (also referred to as *t*-butyl or *tert*-butyl), 1-pentyl, 2-pentyl, 3-pentyl, 1-hexyl, 2-hexyl, 3-hexyl and the like. The term further includes alkyl groups in any combination thereof (e.g. C_{1-2}, C_{1-3}, C_{1-4} and the like). An alkyl radical may be attached to a core molecule where allowed by available valences.

The terms "C_{2-3}alkenyl" and "C_{2-3}alkynyl" mean straight or branched carbon chains having 2 to 3 carbon atoms, wherein a C_{2-3}alkenyl chain has at least one double bond in the chain and a C_{2-3}alkynyl chain has at least one triple bond in the chain. An alkenyl and alkynyl radical may be attached to a core molecule where allowed by available valences.

The term "C_{1-6}alkoxy" or "alkoxy" means a straight or branched chain hydrocarbon alkyl radical or alkyldiyl linking group of the formula -O-C_{1-6}alkyl, comprising from 1 to 6 carbon atoms. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy and the like. The term further includes alkoxy groups in any combination thereof (e.g. C_{1-2}, C_{1-3}, C_{1-4} and the like). An alkoxy radical may be attached to a core molecule where allowed by available valences.

The term "cycloalkyl" refers to a saturated or partially unsaturated, monocyclic, polycyclic or benzofused hydrocarbon ring system composed of from 3 to 14 carbon atoms. Except when specified, the term includes a C_{3-8}cycloalkyl, C_{3-10}cycloalkyl, C_{5-6}cycloalkyl, C_{5-8}cycloalkyl, C_{5-12}cycloalkyl, C_{8-10}cycloalkyl, C_{9-13}cycloalkyl, C_{3-14}cycloalkyl or benzofused C_{3-14}cycloalkyl ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, , cyclohexenyl, cycloheptyl, cyclooctyl, 1*H*-indenyl, indanyl, adamantanyl, 9H-fluorenyl, 1,2,3,4-tetrahydro-naphthalenyl, acenaphthenyl, bicyclo[2.2.1]heptenyl and the like. C_{3-14}cycloalkyl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.

The term "benzofused," used as a prefix for a ring system, means a radical formed by any ring system radical fused with a benzene ring. The benzofused radical may be attached to a core molecule via either ring of the bicyclic system and further substituted on any atom where allowed by available valences.

The term "aryl" refers to monocyclic or bicyclic aromatic ring systems containing from 6 to 12 carbons in the ring. Examples include phenyl, biphenyl, naphthalene, azulenyl, anthracenyl and the like. Aryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.

The term "aromatic" refers to a cycloalkylic hydrocarbon ring system having an unsaturated, conjugated π electron system.

The term "hetero," used as a prefix for a ring system, refers to the replacement of at least one ring carbon atom with one or more heteroatoms independently selected from a nitrogen, oxygen or sulfur atom, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state. Examples include rings wherein 1, 2, 3 or 4 ring members are a nitrogen atom; or, 0, 1, 2 or 3 ring members are nitrogen atoms and 1 member is an oxygen or sulfur atom. When allowed by available valences, up to two adjacent ring members may be heteroatoms; wherein one heteroatom is nitrogen and the other is one heteroatom selected from N, S or O.

The term "heterocyclyl" refers to a nonaromatic (*i.e.* saturated or partially unsaturated) monocyclic, polycyclic or benzofused ring system radical. Heteroatom ring members are selected from at least one of N, O, S, S(O) or SO_2, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state. Examples include 2H-pyrrole, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 2-imidazolinyl (also referred to as 4,5-dihydro-1H-imidazolyl), imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, oxazolidinyl, tetrazolinyl, tetrazolidinyl, piperidinyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, piperazinyl, azetidinyl, azepanyl, dihydro-pyranyl, tetrahydro-furanyl, tetrahydro-thienyl, tetrahydro-pyranyl, tetrahydro-pyridazinyl,

hexahydro-1,4-diazepinyl, hexahydro-1,4-oxazepanyl, 1,3-dioxolanyl, 1,4-dioxanyl, 1,3-benzodioxolyl (also referred to as benzo[1,3]dioxolyl), 2,3-dihydro-1,4-benzodioxinyl (also referred to as 2,3-dihydro-benzo[1,4]dioxinyl) and the like. Heterocyclyl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.

The term "heteroaryl" means an aromatic monocyclic, polycyclic or benzofused ring system radical. Heteroatom ring members are selected from at least one of N, O, S, S(O) or SO_2, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state.

Examples include furanyl, thienyl, pyrrolyl, pyrazolyl, 1*H*-imidazolyl, isothiazolyl, isoxazolyl, oxazolyl, thiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, 1*H*-tetrazolyl, 2*H*-tetrazolyl, 1*H*-[1,2,3]triazolyl, 2*H*-[1,2,3]triazolyl, 4*H*-[1,2,4]triazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, indolyl, azaindolyl, indazolyl, azaindazolyl, isoindolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzoisoxazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalzinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl and the like. Heteroaryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences..

The term "C_{1-6}alkoxy-C_{1-6}alkyl" means a radical of the formula: -C_{1-6}alkyl-O-C_{1-6}alkyl.

The term "C_{1-6}alkoxycarbonyl" means a radical of the formula: -C(O)-O-C_{1-6}alkyl. Examples include C_{1-4}alkoxycarbonyl.

The term "C_{1-6}alkoxycarbonylamino" means a radical of the formula: -NH-C(O)-O-C_{1-6}alkyl. Examples include C_{1-4}alkylcarbonylamino.

The term "(C_{1-6}alkyl)$_{1-2}$amino" means a radical of the formula: -NH-C_{1-6}alkyl or -N(C_{1-6}alkyl)$_2$. Examples include (C_{1-4}alkyl)$_{1-2}$amino.

The term "$(C_{1-6}alkyl)_{1-2}amino$-$C_{1-6}alkyl$" means a radical of the formula: -C_{1-6}alkyl-NH-C_{1-6}alkyl or -C_{1-6}alkyl-N(C_{1-6}alkyl)$_2$. Examples include (C_{1-4}alkyl)$_{1-2}$amino-C_{1-6}alkyl.

The term "$(C_{1-6}alkyl)_{1-2}aminocarbonyl$" means a radical of the formula: -C(O)-NH-C_{1-6}alkyl or -C(O)-N(C_{1-6}alkyl)$_2$. Examples include (C_{1-4}alkyl)$_{1-2}$aminocarbonyl.

The term "$(C_{1-6}alkyl)_{1-2}aminocarbonylamino$" means a radical of the formula: -NH-C(O)-NH-C_{1-6}alkyl or -NH-C(O)-N(C_{1-6}alkyl)$_2$. Examples include (C_{1-4}alkyl)$_{1-2}$aminocarbonylamino.

The term "$(C_{1-4}alkyl)_{1-2}aminosulfonyl$" means a radical of the formula: -SO_2-NH-C_{1-4}alkyl or -SO_2-N(C_{1-4}alkyl)$_2$.

The term "$C_{1-6}alkylcarbonyl$" means a radical of the formula: -C(O)-C_{1-6}alkyl. Examples include C_{1-4}alkylcarbonyl.

The term "$C_{1-6}alkylcarbonylamino$" means a radical of the formula: -NH-C(O)-C_{1-6}alkyl. Examples include C_{1-4}alkylcarbonylamino.

The term "$C_{1-6}alkylsulfonyl$" means a radical of the formula: -SO_2-C_{1-6}alkyl. Examples include C_{1-4}alkylsulfonyl.

The term "$C_{1-6}alkylsulfinylamino$" means a radical of the formula: -NH-S(O)-C_{1-6}alkyl.

The term "$C_{1-6}alkylsulfonylamino$" means a radical of the formula: -NH-SO_2-C_{1-6}alkyl.

The term "$C_{1-6}alkylthio$" means a radical of the formula: -S-C_{1-6}alkyl. Examples include C_{1-4}alkylthio.

The term "amino" means a radical of the formula: –NH_2.

The term "amino-C_{1-6}alkyl" means a radical of the formula: -C_{1-6}alkyl–NH_2.

The term "aminocarbonyl" means a radical of the formula: -C(O)-NH_2.

The term "aminocarbonylamino" means a radical of the formula: -NH-C(O)-NH_2.

The term "aminosulfonyl" means a radical of the formula: -SO_2-NH_2.

The term "aminosulfonylamino" means a radical of the formula: -NH-SO_2-NH_2.

The term "(C_{1-6}alkyl)$_{1-2}$aminosulfonylamino" means a radical of the formula: -NH-SO_2-NH-C_{1-6}alkyl or -NH-SO_2-N(C_{1-6}alkyl)$_2$. Examples include (C_{1-4}alkyl)$_{1-2}$aminosulfonylamino.

The term "aminosulfonylamino-C_{1-6}alkyl" means a radical of the formula: -C_{1-6}alkyl-NH-SO_2-NH_2.

The term "(C_{1-6}alkyl)$_{1-2}$aminosulfonylamino-C_{1-6}alkyl" means a radical of the formula: -C_{1-6}alkyl-NH-SO_2-NH-C_{1-6}alkyl or -C_{1-6}alkyl-NH-SO_2-N(C_{1-6}alkyl)$_2$.

The term "carboxy" means a radical of the formula: -C(O)OH.

The term "C_{3-8}cycloalkyl-C_{1-6}alkyl" means a radical of the formula: -C_{1-6}alkyl-C_{3-8}cycloalkyl. Examples include C_{3-8}cycloalkyl-C_{1-4}alkyl.

The term "C_{3-8}cycloalkyl-C_{1-6}alkoxy" means a radical of the formula: -O-C_{1-6}alkyl-C_{3-8}cycloalkyl. Examples include C_{3-8}cycloalkyl-C_{1-4}alkoxy.

The term "C_{3-8}cycloalkyl-oxy" means a radical of the formula: -O-C_{3-8}cycloalkyl.

The term "(C_{3-8}cycloalkyl)$_{1-2}$amino" means a radical of the formula: -NH-(C_{3-8}cycloalkyl) or -N(C_{3-8}cycloalkyl)$_2$.

The term "(C_{3-8}cycloalkyl-C_{1-4}alkyl)$_{1-2}$amino" means a radical of the formula: -NH-C_{1-4}alkyl-C_{3-8}cycloalkyl or -N(C_{1-4}alkyl-C_{3-8}cycloalkyl)$_2$.

The term "formyl" means a radical of the formula: -C(O)H.

The term "oxo" means a radical of the formula: =O.

The term "halogen" or "halo" means the group chloro, bromo, fluoro or iodo.

The term "haloC_{1-6}alkyl" means a radical of the formula: -C_{1-6}alkyl(halo)n, wherein "n" represents that amount of available valences on C_{1-6}alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include difluoromethyl, trifluoromethyl, trifluoroethyl, chloromethyl and the like.

The term "haloC_{1-6}alkoxy" means a radical of the formula: -O-C_{1-6}alkyl(halo)$_n$, wherein "n" represents that amount of available valences on C_{1-6}alkoxy, which may be substituted with one or more halogen atoms while remaining stable. Examples include difluoromethoxy, trifluoromethoxy, trifluoroethoxy, chloromethoxy and the like.

The term "haloC_{1-6}alkylsulfonyl" means a radical of the formula: -SO_2-C_{1-6}alkyl(halo)n, wherein "n" represents that amount of available valences on C_{1-6}alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.

The term "haloC_{1-6}alkylsulfonylamino" means a radical of the formula: -NH-SO_2-C_{1-6}alkyl(halo)n, wherein "n" represents that amount of available valences on C_{1-6}alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.

The term "haloC_{1-6}alkylthio" means a radical of the formula: -S-C_{1-6}alkyl(halo)n, wherein "n" represents that amount of available valences on C_{1-6}alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.

The term "perfluorinated" means a radical that is substituted with fluoro atoms to the extent allowed by available valences while remaining stable.

The term "substituted," refers to a core molecule on which one or more hydrogen atoms have been replaced with one or more functional radical moieties. The number that is allowed by available valences limits the amount of substituents. Substitution is not limited to the core molecule, but may also occur on a substituent radical, whereby the substituent radical becomes a linking group.

Therapeutic Use

As modulators of the vanilloid VR1 ion channel, the compounds of Formula (I) are useful in methods for treating a VR1 ion channel mediated disease in a subject which disease is affected by the modulation of one or more vanilloid receptors.

Accordingly, the present invention is directed to a method of treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) or a salt or solvate thereof.

The term "VR1 ion channel mediated disease" refers to chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.

An example of a use of the compound of Formula (I) or a salt or solvate thereof includes use in the manufacture of a medicament for treating a VR1 ion channel mediated disease, wherein the VR1 ion channel mediated disease is chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.

An example of a use of the compound of Formula (I) or a salt or solvate thereof includes use as a medicine for treating a VR1 ion channel mediated disease, wherein the VR1 ion channel mediated disease is chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.

The term "prodrug" means a compound of Formula (I) or a form thereof that is converted *in vivo* into a functional derivative form that may contribute to

therapeutic biological activity, wherein the converted form may be: 1) a relatively active form; 2) a relatively inactive form; 3) a relatively less active form; or, 4) any form which results, directly or indirectly, from such *in vivo* conversions.

Prodrugs are useful when said compound may be either too toxic to administer systemically, absorbed poorly by the digestive tract or broken down by the body before it reaches its target. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

The term "metabolite" means a form of a compound of Formula (I) or a form thereof converted by *in vivo* metabolism or a metabolic process to a derivative of said compound.

The term "subject" as used herein, refers to a patient, such as an animal, a mammal or a human, who has been the object of treatment, observation or experiment and is at risk of (or susceptible to) developing a disease that has or will result in VR1 ion channel mediated chronic or acute pain, wherein the pain caused by the disease is inflammatory pain, burning pain or post-operative pain.

The term "effective amount" refers to that amount of a compound of Formula (I) or a form, pharmaceutical composition, medicine or medicament thereof that elicits the biological or medicinal response (such as inhibiting, preventing or ameliorating VR1 ion channel mediated chronic or acute pain) in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor, or other clinician, which includes alleviation of the symptoms of the inflammatory pain, burning pain or post-operative pain being treated.

The effective amount of a compound of Formula (I) or a form thereof is from about 0.001 mg/kg/day to about 300 mg/kg/day.

The term "pharmaceutical composition" refers to a product containing a compound of Formula (I) or a form thereof, such as a product comprising the specified ingredients in the specified amounts, as well as any product that results,

directly or indirectly, from such combinations of the specified ingredients in the specified amounts.

The term "medicament" or "medicine" refers to a product containing a compound of Formula (I) or a form thereof. The present invention includes use of such a medicament for treating VR1 ion channel mediated chronic or acute pain.

The term "pharmaceutically acceptable" refers to molecular entities and compositions that are of sufficient purity and quality for use in the formulation of a pharmaceutical composition, medicine or medicament of the present invention. Since both human use (clinical and over-the-counter) and veterinary use are equally included within the scope of the present invention, a pharmaceutically acceptable formulation would include a pharmaceutical composition, medicine or medicament for either human or veterinary use.

The term "treating" refers, without limitation, inhibiting, ameliorating, facilitating the eradication of, inhibiting the progression of or promoting the stasis of VR1 ion channel mediated chronic or acute pain.

For oral administration, the pharmaceutical composition, medicine or medicament is preferably in the form of a tablet containing, e.g., 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of a compound of formula (I) or a form thereof for the symptomatic adjustment of the dosage to the patient to be treated. Optimal dosages will vary depending on factors associated with the particular patient being treated (e.g., age, weight, diet and time of administration), the severity of the condition being treated, the particular compound being used, the mode of administration and the strength of the preparation. The use of either daily administration or post-periodic dosing may be employed.

A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:

Cpd	Name
1	(*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
2	(*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
3	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
4	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
5	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
6	(*E*)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
7	(*E*)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
8	(*E*)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
9	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
10	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,
11	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,
12	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
13	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
14	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
15	(*E*)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
16	(*E*)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
17	(*E*)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
18	(*E*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
19	(*E*)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

Cpd	Name
20	(*E*)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
21	(*E*)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
22	(*E*)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
23	(*E*)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
24	(*E*)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
25	(*E*)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
26	(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
27	(*E*)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
28	(*E*)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
29	2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol,
30	2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole,
31	N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
32	2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
33	3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
34	4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
35	(*E*)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
36	(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
37	(*E*)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
38	(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
39	(*E*)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

Cpd	Name
40	(*E*)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
41	(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
42	(*E*)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
43	(*E*)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
44	(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
45	(*E*)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
46	1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
47	(*E*)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
48	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol,
49	(*E*)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol,
50	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-acetamide,
51	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanol,
52	(*E*)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl-1H-benzimidazole,
53	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-benzamide,
54	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,
55	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
56	(*E*)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
57	(*E*)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

Cpd	Name
58	(*E*)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
59	(*E*)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
60	(*E*)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
61	(*E*)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
62	(*E*)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
63	(*E*)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
64	(*E*)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
65	(*E*)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
66	(*E*)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
67	(*E*)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
68	(*E*)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
69	(*E*)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
70	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
71	(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
72	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
73	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
74	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
75	(*E*)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

Cpd	Name
76	(*E*)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
77	(*E*)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
78	(*E*)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
79	(*E*)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
80	(*E*)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
81	(*E*)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
82	(*E*)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
83	(*E*)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
84	(*E*)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
85	(*E*)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
86	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
87	(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
88	(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
89	(*E*)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
90	(*E*)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
91	(*E*)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
92	(*E*)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
93	(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,

Cpd	Name
94	(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
95	(*E*)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
96	(*E*)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
97	(*E*)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
98	(*E*)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
99	(*E*)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
100	(*E*)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
101	(*E*)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
102	(*E*)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
103	(*E*)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
104	(*E*)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
105	(*E*)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
106	(*E*)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
107	(*E*)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
108	(*E*)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
109	(*E*)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
110	(*E*)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
111	(*E*)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

Cpd	Name
112	(*E*)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
113	(*E*)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
114	(*E*)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
115	(*E*)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
116	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
117	(*E*)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,
118	(*E*)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
119	(*E*)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
120	(*E*)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
121	(*E*)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
122	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
123	(*E*)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
124	(*E*)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
125	(*E*)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,
126	(*E*)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
127	(*E*)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
128	(*E*)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,
129	2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
130	2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
131	2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
132	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
133	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
134	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
135	1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
136	1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
137	N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
138	2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
139	2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
140	N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
141	1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
142	1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
143	N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
144	2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
145	2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
146	C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
147	1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,

Cpd	Name
148	1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
149	N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
150	2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
151	2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
152	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
153	1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
154	1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
155	N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
156	2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
157	2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
158	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
159	1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
160	1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
161	N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
162	2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
163	2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
164	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
165	1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

Cpd	Name
166	1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
167	N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
168	2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
169	2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
170	N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
171	1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
172	1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
173	N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
174	2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
175	2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
176	C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
177	N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,
178	N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
179	N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
180	N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
181	2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
182	C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
183	N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

Cpd	Name
184	C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
185	C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,
186	C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
187	2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
188	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
189	2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
190	2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
191	2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
192	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
193	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
194	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
195	1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
196	1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
197	N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
198	2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
199	2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
200	N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
201	1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

Cpd	Name
202	1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
203	N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
204	2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
205	2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
206	C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
207	1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
208	1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
209	N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
210	2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
211	2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)- benzenesulfonamide,
212	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
213	1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
214	1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
215	N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
216	2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
217	2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
218	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
219	1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]- ethanone,

Cpd	Name
220	1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]- ethanol,
221	N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
222	2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]- propan-2-ol,
223	2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
224	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
225	1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
226	1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
227	N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
228	2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
229	2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
230	N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
231	1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
232	1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
233	N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
234	2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
235	2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
236	C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
237	N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,

Cpd	Name
238	N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,
239	N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
240	N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,
241	2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
242	C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
243	N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
244	C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,
245	C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,
246	C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,
247	2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
248	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
249	2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
250	2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
251	2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
252	C,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
253	C,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
254	C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
255	1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
256	1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,

Cpd	Name
257	N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
258	2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
259	2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
260	N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,
261	1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
262	1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
263	N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
264	2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
265	2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
266	C,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
267	1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
268	1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
269	N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
270	2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
271	2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
272	C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
273	1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
274	1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

Cpd	Name
275	N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
276	2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
277	2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
278	C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
279	1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
280	1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
281	N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
282	2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
283	2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
284	C,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
285	1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
286	2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
287	N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
288	1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
289	2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
290	N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,
291	1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
292	1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
293	N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

Cpd	Name
294	2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
295	2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
296	C,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
297	N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,
298	N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,
299	N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
300	N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,
301	2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
302	C,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
303	N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,
304	C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,
305	C,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,
306	C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,
307	2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
308	C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
309	(*E*)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
310	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
311	(*E*)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

Cpd	Name
312	(*E*)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
314	(*E*)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
315	(*E*)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
316	(*E*)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
317	(*E*)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
318	(*E*)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
319	(*E*)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
320	(*E*)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
321	(*E*)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
322	(*E*)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
323	(*E*)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
324	(*E*)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
325	(*E*)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
326	(*E*)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
327	(*E*)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
328	(*E*)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
329	(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
330	(*E*)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

Cpd	Name
331	(*E*)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
332	(*E*)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
333	(*E*)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
334	(*E*)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
335	(*E*)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
336	(*E*)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
337	(*E*)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
338	(*E*)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
339	(*E*)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
340	(*E*)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
341	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
342	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
343	(*E*)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
344	(*E*)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
345	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
346	(*E*)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
347	(*E*)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
348	(*E*)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

Cpd	Name
349	(*E*)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
350	N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
351	(*E*)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
357	(*E*)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
358	(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
359	(*E*)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
360	(*E*)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
361	(*E*)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
362	(*E*)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
363	(*E*)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
364	(*E*)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
365	(*E*)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
366	(*E*)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
367	(*E*)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
368	(*E*)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
369	(*E*)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
370	(*E*)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
371	(*E*)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
372	(*E*)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
373	(*E*)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
374	(*E*)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
375	(*E*)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
376	(*E*)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
378	(*E*)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
379	(*E*)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
380	(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
383	2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
384	2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
385	2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
386	2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
387	2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
388	2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
389	2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
390	2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
391	2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
392	2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
393	2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
394	2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
395	2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
396	2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
397	2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
398	(*E*)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
399	N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
400	N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
402	2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
404	2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
405	2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
406	(*E*)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
407	(*E*)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
408	(*E*)-N-(2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
409	(*E*)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
410	(*E*)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
411	(*E*)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
412	(*E*)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

Cpd	Name
413	(*E*)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
414	(*E*)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
415	(*E*)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
416	(*E*)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
417	(*E*)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
418	(*E*)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
419	2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
420	2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
421	2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
422	(*E*)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
423	(*E*)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
424	(*E*)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
425	(*E*)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
426	(*E*)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,
427	(*E*)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
428	(*E*)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
429	(*E*)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
430	(*E*)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
431	(*E*)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
432	(*E*)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
433	(*E*)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
434	(*E*)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
435	(*E*)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
436	(*E*)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
437	(*E*)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
438	(*E*)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
439	(*E*)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
440	(*E*)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
441	(*E*)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
442	2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
443	(*E*)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
444	(*E*)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
445	4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
446	(*E*)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
447	5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
448	(*E*)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-ethanone,
449	(*E*)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,

Cpd	Name
450	(*E*)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-benzamide,
451	(*E*)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
452	(*E*)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-acetamide,
453	(*E*)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-benzoic acid,
454	(*E*)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
455	(*E*)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
456	(*E*)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
457	N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
458	(*E*)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
459	(*E*)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,
460	(*E*)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propionamide,
461	(*E*)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,
462	(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid methyl ester,
463	(*E*)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
464	2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
465	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,
466	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester,
467	N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

Cpd	Name
468	(*E*)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
469	(*Z*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
470	(*E*)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
471	2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
472	2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenol,
473	(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,
474	(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
475	(*E*)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
476	(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
477	(*E*)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
478	(*E*)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
479	(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,
480	(*E*)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
481	(*E*)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl-phenyl)-1H-benzimidazole,
482	(*E*)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
483	(*E*)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzyl)-amine,
484	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzaldehyde,
485	(*E*)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzyl)-amine,

Cpd	Name
486	2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzylamine,
487	(*E*)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
488	(*E*)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
489	2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
490	2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
491	(E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
492	2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
494	2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
497	2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
498	2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzamide,
499	N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
500	5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazole,
774 **501**	2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
255 **502**	2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
503	2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
504	2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
505	2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
506	2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
507	2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol, and

Cpd	Name
508	2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide.

A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:

Cpd	Name
1	(*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
2	(*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
3	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
4	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
5	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
6	(*E*)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
7	(*E*)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
8	(*E*)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
9	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
10	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,
11	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,
12	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
13	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
14	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
15	(*E*)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
16	(*E*)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
17	(*E*)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

Cpd	Name
18	(*E*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
19	(*E*)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
20	(*E*)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
21	(*E*)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
22	(*E*)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
23	(*E*)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
24	(*E*)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
25	(*E*)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
26	(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
27	(*E*)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
28	(*E*)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
29	2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol,
30	2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole,
31	N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
32	2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
33	3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
34	4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
35	(*E*)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
36	(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
37	(*E*)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

Cpd	Name
38	(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
39	(*E*)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
40	(*E*)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
41	(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
42	(*E*)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
43	(*E*)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
44	(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
45	(*E*)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
46	1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
47	(*E*)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
48	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol,
49	(*E*)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol,
50	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-acetamide,
51	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanol,
52	(*E*)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl-1H-benzimidazole,
53	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-benzamide,
54	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,
55	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

Cpd	Name
56	(*E*)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
57	(*E*)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
58	(*E*)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
59	(*E*)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
60	(*E*)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
61	(*E*)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
62	(*E*)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
63	(*E*)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
64	(*E*)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
65	(*E*)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
66	(*E*)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
67	(*E*)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
68	(*E*)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
69	(*E*)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
70	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
71	(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
77	(*E*)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
78	(*E*)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

Cpd	Name
79	(*E*)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
83	(*E*)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
84	(*E*)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
85	(*E*)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
95	(*E*)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
101	(*E*)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
113	(*E*)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
114	(*E*)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
129	2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
130	2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
131	2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
139	2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
145	2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
175	2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
190	2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
198	2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
234	2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
250	2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

Cpd	Name
294	2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
295	2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
309	(*E*)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
310	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
311	(*E*)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
312	(*E*)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
314	(*E*)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
315	(*E*)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
316	(*E*)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
317	(*E*)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
318	(*E*)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
319	(*E*)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
320	(*E*)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
321	(*E*)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
322	(*E*)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
323	(*E*)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
324	(*E*)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
325	(*E*)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

Cpd	Name
326	(*E*)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
327	(*E*)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
328	(*E*)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
329	(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
330	(*E*)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
331	(*E*)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
332	(*E*)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
333	(*E*)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
334	(*E*)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
335	(*E*)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
336	(*E*)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
337	(*E*)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
338	(*E*)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
339	(*E*)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
340	(*E*)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
341	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
342	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
343	(*E*)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
344	(*E*)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
345	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
346	(*E*)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
347	(*E*)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
348	(*E*)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
349	(*E*)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
350	N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
351	(*E*)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
357	(*E*)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
358	(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
359	(*E*)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
360	(*E*)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
361	(*E*)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
362	(*E*)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
363	(*E*)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
364	(*E*)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
365	(*E*)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
366	(*E*)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
367	(*E*)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
368	(*E*)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
369	(*E*)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
370	(*E*)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
371	(*E*)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
372	(*E*)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
373	(*E*)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
374	(*E*)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
375	(*E*)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
376	(*E*)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
378	(*E*)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
379	(*E*)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
380	(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
383	2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
384	2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
385	2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
386	2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
387	2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
388	2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
389	2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
390	2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
391	2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
392	2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
393	2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
394	2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
395	2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
396	2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
397	2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
398	(*E*)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
399	N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
400	N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
402	2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
404	2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
405	2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
406	(*E*)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
407	(*E*)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

Cpd	Name
408	(*E*)-N-(2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
409	(*E*)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
410	(*E*)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
411	(*E*)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
412	(*E*)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
413	(*E*)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
414	(*E*)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
415	(*E*)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
416	(*E*)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
417	(*E*)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
418	(*E*)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
419	2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
420	2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
421	2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
422	(*E*)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
423	(*E*)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
424	(*E*)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
425	(*E*)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
426	(*E*)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,
427	(*E*)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
428	(*E*)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
429	(*E*)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
430	(*E*)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
431	(*E*)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
432	(*E*)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
433	(*E*)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
434	(*E*)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
435	(*E*)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
436	(*E*)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
437	(*E*)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
438	(*E*)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
439	(*E*)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
440	(*E*)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
441	(*E*)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
442	2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
443	(*E*)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
444	(*E*)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
445	4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
446	(*E*)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
447	5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
448	(*E*)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-ethanone,
449	(*E*)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
450	(*E*)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-benzamide,
451	(*E*)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
452	(*E*)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-acetamide,
453	(*E*)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-benzoic acid,
454	(*E*)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
455	(*E*)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
456	(*E*)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
457	N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
458	(*E*)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
459	(*E*)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,
460	(*E*)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propionamide,
461	(*E*)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,
462	(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid methyl ester,

Cpd	Name
463	(*E*)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
464	2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
465	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,
466	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester,
467	N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
468	(*E*)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
469	(*Z*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
470	(*E*)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
471	2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
472	2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenol,
473	(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,
474	(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
475	(*E*)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
476	(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
477	(*E*)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
478	(*E*)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
479	(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,
480	(*E*)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,

Cpd	Name
481	(*E*)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl-phenyl)-1H-benzimidazole,
482	(*E*)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
483	(*E*)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzyl)-amine,
484	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzaldehyde,
485	(*E*)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzyl)-amine,
486	2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzylamine,
487	(*E*)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
488	(*E*)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
489	2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
490	2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
491	(E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
492	2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
494	2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
497	2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
498	2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzamide,
499	N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
500	5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazole,
3774 **501**	2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
4255 **502**	2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
503	2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
504	2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
505	2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
506	2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
507	2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol, and
508	2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide.

A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:

Cpd	Name
1	(*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
2	(*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
3	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
4	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
5	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
9	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
10	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,
11	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,
12	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
13	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
15	(*E*)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

Cpd	Name
16	(*E*)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
17	(*E*)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
18	(*E*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
22	(*E*)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
27	(*E*)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
28	(*E*)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
31	N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
32	2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
34	4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
35	(*E*)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
38	(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
39	(*E*)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
40	(*E*)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
41	(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
42	(*E*)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
44	(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
45	(*E*)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
46	1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
47	(*E*)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

Cpd	Name
50	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-acetamide,
51	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanol,
53	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-benzamide,
56	(*E*)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
58	(*E*)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
59	(*E*)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
61	(*E*)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
62	(*E*)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
63	(*E*)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
66	(*E*)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
67	(*E*)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
68	(*E*)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
69	(*E*)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
70	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
71	(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
77	(*E*)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
78	(*E*)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
79	(*E*)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
84	(*E*)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
95	(*E*)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
114	(*E*)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
129	2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
130	2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
131	2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
139	2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
175	2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
190	2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
198	2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
250	2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
294	2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
295	2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
309	(*E*)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
310	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
311	(*E*)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
312	(*E*)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
314	(*E*)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

Cpd	Name
315	(*E*)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
316	(*E*)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
317	(*E*)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
318	(*E*)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
319	(*E*)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
320	(*E*)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
321	(*E*)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
322	(*E*)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
323	(*E*)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
324	(*E*)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
325	(*E*)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
326	(*E*)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
327	(*E*)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
328	(*E*)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
329	(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
330	(*E*)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
331	(*E*)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
332	(*E*)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

Cpd	Name
333	(*E*)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
334	(*E*)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
335	(*E*)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
336	(*E*)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
337	(*E*)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
338	(*E*)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
339	(*E*)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
340	(*E*)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
341	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
342	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
343	(*E*)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
344	(*E*)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
345	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
346	(*E*)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
347	(*E*)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
348	(*E*)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
349	(*E*)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
350	N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
357	(*E*)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
358	(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
359	(*E*)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
360	(*E*)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
361	(*E*)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
362	(*E*)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
363	(*E*)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
364	(*E*)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
365	(*E*)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
366	(*E*)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
367	(*E*)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
368	(*E*)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
369	(*E*)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
370	(*E*)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
371	(*E*)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
372	(*E*)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
373	(*E*)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
374	(*E*)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
375	(*E*)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
376	(*E*)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
378	(*E*)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
379	(*E*)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
380	(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
383	2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
384	2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
385	2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
386	2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
387	2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
388	2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
390	2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
391	2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
392	2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
393	2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
394	2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
395	2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
396	2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
397	2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
398	(*E*)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
399	N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
402	2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
404	2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
405	2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
406	(*E*)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
407	(*E*)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
410	(*E*)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
411	(*E*)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
412	(*E*)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
413	(*E*)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
414	(*E*)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
415	(*E*)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
416	(*E*)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
417	(*E*)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
418	(*E*)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
419	2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
420	2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
421	2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
422	(*E*)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
423	(*E*)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
424	(*E*)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
426	(*E*)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,
427	(*E*)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
428	(*E*)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
429	(*E*)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
430	(*E*)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
431	(*E*)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
432	(*E*)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
433	(*E*)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
434	(*E*)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
435	(*E*)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
436	(*E*)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
437	(*E*)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
438	(*E*)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
439	(*E*)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
440	(*E*)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
442	2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
444	(*E*)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
445	4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
446	(*E*)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
447	5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
448	(*E*)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-ethanone,
449	(*E*)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
451	(*E*)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
455	(*E*)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
456	(*E*)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
461	(*E*)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,
462	(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid methyl ester,
463	(*E*)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
464	2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
465	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,
466	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester,
467	N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

Cpd	Name
468	(*E*)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
469	(*Z*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
470	(*E*)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
471	2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
475	(*E*)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
476	(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
482	(*E*)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
489	2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
490	2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
491	(E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
492	2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
494	2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
497	2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
498	2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzamide,
500	5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazole,
3774 **501**	2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
4255 **502**	2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
503	2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol, and
504	2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide.

A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:

Cpd	Name
1	(*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
2	(*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
5	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
9	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
12	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
16	(*E*)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
17	(*E*)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
18	(*E*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
22	(*E*)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
31	N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
35	(*E*)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
40	(*E*)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
42	(*E*)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
45	(*E*)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
46	1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
47	(*E*)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
51	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanol,

Cpd	Name
53	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-benzamide,
58	(*E*)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
61	(*E*)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
66	(*E*)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
69	(*E*)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
70	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
71	(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
77	(*E*)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
78	(*E*)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
79	(*E*)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
84	(*E*)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
114	(*E*)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
129	2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
130	2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
131	2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
139	2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
175	2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
190	2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
198	2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
250	2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
294	2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
295	2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
310	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
311	(*E*)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
312	(*E*)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
314	(*E*)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
315	(*E*)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
316	(*E*)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
317	(*E*)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
318	(*E*)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
319	(*E*)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
320	(*E*)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
321	(*E*)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
322	(*E*)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
323	(*E*)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
324	(*E*)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
328	(*E*)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
329	(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
331	(*E*)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
332	(*E*)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
333	(*E*)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
335	(*E*)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
337	(*E*)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
339	(*E*)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
340	(*E*)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
341	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
342	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
344	(*E*)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
345	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
347	(*E*)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
349	(*E*)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
350	N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
357	(*E*)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
358	(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
359	(*E*)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
360	(*E*)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
361	(*E*)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
362	(*E*)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
363	(*E*)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
364	(*E*)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
365	(*E*)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
366	(*E*)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
367	(*E*)-2-{2-[2-(**4**-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
368	(*E*)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
369	(*E*)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
370	(*E*)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
371	(*E*)-2-{2-[2-(2,**4**,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
372	(*E*)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
373	(*E*)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
374	(*E*)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
376	(*E*)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
378	(*E*)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
379	(*E*)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
380	(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
383	2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
384	2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
385	2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
386	2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
387	2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
388	2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
390	2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
391	2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
392	2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
393	2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
394	2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
395	2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
396	2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
397	2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
398	(*E*)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
399	N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
402	2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
404	2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
405	2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
407	(*E*)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
417	(*E*)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
418	(*E*)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
419	2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
420	2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
421	2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
422	(*E*)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
423	(*E*)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
424	(*E*)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
426	(*E*)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,
427	(*E*)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
428	(*E*)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
429	(*E*)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
430	(*E*)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
431	(*E*)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
432	(*E*)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name
433	(*E*)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
434	(*E*)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
435	(*E*)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
436	(*E*)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
437	(*E*)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
438	(*E*)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
439	(*E*)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
440	(*E*)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
442	2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
444	(*E*)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
445	4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
446	(*E*)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
447	5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
448	(*E*)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-ethanone,
449	(*E*)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
451	(*E*)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
455	(*E*)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
456	(*E*)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

Cpd	Name
461	(*E*)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,
462	(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid methyl ester,
463	(*E*)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
464	2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
466	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester,
468	(*E*)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
469	(*Z*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
470	(*E*)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
471	2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
475	(*E*)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
476	(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
482	(*E*)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
489	2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
490	2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
491	(E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
492	2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
494	2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
497	2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
498	2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzamide,

Cpd	Name
500	5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazole,
501	2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
503	2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol, and
504	2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide.

3774

A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:

Cpd	Name
9	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
12	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,
17	(*E*)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
18	(*E*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
69	(*E*)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
70	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
78	(*E*)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
79	(*E*)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
114	(*E*)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
130	2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
310	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
312	(*E*)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

Cpd	Name
319	(*E*)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,
341	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
357	(*E*)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
358	(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
362	(*E*)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
369	(*E*)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
384	2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
390	2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
391	2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
394	2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
398	(*E*)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
399	N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
407	(*E*)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
421	2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
422	(*E*)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,
428	(*E*)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
429	(*E*)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
430	(*E*)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

Cpd	Name
434	(*E*)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
442	2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
449	(*E*)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
461	(*E*)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,
464	2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
468	(*E*)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
469	(*Z*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
471	2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
489	2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
492	2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol, and
503	2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol.

A representative prophetic compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:

Cpd	Name
72	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
73	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
74	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
75	(*E*)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
76	(*E*)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
80	(*E*)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

Cpd	Name
81	(*E*)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
82	(*E*)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
86	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
87	(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
88	(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
89	(*E*)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
90	(*E*)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
91	(*E*)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
92	(*E*)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
93	(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
94	(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
96	(*E*)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
97	(*E*)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
98	(*E*)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
99	(*E*)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
100	(*E*)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
102	(*E*)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
103	(*E*)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,

Cpd	Name
104	(*E*)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
105	(*E*)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
106	(*E*)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
107	(*E*)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
108	(*E*)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
109	(*E*)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
110	(*E*)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
111	(*E*)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
112	(*E*)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
115	(*E*)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
116	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
117	(*E*)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,
118	(*E*)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
119	(*E*)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
120	(*E*)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
121	(*E*)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
122	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
123	(*E*)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

Cpd	Name
124	(*E*)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
125	(*E*)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,
126	(*E*)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
127	(*E*)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
128	(*E*)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,
132	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
133	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
134	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
135	1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
136	1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
137	N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
138	2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
140	N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
141	1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
142	1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
143	N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
144	2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
146	C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

Cpd	Name
147	1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
148	1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
149	N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
150	2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
151	2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
152	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
153	1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
154	1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
155	N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
156	2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
157	2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
158	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
159	1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
160	1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
161	N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
162	2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
163	2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
164	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

Cpd	Name
165	1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
166	1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
167	N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
168	2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
169	2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
170	N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
171	1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
172	1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
173	N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
174	2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
176	C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
177	N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,
178	N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
179	N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
180	N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
181	2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
182	C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
183	N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

Cpd	Name
184	C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
185	C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,
186	C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
187	2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
188	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
189	2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
191	2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
192	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
193	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
194	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
195	1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
196	1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
197	N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
199	2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
200	N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
201	1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
202	1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
203	N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

Cpd	Name
204	2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
205	2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
206	C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
207	1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
208	1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
209	N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
210	2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
211	2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)- benzenesulfonamide,
212	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
213	1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
214	1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
215	N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
216	2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
217	2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
218	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
219	1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]- ethanone,
220	1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]- ethanol,
221	N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

Cpd	Name
222	2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]- propan-2-ol,
223	2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
224	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
225	1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
226	1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
227	N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
228	2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
229	2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
230	N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
231	1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
232	1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
233	N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
235	2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
236	C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
237	N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,
238	N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,
239	N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
240	N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,

Cpd	Name
241	2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
242	C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
243	N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
244	C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,
245	C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,
246	C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,
247	2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
248	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
249	2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
251	2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
252	C,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
253	C,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
254	C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
255	1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
256	1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
257	N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
258	2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
259	2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
260	N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,

Cpd	Name
261	1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
262	1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
263	N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
264	2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
265	2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
266	C,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
267	1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
268	1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
269	N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
270	2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
271	2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
272	C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
273	1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
274	1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
275	N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
276	2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
277	2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
278	C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

Cpd	Name
279	1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
280	1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
281	N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
282	2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
283	2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
284	C,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
285	1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
286	2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
287	N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
288	1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
289	2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
290	N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,
291	1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
292	1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
293	N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
296	C,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
297	N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,
298	N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,
299	N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

Cpd	Name
300	N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,
301	2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
302	C,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
303	N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,
304	C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,
305	C,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,
306	C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,
307	2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, and
308	C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide.

General Synthetic Methods

Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated in the schemes that follows. Since the schemes are an illustration, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.


Compounds of the present invention can be synthesized using the methods described in the schemes that follow.

The terms used in describing the invention are commonly used and known to those skilled in the art. As used herein, the following abbreviations and formulas have the indicated meanings:

Abbreviation	Meaning
Boc	*tert*-butoxycarbonyl
BOP	benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate
AcOH	acetic acid
Cpd	compound
DBU	1,8-diazabicyclo[5.4.0]undec-7-ene
DCM	dichloromethane
DIEA	*N,N*-diisopropyl ethyl amine
DME	ethylene glycol dimethyl ether
DMF	*N,N*-dimethylformamide
DMSO	dimethyl sulfoxide
EtOAc	ethyl acetate
EtOH	ethanol
HPLC	high performance liquid chromatography
LiOH	lithium hydroxide
min	minute(s)
n-BuLi	*n*-butyl lithium
h/hr/hrs	hour(s)
mCPBA	*m*-chloroperbenzoic acid
MeOH	methanol
MTBE	methyl-t-butyl ether
$PdCl_2$(dppf) or $Pd(dppf)Cl_2CH_2Cl_2$	[1,1'-bis-(diphenylphosphino)ferroceno] dichloropalladium (II) dichloromethane complex
$Pd(PPh_3)_4$	palladium tetrakistriphenylphosphine
RT or rt	room temperature
TBAB	tetrabutylammonium bromide
TBSOTf	*t*-butyldimethylsilyl trifluoromethane sulfonate
Et_3N	triethylamine
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TLC	thin layer chromatography

Reaction Scheme AA


Scheme AA illustrates a general synthesis of benzimidazoles of formula AA5, representative of a compound of Formula (I).



Typically, a solution of 4-bromobenzene-1,2-diamine **AA1** and a suitable carboxylic acid **AA2** in phosphorous oxychloride ($POCl_3$) is heated at reflux to obtain bromobenzimidazole **AA3**.

Alternatively, the acid can be converted to an acid chloride using oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride.


The acid chloride **AA2** is heated with 4-bromobenzene-1,2-diamine **AA1** in acetic acid to give **AA3**. A suitably substituted phenyl group can be appended to **AA3** by a variety of coupling reactions (Suzuki, Stille) that are well known to those versed in the art. A particularly useful substitution method employs a palladium catalyzed cross-coupling Suzuki reaction (Huff, B. *et. al. Org. Syn.* 1997, 75: 53-60; and, Goodson, F. E. et. al. *Org. Synth.* 1997, 75: 61-68).



As an example, a mixture of bromobenzimidazole **AA3** is reacted with a suitable phenyl boronic acid **AA4** in the presence of a reagent such as cesium carbonate and a catalytic amount of a palladium catalyst such as $PdCl_2dppf$ in a solvent such as a mixture of dioxane and ethanol at elevated temperatures to give **AA5**. The reaction times can be reduced by carrying out this procedure at similar (about 100 °C) or lower temperatures in a microwave synthesizer. Other palladium catalysts suitable for this type of reaction include $Pd(PPh_3)_4$.


Reaction Scheme BB

Cinnamic acids, as required, can be synthesized via procedures described in reaction Scheme BB.



BB1 BB2

A solution of arylaldehyde **BB1** and (carbethoxymethylene)triphenyl phosphorane in a solvent such as toluene or benzene in the presence of a base such as NaOH is stirred usually at elevated temperatures to give the corresponding cinnamate ester. The ester is hydrolyzed under standard conditions to provide the corresponding cinnamic acid **BB2**.




BB3

Phenylpropionic acid **BB3**, as required, can be synthesized from cinnamic acid **BB2** by hydrogenation using a variety of standard procedures. As shown above, a mixture of **BB2** in ethanol with a catalytic amount of palladium on carbon (10 %) is stirred at room temperature in an atmosphere of hydrogen (50 psi) to provide acid **BB3**.


Reaction Scheme BB'

Reaction Scheme BB' is a variation of Reaction Scheme BB.



BB1 BB2


Reaction of aldehyde **BB1** with malonic acid and a catalytic amount of piperidine in pyridine at elevated temperatures produces cinnamic acid **BB2** in high yield.




Acid **BB2** is converted to the acid chloride by reaction with oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride. The acid chloride is then heated with **AA1** in acetic acid to give **BB'1**, which is further elaborated in place of **AA3** as described in reaction Scheme AA.

Reaction Scheme CC

Reaction Scheme CC provides a method to prepare substituted 4-bromobenzene-1,2-diamine intermediates.




As an example, to a solution of a suitably substituted 4-bromoaniline **CC1** in trifluoroacetic anhydride is added KNO_3 portionwise at a suitable temperature. The reaction mixture may then be warmed to room temperature for optimal conversion to nitroamide **CC2**.



Sequentially, using standard procedures, the amide is hydrolyzed and the nitro group is reduced to give bromodiamine **CC3**. Intermediate **CC3** is further elaborated as described in reaction Scheme AA.


Reaction Scheme DD

An alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme DD.



A substituted bromobenzimidazole **DD1** (representative of **AA3** in Scheme AA) is protected (using a protecting group such as Boc), then converted to a pinicolboronate ester **DD2** under standard Suzuki coupling conditions (Prieto, M. *et. al., J. Org. Chem.* 2004, 69: 6812-6820; McDonald, D. *et. al., Bioorg. Med. Chem. Lett.* 2005, 15: 5241-5246; and, Poon, S. F. *et. al. Bioorg. Med. Chem. Lett.* 2004, 14, 5477-5480).

In a typical procedure, a mixture of bromo-benzimidazole **DD1**, bis-(pinacolato)diboron, potassium carbonate and a catalytic amount of a palladium catalyst such as $PdCl_2$dppf in DMF is heated at elevated temperatures to give boronate ester **DD2**. Frequently, the reaction durations can be reduced by carrying out this procedure at similar or lower temperatures in a microwave irradiation apparatus.




Boronate ester **DD2** can be converted to compounds of the present invention (Boc protected **DD3**) by Suzuki coupling with a phenyl halide, mesylate or triflate $(R_1)_pPh$-X. In this instance, borane **DD2** is reacted with a suitable aryl halide, tetrakis (triphenylphosphine) palladium (0) and tri-tert-butylphosphonium

tetrafluoroborate in 2M aqueous potassium carbonate in toluene at 100 °C to give the protected form of **DD3**. Deprotection with an acid such as TFA gives **DD3**.

Reaction Scheme EE

Reaction Scheme EE describes methods to prepare representative compounds of the present invention.




Aniline **EE1** can be converted to a variety of amides, carbamates or ureas **EE2** by utilizing any number of acylation methods that are commonly used by persons versed in the art. As an example, reaction of **EE1** in a solvent such as THF with a substituted acid chloride and a base such as triethylamine gives the corresponding amide of **EE2**. As a further example, reaction of **EE1** in THF with a substituted chloroformate and triethylamine gives the corresponding substituted carbamate of **EE2**.

EE1 can be converted to sulfonamides by utilizing various sulfonylation conditions. For instance, reaction of **EE1** in a solvent such as THF with an alkylsulfonyl chloride and triethylamine gives the alkylsulfonamide **EE3**. **EE1** can be selectively, and successively substituted to give **EE3**. An efficient method of achieving this is via reductive alkylation with aldehydes or ketones (see Mattson, R. J. *et. al. J. Org. Chem.* 1990, 55, 2552-2554) and references cited therein]. In

this procedure, equal amounts of **EE1** and an aldehyde or ketone are stirred with titanium (IV) isopropoxide, followed the addition of sodium cyanoborohydride in a solvent such as ethanol to give substituted amine **EE3**.

Reaction Scheme FF


A synthetic sequence to produce compounds of the present invention wherein L is cyclopropyl is described in reaction Scheme **FF**.



Reaction of cinnamate ester **FF1**, in this case a methyl ester, with trimethylsulfonium iodide methylide in a solvent such as DMSO and sodium hydride (as exemplified by Burger, A. *et. al. J. Med. Chem.* 1970, 13, 33-35), gives cyclopropyl ester **FF2**. Hydrolysis of **FF2** gives acid **FF3**, which is further elaborated into the benzimidazoles described in Scheme AA.

Reaction Scheme GG

Reaction Scheme GG describes an alternative method to prepare cyclopropyl acid intermediates.




Cinnamic acids are converted to the corresponding Weinreb amide, by conversion to the acid chloride as described in Reaction Scheme AA and BB'. The acid chloride is reacted with N,N-dimethylhydroxylamine hydrochloride and a base such as triethylamine in methylene chloride to give amide **GG2**.

Amide **GG2** is converted to cyclopropyl amide **GG3** as described in Scheme FF. The amide **GG3** is then hydrolyzed to give acid **GG4**, typically by reaction with potassium tertiary butoxide in THF.

Reaction Scheme HH


A synthetic sequence to produce compounds of the present invention wherein R_1Ar is benzenesulfonamide is described in reaction Scheme HH.



Coupling by Suzuki reaction of boronate ester **DD2** from reaction Scheme DD and bromobenzene-t-butylsulfonamide **HH1** followed by deprotection with TFA gives the product **HH2**.

Reaction Scheme II


A synthetic sequence to produce compounds of the present invention wherein R is an ether group is described in reaction Scheme **II**.



An ester of commercially available 4-hydroxycinnamic acid **II1** can be converted to ether analogs by a number of routes including the Williamson reaction. In this well-known procedure, **II1** and an alkyl halide is reacted with a base such as cesium carbonate in a solvent such as acetonitrile to give the product **II2**.

More effective electrophiles can be derivatives of alcohols such as mesylates, p-toluene sulfonates or trifluoromethanesulfonates (triflates). An


effective alternative method is the conversion of **II1** to ether analogs **II2** via the Mitsunobu reaction (as reviewed by Mitsunobu, O., *Synthesis*, 1981, 1-28).



Ether analogs **II2** can be further reduced to acid **II3** using standard techniques.

Reaction Scheme JJ

Reaction Scheme JJ describes methods to prepare cinnamic acids that contain substituted amino groups.




Cinnamate ester **JJ1** can be converted to a variety of amides, carbamates or ureas **JJ2** by utilizing any number of acylation methods that are commonly used by persons versed in the art. As an example, reaction of **JJ1** in a solvent such as THF with a substituted acid chloride and a base such as triethylamine gives the corresponding amide of **JJ2**. As a further example, reaction of **JJ1** in THF with a substituted chloroformate and triethylamine gives the corresponding substituted carbamate of **JJ2**. **JJ1** can be converted to sulfonamides by utilizing various sulfonylation conditions.

For instance, reaction of **JJ1** in a solvent such as THF with an alkylsulfonyl chloride and triethylamine gives the alkylsulfonamide **JJ3**. **JJ1** can be selectively,

and successively substituted to give **JJ4**. An efficient method of substitution is via reductive alkylation with aldehydes or ketones (see Mattson, R. J. *et. al. J. Org. Chem.*, 1990, 55, 2552-2554 and references cited therein). In this procedure, equal amounts of **JJ1** and an aldehyde or ketone are stirred with titanium (IV) isopropoxide, followed the addition of sodium cyanoborohydride in a solvent such as ethanol to give substituted amine **JJ4**.


Reaction Scheme KK

A synthetic sequence to prepare compounds of the present invention wherein L is acetylene is described in Reaction Scheme KK.




KK1 KK2

When not commercially available, propiolic acids **KK2** are prepared by reaction of acetylenes **KK1** with n-butyl lithium in THF at –78 °C warming to 0 °C for 30 min. The mixture is cooled to –78 °C, and transferred to a saturated solution of carbon dioxide in THF at –78 °C. The reaction is slowly warmed to rt to give the corresponding propiolic acid **KK2**.




Reaction of the propiolic acid **KK2** with 4-bromobenzene-1,2-diamine dihydrochloride **KK3** in refluxing ethylene glycol gives chlorovinylbenzimidazole **KK4**.




Reaction of **KK3** with a phenyl boronic acid under Suzuki conditions in a microwave synthesizer and thermal conditions as described in Reaction Scheme AA gives acetylene compounds **KK4**.

Reaction Scheme LL

An alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme LL.




Protected bromodiamine **LL1** is coupled with a suitable boronic acid via Suzuki coupling as described in previous reaction schemes to give the diamine **LL2**.




LL2 is then reacted with an acid or acid chloride to give **LL3** (as described in reaction Schemes AA or BB').

Reaction Scheme MM


A synthetic sequence to produce compounds of the present invention wherein L is vinyl or ethyl that may be used as an alternative to Scheme BB' is described in reaction Scheme MM.



A solution of **AA1** and dichloroimine **MM1** (as described in McElvain, S. M. *et. al. J. Am. Chem. Soc.* 1942, 64, 1825) in ethanol is heated to give chloromethyl benzimidazole **MM2** (as described in Komoriya et. al. *Bioorg. Med. Chem.*, 2004, 12, 2099-2114).




Heating in dichloroethane with triphenylphosphine converts **MM2** to the phosphonium salt **MM3**.




Reaction of **MM3** with various aldehydes or ketones in a solution of anhydrous THF and EtOH with a base such as DBU (1,8-diazabicyclo[4.5.0]undec-7-ene) gives bromobenzimidazole **BB'1**, which is further elaborated as described in reaction Scheme AA.

Reaction Scheme NN

An alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme NN.




The biaryldiamine **LL2** is reacted with dichloroimine **MM1** as described in reaction Scheme MM to give **NN1**.



As described in reaction Scheme MM, **NN1** is carried forward to give **NN2**.

Reaction Scheme OO


Compounds of the present invention wherein L is ethylene can be prepared by the alternate route described in Reaction Scheme OO.



Compounds of the present invention such as **NN3**, wherein L is vinyl, are dissolved in a solvent such as methanol, and are hydrogenated using a catalyst such as 10 % Pd on carbon to give **OO1**.

Reaction Scheme PP


A synthetic sequence to produce compounds of the present invention wherein L is cyclopropyl is described in reaction Scheme PP.



Reaction of olefin **PP1** with an alkyl diazoacetate, such as ethyl diazoacetate, in the presence of a catalyst, such as copper(I)trifluoromethane sulfonate and Evans' chiral ligand (Evans, D.A.; Woerpel, K.A.; Hinman, M.M.; Faul, M.M. *J.Am. Chem. Soc.* **1991**, 113, 726-728) in a solvent such as chloroform, gives a cyclopropyl ester enantiomer **PP2**.

The (R,R)-cyclopropyl ester **PP2** enantiomer is obtained when a chiral ligand such as 2,2-bis-[2-((4S)-(1,1-dimethylethyl)-1,3-oxazolinyl)]propane

Compound **38b** is used. The (S,S)-cyclopropyl ester enantiomer is obtained when the chiral ligand 2,2-bis-[2-((4R)-(1,1-dimethylethyl)-1,3-oxazolinyl)]propane Compound **38a** is used. The configurations of the cyclopropyl moiety were predicted based on Evans' *J.Am. Chem. Soc.* **1991** report. Hydrolysis of the ester **PP2** gives acid **PP3**, which is further elaborated into the benzimidazoles of Scheme AA.




PP4

To determine the enantiomeric excess of the asymmetric cyclopropanation products **PP2**, acid **PP3** is reacted with N,O-dimethylhydroxyl amine in the presence of a base such as diisopropylethylamine, and an amide coupling reagent such as BOP, in a solvent such as DMF to produce the methoxy methyl amide **PP4**.


The resulting ^{1}H NMR of amide **PP4** in the presence of an appropriate amount of chiral shifting agent, such as (R)-(-)-2,2,2-trifluoro-1-(9-anthryl)ethanol, gives base line resolution of the resulting methoxy singlets. The ratio of the integration of the methoxy singlets gives the ee value. Thus, the NMR showed methoxy singlets around 3.47 and 3.45 ppm. The integration of the singlets was 1 and 99, respectively; thus providing an ee value of 99%.

Reaction Scheme QQ


A synthetic sequence to produce compounds of the present invention wherein R_1 is an alcohol is described in reaction Scheme QQ.



As elaborated in Scheme **BB'**, the aldehyde **QQ1** is reacted with malonic acid and a catalytic amount of piperidine in pyridine at elevated temperatures to provide an acid **QQ2**. Acid **QQ2** is converted to an acid chloride **QQ3** by reaction with oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride.



As elaborated in Scheme **AA**, the acid chloride **QQ3** is heated with 4-bromobenzene-1,2-diamine **AA1** in acetic acid to give a bromobenzimidazole **QQ4**.



As elaborated in Scheme **AA**, a suitably substituted phenyl boronic acid is reacted with benzimidazole **QQ4** in the presence of a reagent and a catalytic amount of a palladium catalyst in a solvent to give an alcohol substituted benzimidazole **QQ5**, representative of a compound of Formula (I).

Example 1

(*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone (Cpd **1**)

Step A. (*E*)-5-bromo-2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazole

To a solution of 3-(4-tert-butyl-phenyl)-acrylic acid (12 g, 58.7 mmol) in $POCl_3$ (200 mL), was slowly added 4-bromo-benzene-1,2-diamine (10g, 53.4 mmol). The solution was heated at reflux for 18 h. The solution was

concentrated, and the residual $POCl_3$ was azeotropically removed with toluene. The residue was partitioned between EtOAc and 10% Na_2CO_3. The organic layer was washed with brine, dried over Na_2SO_4, filtered, and the filtrate was concentrated. The residue was purified by chromatography (silica, EtOAc: hexanes, 3:7) to give the title Compound **1a** (7.1 g, 31% yield). ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm): 7.64 (d, 1H, J=13.9 Hz) 7.62 (s, 1H) 7.41 (d, 2H, J=8.4 Hz) 7.36 (d, 1H, J=8.5 Hz) 7.33 (d, 2H, J=8.4 Hz) 7.28 (s, 1H) 7.22 (dd, 1H, J=1.8 Hz, J=8.5 Hz) 7.02 (d, 1H, J=16.5 Hz) 1.25 (s, 9H).

Step B. (*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone

A solution of Compound **1a** (0.106 g, 0.30 mmol), 2-acetylbenzeneboronic acid (136 mg; 0.76 mmol), $PdCl_2$dppf (0.06 mmol) and Cs_2CO_3 (0.244 g, 0.75 mmol) in 1,4-dioxane: EtOH 5:1 was heated to 115 °C. After 18 h, the solution was cooled and concentrated. The residue was purified using preparative TLC plates (silica gel, 20 X 20 cm, 2000 microns, EtOAc:hexanes 3:7) to give the title Compound **1** (0.0146 g). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.54 (m, 11H) 7.23 (dd, 1H, J=1.6 Hz, J=8.3 Hz) 7.15 (d, 1H, J=16.5 Hz) 2.02 (s, 3H) 1.36 (s, 9H). MS (ESI, pos. ion) *m/z*: 395.3 (M+1).

Using the procedures described in Example 1 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
3	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol The title compound (0.0048 g) was prepared from 2-hydroxybenzeneboronic acid (0.0345 g, 0.25 mmol) and Compound **1a** (0.029 g, 0.1 mmol). ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm): 7.56 (s, 1H) 7.31 (dd, 2H, J=12.2 Hz, J=24.1 Hz) 7.10 (m, 8H) 6.86 (t, 1H, J=7.3 Hz) 6.78 (d, 1H, J=16.4 Hz) 1.19 (s, 9H). MS (ESI, pos. ion) *m/z*: 368.3 (M+1).

Cpd	Name and Data
4	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide The title compound (0.001 g) was prepared from 2-N-acetyl-benzeneboronic acid (0.136 g, 0.76 mmol) and Compound **1a** (0.106 g, 0.3 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.44 (m, 4H) 7.24 (m, 6H) 6.91 (d, 1H, J=12.4 Hz) 6.47 (d, 1H, J=12.4 Hz) 1.86 (s, 1H) 1.20 (s, 9H). MS (ESI, pos. ion) *m/z*: 410.2 (M+1).
5	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide The title compound (0.001 g) was prepared from 2-aminocarbonyl benzeneboronic acid (0.136 g, 0.76 mmol) and Compound **1a** (0.106 g, 0.3 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.48 (m, 6H) 7.37 (m, 5H) 7.26 (dd, 1H, J=1.6 Hz, J=8.3 Hz) 7.04 (d, 1H, J=16.5 Hz) 1.26 (s, 9H). MS (ESI, pos. ion) *m/z*: 396.1 (M+1).
6	(*E*)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide The title compound (0.001 g) was prepared from 3-aminocarbonylbenzene boronic acid (0.136 g, 0.76 mmol) and Compound **1a** (0.106 g, 0.3 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 8.22 (t, 1H, J=1.7 Hz) 7.88 (m, 3H) 7.62 (m, 6H) 7.51 (m, 2H) 7.17 (d, 1H, J=16.5 Hz) 1.38 (s, 9H). MS (ESI, pos. ion) *m/z*: 396.1 (M+1).
7	(*E*)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide The title compound (0.002 g) was prepared from 4-aminocarbonylbenzene boronic acid (0.136 g, 0.76 mmol) and Compound **1a** (0.106 g, 0.3 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.97 (m, 2H) 7.77 (m, 4H) 7.60 (m, 4H) 7.47 (d, 2H, J=8.4 Hz) 7.13 (d, 1H, J=16.5 Hz) 1.36 (s, 9H). MS (ESI, pos. ion) *m/z*: 410.2 (M+1).
8	(*E*)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide The title compound 0.0038 g) was prepared from 4-N-acetylbenzeneboronic acid (0.136 g, 0.76 mmol) and Compound **1a** (0.106 g, 0.3 mmol) to give the title compound (0.0038 g). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.73 (m, 2H) 7.61 (m, 7H) 7.49 (m, 3H) 7.12 (d, 1H, J=16.5 Hz) 2.17 (s, 3H) 1.36 (s, 9H). MS (ESI, pos. ion) *m/z*: 410.2 (M+1).
9	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide The title compound (0.0045 g) was prepared from 2-methanesulfonamide benzeneboronic acid (0.163 g, 0.76 mmol) and Compound **1a** (0.106 g, 0.3 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.62 (m, 6H) 7.50 (d, 2H, J=8.5 Hz) 7.41 (m, 2H) 7.34 (m, 2H) 7.17 (d, 1H, J=16.5 Hz) 2.75 (s, 3H) 1.37 (s, 9H). MS (ESI, pos. ion) *m/z*: 446.2 (M+1).

Cpd	Name and Data
10	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester The title compound (0.0016 g) was prepared from 2-N-Boc-benzeneboronic acid (0.180 g, 0.76 mmol) and (*E*)-5-bromo-2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-aminobenzimidazole Compound 1b (0.106 g, 0.3 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.62 (m, 5H) 7.50 (m, 2H) 7.33 (dd, 1H, J=1.6 Hz, J=8.3 Hz) 7.14 (m, 3H) 6.83 (m, 2H) 3.37 (s, 9H) 1.37 (s, 9H). MS (ESI, pos. ion) *m/z*: 468.1 (M+1).
11	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine A solution of (*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester (0.005 g, 0.01 mmol) in methylene chloride (1 mL) was treated with trifluoroacetic acid (0.5 mL). The solution was stirred at room temperature for 4 h, then concentrated to give the title compound (0.003 g). ^{1}H-NMR (400 MHz ,CD_3OD) δ (ppm) 8.03 (d, 1H, J=16.5 Hz) 7.90 (d, 1H, J=8.5 Hz) 7.85 (s, 1H) 7.74 (d, 2H, J=8.4 Hz) 7.65 (dd, 1H, J=1.5 Hz, J=8.5 Hz) 7.59 (d, 2H, J=8.4 Hz) 7.43 (m, 5H) 1.39 (s, 9H). MS (ESI, pos. ion) *m/z*: 368.1 (M+1).
12	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol The title compound (0.0046 g) was prepared from 2-hydroxymethylbenzene boronic acid (0.102 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.59 (m, 5H) 7.49 (d, 2H, J=8.4 Hz) 7.40 (m, 2H) 7.34 (m, 2H) 7.27 (dd, 1H, J=1.6 Hz, J=8.3 Hz) 7.16 (d, 1H, J=16.6 Hz) 4.58 (s, 2H) 1.37 (s, 9H). MS (ESI, pos. ion) *m/z*: 383.2 (M+1).
24	(*E*)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide Using the procedure of Example 1, Step B, the title compound (0.001 g) was prepared from 2-N-acetylbenzeneboronic acid (0.136 g, 0.76 mmol) and (*E*)-5-bromo-2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazole Compound **1c** (0.10 g, 0.30 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.61 (m, 5H) 7.39 (m, 6H) 7.18 (d, 1H, J=16.5 Hz) 1.99 (s, 3H). MS (ESI, pos. ion) *m/z*: 390.2 (M+1).
25	(*E*)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide The title compound (0.0102 g) was prepared from 3-N-acetylbenzeneboronic acid (0.136 g, 0.76 mmol) and Compound **1c** (0.10 g, 0.30 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.78 (d, 1H, J=0.9 Hz) 7.63 (s, 1H) 7.44 (m, 5H) 7.26 (m, 4H) 7.01 (d, 1H, J=16.5 Hz) 2.06 (s, 3H). MS (ESI, pos. ion) *m/z*: 390.1 (M+1).

Cpd	Name and Data
26	(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide The title compound (0.0031 g) was prepared from 2-aminocarbonylbenzene boronic acid (0.125 g, 0.76 mmol) and Compound **1c** (0.10 g, 0.30 mmol). ^{1}H-NMR (400 MHz, $CDCl_3$ + CD_3OD) δ (ppm) 7.62 (s, 1H) 7.40 (m, 9H) 7.18 (td, 1H, J=8.4 Hz, J=10.1 Hz) 7.01 (d, 1H, J=16.5 Hz). MS (ESI, pos. ion) *m/z*: 376.2 (M+1).
27	(*E*)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone The title compound (0.001 g) was prepared from 2-acetylbenzeneboronic acid (0.125 g, 0.76 mmol) and Compound **1c** (0.10 g, 0.30 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.49 (m, 5H) 7.37 (m, 4H) 7.23 (td, 1H, J=8.4 Hz, J=10.3 Hz) 7.14 (dd, 1H, J=1.7 Hz, J=8.3 Hz) 7.06 (d, 1H, J=16.5 Hz) 1.91 (s, 3H). MS (ESI, pos. ion) *m/z*: 375.2 (M+1).
28	(*E*)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide The title compound (0.0021 g) was prepared from 2-methylsulfonylamino benzeneboronic acid (0.163 g, 0.76 mmol) and Compound **1c** (0.10 g, 0.30 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.50 (m, 5H) 7.36 (m, 1H) 7.26 (m, 5H) 7.07 (d, 1H, J=16.5 Hz) 2.64 (s, 3H). MS (ESI, pos. ion) *m/z*: 426.1 (M+1).
30	(*E*)-2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole The title compound (0.0182 g) was prepared from 3-methylphenylbenzene boronic acid (0.052 g, 0.38 mmol) and 5-bromo-2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazole Compound **5a** (0.055 g, 0.15 mmol). ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm) 7.33 (m, 3H) 7.18 (m, 5H) 7.03 (d, 1H, J=7.4 Hz) 6.95 (d, 2H, J=8.3 Hz) 2.85 (m, 2H) 2.57 (t, 2H, J=7.5 Hz) 2.30 (s, 3H) 2.06 (m, 2H) 1.17 (s, 9H). MS (ESI, pos. ion) *m/z*: 383.2 (M+1).

Example 2

(*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol (Cpd **2**)

A solution of (*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone Cpd **1** (0.005 g, 0.01 mmol) in ethanol (0.5 mL) was treated with $NaBH_4$ (0.003 g, 0.08 mmol). After 3 h, the reaction mixture was applied to a preparative TLC plate (2000 microns, silica gel, 20 x 20) and developed using EtOAc: hexanes, 1:1. The desired band was extracted and concentrated to give the title compound (0.002 g). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.69 (m, 1H) 7.62 (m, 3H) 7.50 (m, 3H) 7.41 (ddd, 2H, J=2.5 Hz, J=10.1 Hz, J=14.1 Hz) 7.32 (dt, 1H, J=1.4 Hz, J=7.5 Hz) 7.23 (m, 2H) 7.17 (d, 1H, J=16.5 Hz) 4.99 (q, 1H,

J=6.3 Hz) 1.38 (s, 9H) 1.35 (d, 1.5H, J=6.1 Hz) 1.33 (d, 1.5H, J=6.1 Hz). MS (ESI, pos. ion) *m/z*: 397.2 (M+1).

Example 3

(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide (Cpd **13**)

Step A. (*E*)-5-bromo-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole

Using the procedure of Example 1, Step A, the title Compound **10c** (0.910 g) was prepared from 3-(4-trifluoromethyl-phenyl)-acrylic acid Compound **10a** (1.5 g, 6.9 mmol) and 4-bromo-benzene-1,2-diamine (1.3 g, 6.9 mmol). ^{1}H-NMR (400 MHz, $CDCl_3$ + DMSO(d6)) δ(ppm) 7.78 (d, 1H, J=16.5 Hz) 7.73 (d, 1H, J=1.7 Hz) 7.66 (m, 4H) 7.48 (d, 2H, J=8.0 Hz) 7.33 (dd, 1H, J=1.8 Hz, J=8.5 Hz) 7.23 (d, 1H, J=16.5 Hz).

Step B. (*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide

Using the procedure of Example 1, Step B, the title compound (0.001 g) was prepared from 2-carboxamidophenylbenzeneboronic acid (0.120 g, 0.76 mmol) and Compound **10c** (0.110 g, 0.30 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.74 (d, 2H, J=8.2 Hz) 7.63 (m, 3H) 7.57 (s, 1H) 7.40 (m, 6H) 7.22 (d, 1H, J=16.5 Hz). MS (ESI, pos. ion) *m/z*: 408.1 (M+1).

Using the procedures described in Example 3 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
14	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol The title compound (0.001 g) was prepared from 2-hydroxybenzeneboronic acid (0.105 g, 0.38 mmol) and Compound **10c** (0.110 g, 0.30 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.74 (d, 2H, J=8.3 Hz) 7.63 (dd, 3H, J=8.7 Hz, J=17.1 Hz) 7.56 (s, 1H) 7.50 (d, 1H, J=8.3 Hz) 7.38 (dd, 1H, J=1.5 Hz, J=8.4 Hz) 7.22 (m, 2H) 7.06 (m, 1H) 6.82 (m, 2H). MS (ESI, pos. ion) *m/z*: 381.3 (M+1).

Cpd	Name and Data
15	(*E*)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone The title compound (0.001 g) was prepared from 2-acetylbenzeneboronic acid (0.125 g, 0.76 mmol) and Compound **10c** (0.110 g, 0.30 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.75 (d, 2H, J=8.2 Hz) 7.60 (m, 4H) 7.48 (m, 2H) 7.38 (m, 3H) 7.23 (d, 1H, J=16.6 Hz) 7.16 (dd, 1H, J=1.7 Hz, J=8.3 Hz) 1.92 (s, 3H). MS (ESI, pos. ion) *m/z*: 407.3 (M+1).
16	(*E*)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol A solution of (*E*)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone Compound **15** (0.005 g, 0.01 mmol) in ethanol (0.5 mL) was treated with $NaBH_4$ (0.003 g, 0.08 mmol). After 3 h, the solution was applied to a preparative TLC plate (2000 microns, silica gel, 20 x 20) and developed using EtOAc: hexanes, 1:1. The desired band was extracted and concentrated to give the title compound (0.001 g). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.87 (d, 1H, J=8.2 Hz) 7.76 (d, 1H, J=8.0 Hz) 7.67 (m, 1H) 7.51 (s, 1H) 7.42 (m, 1H) 7.32 (m, 1H) 7.25 (m, 1H) 4.98 (q, 1H, J=6.4 Hz) 1.35 (d, 1H, J=6.4 Hz). MS (ESI, pos. ion) *m/z*: 409.2 (M+1).
17	(*E*)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide The title compound (0094 g) was prepared from 2-methylsulfonyl aminobenzeneboronic acid (0.163 g, 0.76 mmol) and Compound **10c** (0.110 g, 0.30 mmol). ^{1}H-NMR (400 MHz, DMSO(d6)) δ (ppm) 12.82 (s, 1H) 8.89 (s, 1H) 7.91 (d, 2H, J=8.1 Hz) 7.80 (m, 2H) 7.75 (s, 1H) 7.70 (m, 1H) 7.58 (d, 1H, J=6.9 Hz) 7.37 (m, 6H) 2.73 (d, 3H, J= 28.8Hz). MS (ESI, pos. ion) *m/z*: 458.2 (M+1).
31	N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide Using the procedure of Example 1, Step A., 5-bromo-2-[2-(4-trifluoroethyl-phenyl)-ethyl]-1H-benzimidazole Compound **3b** was prepared from 3-(4-trifluoromethyl-phenyl)-propionic acid (1.04 g, 5.04 mmol) and 4-bromo-benzene-1,2-diamine (0.946 g, 5.06 mmol). Using the procedure of Example 1, Step B., the title compound was prepared from 2-methylsulfonylaminobenzeneboronic acid (0.367 g, 1.7 mmol) and Compound **3b** (0.188 g , 0.51 mmol). ^{1}H-NMR (400 MHz, (CD_3OD) δ (ppm) 7.64-7.50 (m, 5H), 7.47-7.34 (m, 4H), 7.34-7.27 (m, 2H), 3.27 (s, 4H), 2.71 (s, 3H). MS (ESI, pos. ion) *m/z*: 460.16 (M+1).

Example 4

(*E*)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide (Cpd **19**)

Step A. 3-(4-trifluoromethoxy-phenyl)-acrylic acid

A solution of 4-trifluoromethoxybenzaldehyde (26.3 mmol), malonic acid (5.6 g, 53.8 mmol) and piperidine (0.265 mL, 2.7 mmol) in pyridine (15 mL) was heated to 70 ^{0}C for 18 h. Water (200 mL) was added to the reaction solution. The mixture was acidified to pH 4 using concentrated hydrochloric acid. The solution was filtered. The solid was washed with water. The solid was dried *in vacuo* to give the title Compound **4a** (1.2 g). ^{1}H-NMR (d6-DMSO) δ (ppm): 6.80 (d, J = 16.02 Hz, 1H), 6.72 (m, 2H), 6.38 (m, 2H), 5.55 (d, J = 16.00 Hz, 1H).

Step B. 3-(4-trifluoromethoxy-phenyl)-acryloyl chloride

A solution of Compound **4a** (1.2 g, 5.2 mmol) in methylene chloride (20 mL) was treated with oxalyl chloride (7.8 mL, 3.6 mmol). To the solution was added DMF (0.02 mL). The reaction solution was stirred at room temperature for 2 h. The reaction solution was concentrated. The residue was dried *in vacuo* to provide Compound **4b**, which was used without further purification in the next step.

Step C. (*E*)-5-bromo-2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazole

A solution of Compound **4b** (1g, 4 mmol) in acetic acid (10 mL) was added slowly to a solution of 4-bromo-benzene-1,2-diamine (0.744g, 4 mmol) in acetic acid (10 mL). The solution was heated to 100 ^{0}C for 18 h. The solution was cooled to room temperature. To the solution was added ethyl acetate :hexanes 3:7 (100 mL). The solution was filtered. The solid was dried *in vacuo* to give the title Compound **4c** (1.1 g). ^{1}H-NMR (400 MHz, DMSO d6) ppm 8.12 (d, J = 16.60 Hz, 1H), 7.98 (m, 1H), 7.87 (m, 2H), 7.82-7.68 (m, 1H), 7.67-7.37 (m, 4H), 7.34 (d, J = 16.58 Hz, 1H). MS (ESI pos. ion) *m/z*: 383.2 and 385.2.

Step D. (*E*)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide

Using the procedure of Example 1, Step B, the title Compound 19 was prepared from 2-carboxamido-phenylbenzene boronic acid and Compound **4c**.

Using the procedures described in Example 4 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
20	(*E*)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone The title compound (0.001 g) was prepared from 2-acetylbenzeneboronic acid (0.280 g, 1.7 mmol) and Compound **4c** (0.195 g, 0.51 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.66 (d, *J* = 8.72 Hz, 2H), 7.61-7.43 (m, 4H), 7.43-7.32 (m, 3H), 7.24 (d, *J* = 8.19 Hz, 2H), 7.19-7.06 (m, 2H), 1.96-1.86 (m, 3H). MS (ESI, pos. ion) *m/z*: 423.14 (M+1).
21	(*E*)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol Using the procedure of Example 2, the title compound was prepared from Compound **20**. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.76-7.80 (d, J=8.84Hz, 2H) 7.60-7.70 (m, 3H) 7.50 (bs, 1H) 7.40-7.44 (ddd, J=1.26, 7.32Hz, 1H) 7.29-7.37 (m, 3H) 7.20-7.25 (m, 3H) 4.96-5.02 (q, J= 6.57Hz, 1H) 1.34-1.36 (d, J=6.32Hz, 3H). MS (ESI, pos. ion) m/z: 425.2 (M+1).
22	(*E*)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide The title compound (0.05 g) was prepared from 2-methylsulfonyl aminobenzeneboronic acid (0.521 g, 2.4 mmol) and Compound **4c** (0.463 g, 1.2 mmol). ^{1}H-NMR (400 MHz, DMSO(d6)) δ (ppm) 12.76 (d, J = 5.43 Hz, 1H), 8.90 (d, J = 4.68 Hz, 1H), 7.83 (d, J = 8.72 Hz, 2H), 7.65 (m, 1H), 7.50-7.22 (m, 8H), 2.76 (s, 1.5H), 2.69 (s, 1.5H). MS (ESI, pos. ion) *m/z*: 474.2 (M+1).

Example 5

2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol (Cpd **29**)

Step A. 5-bromo-2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazole

Using the procedure of Example 1, Step A, the title Compound **5a** (0.512 g) was prepared from 4-(4-tert-butyl-phenyl)-butyric acid (2.0 g, 10.7 mmol) and 4-bromo-benzene-1,2-diamine (2.0 g, 10.7 mmol). ^{1}H-NMR (400 MHz, $CDCl_3$) δ(ppm) 7.73 (d, 1H, J=1.6 Hz) 7.45 (d, 1H, J=8.5 Hz) 7.38 (dd, 1H, J=1.8Hz, J=8.5Hz) 7.32 (m, 3H) 7.12 (d, 2H, J=8.3 Hz) 2.97 (m, 2H) 2.73 (t, 2H, J=7.4 Hz) 2.23 (m, 2H) 1.33 (s, 9H).

Step B. 2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol

Using the procedure outlined in Example 1, Step B, the title Compound **29** (0.0083 g) was prepared from 2-hydroxybenzeneboronic acid (0.07 g, 0.5 mmol) and Compound **5a** (0.074 g, 0.2 mmol). ^{1}H-NMR (400 MHz,$CDCl_3$) δ (ppm) 7.51 (s, 1H) 7.39 (d, 1H, J=8.1 Hz) 7.16 (m, 6H) 6.95 (d, 3H, J=8.2 Hz) 6.88 (t, 1H, J=7.4 Hz) 2.73 (t, 2H, J=7.5 Hz) 2.52 (t, 2H, J=7.3 Hz) 2.00 (m, 2H) 1.20 (s, 9H). MS (ESI, pos. ion) *m/z*: 385.3 (M+1).

Example 6

2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol (Cpd **32**)

Step A. 3-(4-tert-butyl-phenyl)-propionic acid

A mixture of 3-(4-tert-butyl-phenyl)-acrylic acid (12.28 g, 60.1 mmol) and 10% palladium on carbon (0.6 g) in ethanol was hydrogenated at 50 psi hydrogen for 2 hours. The reaction mixture was filtered over a pad of celite, a nylon disk, and the solvents were removed *in vacuo* to yield the title Compound **6a** (12.36 g, 59.9 mmol) as a white crystalline powder. ^{1}H-NMR (d6-DMSO) δ (ppm): 12.10 (s, 1H), 7.29 (d, 2H), 7.12 (d, 2H), 2.88 (t, 2H), 2.50 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion) *m/z*: 228.9 ($M+Na^{+}$).

Step B. 5-bromo-2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazole

To a solution of Compound **6a** (1.04 g, 5.04 mmol), in 25 mL of $POCl_3$ was added 4-bromo-benzene-1,2-diamine (0.946 g, 5.06 mmol). The reaction mixture was refluxed under a nitrogen atmosphere for 2.5 h then concentrated *in vacuo*. The residue was treated with 25 mL benzene and evaporated *in vacuo*. The residue was partitioned between 50 mL EtOAc and 50 mL saturated $NaHCO_3$. The organic fractions were washed with 50 mL of saturated $NaHCO_3$ and with 50 mL brine. The organic fraction was dried with Na_2SO_4, filtered and the filtrate was concentrated *in vacuo*. The residue was purified by chromatography (silica gel, EtOAc:Heptane, 2:8-4:6)) to yield the title Compound **6b** (0.726 g, 2.03 mmol) as a tan powder. ^{1}H-NMR (d6-DMSO) δ (ppm): 12.48-12.32 (m, 1H), 7.74-7.58 (m, 1H), 7.51-7.38 (m, 1H), 7.33-7.22 (m, 3H), 7.17 (d, 2H), 3.10 (m, 4H), 1.27 (s, 9H). MS (ESI pos. ion) *m/z*: 357.1/359.1 ($M+H^+$).

Step C. 2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol

A mixture of Compound **6b**, (0.036 g, 0.10 mmol), 2-hydroxy phenyl boronic acid (0.022 g, 0.16 mmol), Cs_2CO_3 (0.074 g, 0.23 mmol), and $PdCl_2$(dppf) (0.008 g, 0.01 mmol) in 2 mL 5:1 dioxane/EtOH in a sealed tube was heated at 100 °C for 15 minutes in a microwave synthesizer. More 2-hydroxy phenyl boronic acid (0.024 g, 0.17 mmol) and more $PdCl_2$(dppf) (0.010 g, 0.01 mmol) were added and the reaction was heated at 120 °C for 20 minutes. The reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fraction was evaporated, and the residue was purified by chromatography. (reverse-phase, acetonitrile:water + 0.1% TFA, 25:75-95:5). The relevant fractions were frozen and lyophilized to give the product Compound **32** (0.013 g, 0.04 mmol) as a tan powder. ^{1}H-NMR (d6-DMSO) δ (ppm): 14.55 (br s, 1H), 9.69 (s, 1H), 7.87 (s, 1H), 7.77 (d, 1H), 7.65 (d, 1H), 7.36-7.30 (m, 3H), 7.24-7.15 (m, 3H), 6.98 (d, 1H), 6.92 (t, 1H), 3.40 (t, 2H), 3.17 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion) *m/z*: 371.2 ($M+H^+$).

Using the procedures described in Example 6 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
33	3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol The title compound (0.016 g) was prepared from 3-hydroxy phenyl boronic acid (0.037 g) and Compound **6b** (0.036 g). ^{1}H-NMR (d6-DMSO) δ (ppm): 14.62 (br s, 1H), 9.62 (s, 1H), 7.88 (s, 1H), 7.81 (d, 1H), 7.71 (dd, 1H), 7.36-7.27 (m, 3H), 7.18 (d, 2H), 7.13 (d, 1H), 7.08 (t, 1H), 6.82 (dd, 1H), 3.40 (t, 2H), 3.16 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion): 371.2 ($M+H^+$).
34	4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol The title compound (0.022 g) was prepared from 4-hydroxy phenyl boronic acid (0.032 g) and Compound **6b** (0.036 g). ^{1}H-NMR (d6-DMSO) δ (ppm): 14.61 (br s, 1H), 9.65 (s, 1H), 7.85 (s, 1H), 7.78 (d, 1H), 7.71 (dd, 1H), 7.56 (d, 2H), 7.33 (d, 2H), 7.18 (d, 2H), 6.89 (d, 2H), 3.39 (t, 2H), 3.16 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion) *m/z*: 371.2 ($M+H^+$).

Example 7

(*E*)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol (Cpd **35**)

Step A. (*E*)-3-(4-trifluoromethylsulfanyl-phenyl)-acrylic acid ethyl ester

To a solution of 4-trifluoromethylsulfanyl-benzaldehyde (15.46 g, 75.0 mmol) in 350 mL of benzene was added (carbethoxymethylene)triphenyl-phosphorane (26.14 g, 75.0 mmol). The reaction mixture was refluxed under a nitrogen atmosphere for 6 hours. The solvents were removed *in vacuo* and the resulting material was triturated with 350 mL of diethyl ether and filtered. The filtrate was concentrated *in vacuo* and triturated once more with 50 mL diethyl ether and filtered. The filtrate was evaporated *in vacuo* and purified by chromatography (silica, EtOAc:heptane, 0:10-1:9) to obtain the title Compound **7a** (15.8 g, 57.3 mmol) as a white solid. ^{1}H-NMR (400MHz, d6-DMSO) δ (ppm): 7.89 (d, 2H), 7.75 (d, 2H), 7.70 (d, 1H), 6.77 (d, 1H), 4.21 (q, 2H), 1.27 (t, 3H). MS (ESI pos. ion) *m/z*: 277.0 ($M+H^+$).

Step B. (*E*)-3-(4-trifluoromethylsulfanyl-phenyl)-acrylic acid

To a solution of Compound **7a** (10.31 g, 37.3 mmol), in 300 mL of ethanol was added 3N aqueous NaOH solution (13.0 mL, 39.0 mmol). The reaction mixture was stirred for 21 hours, then evaporated *in vacuo*. The residue was dissolved in 250 mL water, and to it was added 1N aqueous HCl (45 mL, 45 mmol). The resulting precipitate was filtered, rinsed with water and dried under a stream of air to yield the title Compound **7b** (8.967 g, 36.1 mmol) as a white powder. ^{1}H-NMR (400M Hz, d6-DMSO) δ (ppm): 12.58 (s, 1H), 7.85 (d, 2H), 7.74 (d, 2H), 7.63 (d, 1H), 6.66 (d, 1H).

Step C. (*E*)-5-bromo-2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazole

To a suspension of Compound **7b** (1.240 g, 5.00 mmol) in 100 mL of CH_3CN was added $POCl_3$ (2.3 mL, 25.1 mmol) and 4-bromo-benzene-1,2-diamine (0.938 g, 5.01 mmol). The reaction mixture was heated at reflux under a nitrogen atmosphere for 18 hours, cooled slightly then additional 4-bromo-benzene-1,2-diamine (0.468 g, 2.50 mmol) was added. Refluxing was continued for 6 hours, then a final amount of 4-bromo-benzene-1,2-diamine (0.468 g, 2.50 mmol) was added. After heating for an additional 15 hours, the reaction mixture was concentrated *in vacuo*. The residue was purified by chromatography (silica, NH_3 in MeOH (2M):CH_2Cl_2, 1:99-5:95) then a second time (EtOAc:heptane, 1:9-1:1)) to afford the title Compound **7c** (1.255 g, 3.14 mmol) as a tan powder. ^{1}H-NMR (400MHz, d6-DMSO) δ (ppm): 12.96-12.83 (br d, 1H), 7.87-7.68 (m, 6H), 7.60-7.45 (m, 1H), 7.39-7.29 (m, 2H). MS (ESI pos. ion) *m/z*: 398.9/400.9 ($M+H^+$).

Step D. (*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol

To a solution of Compound **7c** (0.040 g, 0.10 mmol) and 2-hydroxymethyl phenyl boronic acid (0.029 g, 0.19 mmol) in 3 mL dioxane in a small pressure tube was added aqueous Na_2CO_3 solution (0.13 mL, 2M, 0.26 mmol) followed by

$PdCl_2$(dppf) (0.008 g, 0.01 mmol). The vessel was flushed with argon, capped and heated in an oil bath at 120 °C for 1 hour. The reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fractions were dried with Na_2SO_4, filtered and the filtrate was evaporated. The residue was purified by chromatography (reverse-phase, acetonitrile:water + 0.1% TFA, 1:3-95:5). The relevant fractions were mixed with poly(vinylpyridine), filtered, frozen and lyophilized to give the title Compound **35** (0.027 g, 0.063 mmol) as a yellow powder. ^{1}H-NMR (400 MHz, d6-DMSO) δ (ppm): 7.89-7.78 (m, 5H), 7.71-7.57 (m, 3H), 7.44-7.28 (m, 5H), 4.44 (s, 2H). MS (ESI pos. ion) *m/z*: 426.7 ($M+H^+$).

Using the procedures described in Example 7 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
36	(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol The title compound (0.029 g) was prepared from 2-hydroxy phenyl boronic acid (0.028 g) and Compound **7c** (0.040 g). ^{1}H-NMR (400MHz, d6-DMSO) δ (ppm): 9.61 (s, 1H), 7.90-7.79 (m, 6H), 7.70 (d, 1H), 7.54 (d, 1H), 7.42 (d, 1H), 7.33 (dd, 1H), 7.19 (dt, 1H), 6.98 (d, 1H), 6.91 (dt, 1H). MS (ESI pos. ion) *m/z*: 412.8 ($M+H^+$).
37	(*E*)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide The title compound (0.016 g) was prepared from N-[2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide (0.052 g) and Compound **7c** (0.040 g). ^{1}H-NMR (400MHz, d6-DMSO) δ (ppm): 9.24 (s, 1H), 7.86 (d, 2H), 7.82-7.75 (m, 3H), 7.67 (d, 1H), 7.57 (s, 1H), 7.51 (d, 1H), 7.44-7.24 (m, 5H), 1.89 (s, 3H). MS (ESI pos. ion) *m/z*: 453.8 ($M+H^+$).
38	(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide The title compound (0.031 g) was prepared from 2-benzamido boronic acid (0.034 g) and Compound **7c** (0.040 g). ^{1}H-NMR (400 MHz, d6-DMSO) δ (ppm): 7.91-7.79 (m, 5H), 7.73-7.66 (m, 3H), 7.54-7.38 (m, 6H), 7.31 (s, 1H). MS (ESI pos. ion) *m/z*: 439.8 ($M+H^+$).

Cpd	Name and Data
39	(*E*)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone The title compound (0.027 g) was prepared from 2-acetyl phenyl boronic acid (0.034 g) and Compound **7c** (0.040 g). ^{1}H-NMR (400MHz, d6-DMSO) δ (ppm): 7.87 (d, 2H), 7.84-7.77 (m, 3H), 7.69 (d, 1H), 7.55-7.47 (m, 2H), 7.64-7.58 (m, 3H), 7.40 (d, 1H), 7.21 (dd, 1H), 2.09 (s, 3H). MS (ESI pos. ion) *m/z*: 438.7 ($M+H^+$).

Example 8

(*E*)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone (Cpd **40**)

Step A. (*E*)-3-(4-trifluoromethanesulfonyl-phenyl)-acrylic acid

To a suspension of Compound **7b** (2.483 g, 10.01 mmol), in 50 mL of TFA was added 30% H_2O_2 solution (8 mL, 83 mmol). The reaction mixture was stirred for 21 h, then poured into 250 mL of ice water. The resulting precipitate was filtered off, rinsed with water and dried under vacuum at 50 °C to yield the title Compound **8a** (2.281 g, 8.14 mmol) as a white powder. ^{1}H-NMR (400MHz, d6-DMSO) δ (ppm): 12.80 (s, 1H), 8.15 (s, 4H), 7.73 (d, 1H), 6.83 (d, 1H). MS (ESI pos. ion) *m/z*: 278.9 ($M-H^+$).

Step B. (*E*)-5-bromo-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazole

To a suspension of Compound **8a** (1.405 g, 5.01 mmol) in 100 mL of acetonitrile was added $POCl_3$ (2.3 mL, 25.1 mmol). The reaction mixture was refluxed under a nitrogen atmosphere for 30 minutes, then cooled slightly. To this reaction mixture was added 4-bromo-benzene-1,2-diamine (0.946 g, 5.06 mmol) and the reaction was refluxed for 2 h before additional 4-bromo-benzene-1,2-diamine (0.942 g, 5.04 mmol) was added. After an hour of heating, the reaction mixture was cooled and filtered over a pad of celite. The filter cake was rinsed with acetonitrile, ethyl acetate, and methanol. The filtrate was stirred with aqueous $NaHCO_3$/EtOAc. The organic fraction was evaporated, and partitioned between 100 mL EtOAc and 100 mL saturated $NaHCO_3$. The organic fraction was dried

with Na_2SO_4, filtered, and the filtrate was evaporated. The residue was purified by chromatography (silica gel, EtOAc:heptane, 1:4-1:1)) to yield the title Compound **8b** (1.595 g, 3.70 mmol) as a tan powder. ^{1}H-NMR (400 MHz, d6-DMSO) δ (ppm): 13.00 (d, 1H), 8.14 (q, 4H), 7.87-7.73 (m, 2H), 7.63-7.50 (m, 2H), 7.40-7.33 (m, 1H). MS (ESI pos. ion) *m/z*: 430.8/432.8 ($M+H^+$).

Step C. (*E*)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone

A solution of Compound **8b** (0.043 g, 0.10 mmol), and 2-acetyl phenyl boronic acid (0.035 g, 0.21 mmol) in 3 mL dioxane was stirred in a small pressure tube. Aqueous Na_2CO_3 solution (0.13 mL, 2M, 0.26 mmol) was added followed by $PdCl_2$(dppf) (0.007 g, 0.01 mmol). The vessel was flushed with argon, capped and heated in an oil bath at 120 °C for 1 h. The reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fraction was dried with Na_2SO_4, filtered, and the filtrate was evaporated. The residue was flushed over a plug of silica gel with 100% EtOAc then evaporated. The crude material was purified by chromatography (reverse-phase, acetonitrile/water + 0.1% TFA, 1:3-95:5). The appropriate fractions were mixed with poly(vinylpyridine), filtered, frozen and lyophilized to give the title Compound **40** (0.022 g, 0.047 mmol) as a yellow powder. ^{1}H-NMR (400 MHz, d6-DMSO) δ (ppm): 8.16 (q, 4H), 7.87 (d, 1H), 7.70 (d, 1H), 7.64-7.56 (m, 3H), 7.55-7.47 (m, 3H), 7.21 (d, 1H), 2.09 (s, 3H). MS (ESI pos. ion): 471.0 ($M+H^+$).

Using the procedures described in Example 8 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
41	(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol The title compound (0.024 g) was prepared from 2-hydroxy phenyl boronic acid (0.029 g) and Compound **8b** (0.043 g). ^{1}H-NMR (400MHz, d6-DMSO) δ (ppm): 9.53 (s, 1H), 8.16 (q, 4H), 7.85 (d, 1H), 7.77 (s, 1H), 7.65 (d, 1H), 7.58 (d, 1H), 7.47 (d, 1H), 7.33 (d, 1H), 7.17 (dt, 1H), 6.97 (d, 1H), 6.90 (dt, 1H). MS (ESI pos. ion) *m/z*: 445.0 (M+H$^+$).
42	(*E*)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol The title compound (0.030 g) was prepared from 2-hydroxymethyl phenyl boronic acid (0.027 g) and Compound **8b** (0.043 g). ^{1}H-NMR (400MHz, d6-DMSO) δ (ppm): 8.16 (q, 4H), 7.89 (d, 1H), 7.69 (d, 1H), 7.62 (d, 2H), 7.58 (d, 1H), 7.43-7.33 (m, 2H), 7.30 (dd, 2H), 4.44 (s, 2H). MS (ESI pos. ion) *m/z*: 459.0 (M+H$^+$).
43	(*E*)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide The title compound (0.011 g) was prepared from N-[2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide (0.053 g) and Compound **8b** (0.043 g). ^{1}H-NMR (400MHz, d6-DMSO) δ (ppm): 9.23 (s, 1H), 8.15 (q, 4H), 7.85 (d, 1H), 7.67 (d, 1H), 7.62-7.55 (m, 2H), 7.51 (d, 1H), 7.42-7.23 (m, 4H), 1.89 (s, 3H). MS (ESI pos. ion) *m/z*: 486.1 (M+H$^+$).
44	(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide The title compound (0.018 g) was prepared from 2-benzamido boronic acid (0.034 g) and Compound **8b** (0.043 g). ^{1}H-NMR (400MHz, d6-DMSO) δ (ppm): 8.16 (q, 4H), 7.88 (d, 1H), 7.70-7.64 (m, 3H), 7.59 (d, 1H), 7.54-7.39 (m, 4H), 7.36 (dd, 1H), 7.30 (s, 1H). MS (ESI pos. ion) *m/z*: 472.0 (M+H$^+$).

Example 9

(*E*)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol (Cpd **45**)

1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol (Cpd **46**)

To a solution of Compound **40** (0.047 g, 0.10 mmol) in 5 mL EtOH was added $NaBH_4$ (0.028 g, 0.74 mmol). After 1 h, an additional amount of $NaBH_4$


(0.024 g, 0.63 mmol) was added. After an additional 4.5 h, the reaction was diluted into 25 mL EtOAc and washed twice with 25 mL water/brine. The organic fractions were dried with Na_2SO_4, filtered and the filtrate was evaporated. The residue was purified by chromatography (reverse-phase (acetonitrile/water with 0.1% TFA, 1:3-95:5). The two products were isolated, frozen and lyophilized to give the products Compound **45** (0.024 g, 0.051 mmol) as a yellow powder and Compound **46** (0.020 g, 0.042 mmol) as a white powder.

Compound **45**: ^{1}H-NMR (400MHz, d6-DMSO) δ (ppm): 8.18 (dd, 4H), 7.93 (d, 1H), 7.74 (d, 1H), 7.67 (d, 1H), 7.64-7.57 (m, 2H), 7.43 (dt, 1H), 7.35-7.27 (m, 2H), 7.21 (dd, 1H), 4.80 (q, 1H), 1.22 (d, 3H). MS (ESI pos. ion) *m/z*: 472.8 ($M+H^+$).

Compound **46**: ^{1}H-NMR (400 MHz, d6-DMSO) δ (ppm): 8.12 (d, 2H), 7.82-7.74 (m, 3H), 7.70-7.63 (m, 2H), 7.47-7.37 (m, 2H), 7.32 (dt, 1H), 7.18 (dd, 1H), 4.72 (q, 1H), 3.47 (t, 2H), 3.40 (t, 2H), 1.19 (d, 3H). MS (ESI pos. ion) *m/z*: 474.8 ($M+H^+$).

Example 10


(*E*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol(Cpd **18**)



Step A. 3-(4-trifluoromethyl-phenyl)-acrylic acid

A solution of 4-trifluoromethylbenzaldehyde (7.7 mL, 57.7 mmol), malonic acid (12.0 g, 115.4 mmol), 0.567 μL piperidine (5.75 mmol) in 30 mL of pyridine was stirred at 70 °C for 18 h. The reaction solution was cooled to room temperature. Water (300 mL) was added and the resulting mixture was acidified to pH 4 (litmus) using concentrated hydrochloric acid to give a precipitate. The


solid was filtered, and washed with water until the filtrate was neutral. The solid product was dried *in vacuo* to give the title Compound **10a** as a white powder (11.2 g, 90 %). ^{1}HNMR (400MHz, DMSO-d_6) δ (ppm): 12.60 (bs, 1H), 7.92 (d, 2H, J= 8.2 Hz), 7.77 (d, 2H, J=8.2 Hz), 7.66 (d, 1H, J=16.0 Hz), 6.70 (d, 1H, J=16.0 Hz).



Step B. (*E*)-5-bromo-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole

A solution of Compound **10a** (20.6g, 95.4 mmol) in anhydrous methylene chloride (200 mL) was treated with oxalyl chloride (16.6 mL, 190 mmol) and "3 drops" of anhydrous dimethylformamide. The resulting solution was stirred at room temperature under an argon atmosphere for 18 h. The solvent was concentrated to give 3-(4-trifluoromethyl-phenyl)-acryloyl chloride Compound **10b** as a solid, which was used without further purification in the next step.


To a solution of 4-bromo-benzene-1,2-diamine (16.1 g, 86.7 mmol) in acetic acid (100 mL) was added dropwise a solution of Compound **10b** (assumed 95.4 mmol) in acetic acid (100 mL). The reaction mixture was stirred at 100 °C for 18 h. The reaction mixture was cooled to room temperature, and a mixture of ethyl acetate and hexanes 3:7 (500 mL) was added. The mixture was triturated at room temperature for 3 h to give a precipitate. The solid was filtered, and dried *in vacuo* to give the title Compound **10c** (23.2 g, 73 %). ^{1}H NMR (400MHz, DMSO-d_6/$CDCl_3$) δ (ppm): 8.45 (d, 1H, J=16.7 Hz), 7.84-7.90 (m, 1H), 7.74 (d, 2H, J=8.3 Hz), 7.56-7.62 (m, 3H), 7.50-7.52 (m, 1H), 7.34 (d, 1H, 16.7 Hz).



10d

Step C. 2-(2-bromo-phenyl)-propan-2-ol

To a solution of methyl 2-bromobenzoate (20.76 g, 96 mmol) in 120 mL of anhydrous ether under Argon at 0 °C was slowly added methylmagnesium bromide (77 mL, 3.26 M) at a rate that the internal temperature of the mixture was below 20 °C. A white suspension resulted, and the mixture was stirred at room temperature for 2 h. The mixture was cooled in an ice-water bath. To the reaction mixture was very slowly added hydrochloric acid (400 mL, 0.5 M). The pH of the final mixture was adjusted to less than about 6 with few drops of 2M hydrochloric acid. The layers were separated, and the aqueous layer was extracted twice with ether. The organic layers were combined and dried over magnesium sulfate. The organic fraction was filtered, and the filtrate was concentrated to yield the title compound as a pale yellow liquid, which was distilled under vacuum to afford the title Compound **10d** as a colorless liquid (16.9 g, 82 %, b.p. about 65-70 °C/ 0.3 mmHg). ^{1}H NMR (400MHz, $CDCl_3$) δ (ppm): 7.67 (dd, 1H, J= 1.7, 7.9 Hz), 7.58 (dd, 1H, J= 1.3, 7.9 Hz), 7.30 (ddd, 1H, J= 1.4, 7.4, 7.9 Hz), 7.10 (ddd, 1H, J= 1.7, 7.4, 7.8 Hz), 2.77 (br s, 1H), 1.76 (s, 6H).




10d 10e

Step D. 3,3-dimethyl-3H-benzo[c][1,2]oxaborol-1-ol

To a solution of n-BuLi (166 mL, 2.6 M, 432 mmol) in 200 mL of THF at -78 °C under argon was slowly added a solution of Compound **10d** (42.2 g, 196 mmol) in 60 mL of THF at a rate that the internal temperature remained below -70 °C. The mixture was stirred at -75 °C for 2 h. To the reaction mixture was then added triisopropylborate (59 mL, 255 mmol) in three portions. The mixture was allowed

to warm slowly to room temperature overnight. The mixture was then cooled to 0 °C, and was carefully quenched with dilute hydrochloric acid (250 mL, 2N). The mixture was then stirred at room temperature for 1 h. The pH of the mixture was checked and adjusted to acidic using additional 2N HCl if prophetic. The two layers were separated, and the aqueous layer was extracted twice with ether. The organic layers were combined, and dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to yield a pale yellow oil. The residue was then diluted with ethyl acetate (400 mL) and, washed with 1N sodium hydroxide solution (150 mL x 3). The basic aqueous layers were combined and acidified with 2N HCl. The clear solution turned cloudy when the acid was added. The mixture was extracted with ether (150 mL x 3). The organic layers were combined and dried with magnesium sulfate. The solution was filtered, and the filtrate was concentrated under reduced pressure to yield the title Compound **10e** as a colorless oil (26.2 g, 82 %) which was used without further purification in the next step. ^{1}H NMR (400MHz, DMSO-d_6) δ (ppm): 9.00 (s, 1H), 7.66 (dm, 1H, J= 7.3 Hz), 7.45 (dt, 1H, J= 1.1, 7.7 Hz), 7.40 (dm, 1H, J= 7.6 Hz), 7.31 (dt, 1H, J= 1.2, 7.1 Hz), 1.44 (s, 6H).



Step E. (*E*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol

To a mixture of Compound **10e** (11.7 g, 71 mmol), Compound **10c** (19.9 g, 54 mmol), sodium carbonate (46 g, 435 mmol) and $PdCl_2(dppf)\cdot CH_2Cl_2$ (8.9 g, 11 mmol) in a 1 L round bottom flask equipped with water condenser was added 400

mL of anhydrous DME and 200 mL of water. The mixture was evacuated and filled with Argon three times. The mixture was heated to 100 °C for 20 h. The mixture was then cooled to room temperature. The biphasic system was transferred to a 1 L separatory funnel and the two layers were separated. The organic layer was washed with brine (2 x 300 mL). The aqueous layers were combined and extracted with ethyl acetate once (about 300 mL). The organic layers were combined, dried with sodium sulfate, and filtered. The volume of the filtrate was reduced to about 170 mL under reduced pressure. The mixture was then filtered through a pad of silica gel and the pad was washed with ethyl acetate until the filtrate did not contain any product. After concentration, a light pink/ beige solid was obtained. The solid was triturated with 50 mL ethyl acetate, and the mixture was heated to 85 °C for 5 min. The mixture was slowly cooled to r.t., then cooled at 0 °C for 0.5 h. The mixture was filtered, and the solid was washed with cold ethyl acetate twice, and dried under vacuum at 40 °C to yield the title Compound **18** as a light beige solid (7.58 g, 33 %). RP-HPLC 95 % pure. ^{1}H NMR (400MHz, DMSO-d_6) δ (ppm): 12.73 (m, 1H,), 7.90 (d, 2H, J= 8.2 Hz), 7.85 (dd, 1H, J= 8.0, 0.6 Hz), 7.78 (d, 2H, J= 8.4 Hz), 7.74 (d, 1H, J= 16.8 Hz), 7.59-7.47 (m, 1H), 7.41 (s, 1H), 7.37-7.32 (m, 2H), 7.21 (dt, 1H, J= 1.2, 7.4 Hz), 7.06 (s, 1H), 7.02 (d, 1H, J= 7.4 Hz), 4.85 (s, 1H), 1.21 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{25}H_{21}F_3N_2O$: 423.2 (M + H), Found 423.3. m.p. (uncorr.) 250-251 °C.

Using the procedures described in Example 10 and corresponding reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
23	(*E*)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 7.84 (dd, J=1.26, 8.084Hz, 1H) 7.75-7.85 (m, 2H) 7.66 (d, J=16.4Hz) 7.53-7.58 (m, 1H) 7.45 (bs, 1H) 7.34-7.38 (m, 3H) 7.17-7.26 (m, 3H) 7.09 (dd, J=1.58, 7.58Hz, 1H) 1.36 (s, 6H). MS (ESI, pos. ion) *m/z*: 439.2 (M+1).

Cpd	Name and Data
47	(*E*)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol ^{1}H NMR (400MHz, CD_3OD) δ (ppm): 8.07 (d, 2H, J= 8.6 Hz), 7.98 (d, 2H, J= 8.6 Hz), 7.78 (dd, 1H, J= 1.1, 8.1 Hz), 7.69 (d, 1H, J= 16.5 Hz), 7.54 (d, 1H, J= 8.2 Hz), 7.44 (d, 1H, J= 16.5 Hz), 7.42 (br s, 1H), 7.31 (ddd, 1H, J= 1.5, 7.8, 8.1 Hz), 7.18 (dt, 1H, J= 1.3, 7.4 Hz), 7.16 (dd, 1H, J= 1.5, 8.3 Hz), 7.03 (dd, 1H, J= 1.4, 7.5 Hz), 1.31 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{25}H_{21}F_3N_2O_3S$: 487.1 (M + H), Found 487.1.
78	(E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol ^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.79 (dd, 1H, J= 8.1, 1.1 Hz), 7.63-7.54 (m, 3H), 7.51 (br d, 1H, J= 9.7, 7.4 Hz), 7.40-7.38 (m, 3H), 7.31 (m, 1H), 7.19 (dt, 1H, J= 1.4, 7.4 Hz), 7.15 (d, 1H, J= 16.5 Hz), 7.13 (dd, 1H, J= 7.9, 1.8 Hz), 7.04 (dd, 1H, J= 7.5, 1.4 Hz), 1.30 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{24}H_{21}ClN_2O$: 389.1 (M + H), Found 389.3.
84	(*E*)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.00 (d, J=8 Hz, 2H), 7.91 (d, J=8 Hz, 2H), 7.82 (dd, J=1.6, 8 Hz, 1H), 7.70 (d, J=16.4 Hz, 2H), 7.41 (s, 1H), 7.36 (dt, J=1.6, 8 Hz, 1H), 7.34 (s, 1H), 7.23 (dt, J=1.6, 8 Hz, 1H), 7.19 (dd, J=1.6, 8 Hz, 1H), 7.07 (dd, J=1.6, 8 Hz, 1H), 3.16 (s, 3H), 1.26 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{25}H_{24}N_2O_3S$: 433.1 (M + H), Found 433.4.
114	(*E*)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol ^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.89-7.87 (m, 2H), 7.79 (dd, 1H, J= 8.1, 1.1 Hz), 7.67-7.56 (m, 3H), 7.52 (m, 1H), 7.40 (br s, 1H), 7.31 (m, 1H), 7.27 (d, 1H, J= 16.6 Hz), 7.18 (dt, 1H, J= 1.3, 7.4 Hz), 7.14 (dd, 1H, J= 8.3, 1.4 Hz, 1H), 7.04 (dd, 1H, J= 7.52, 1.38 Hz), 1.31 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{25}H_{21}F_3N_2O$: 423.2 (M + H), Found 423.3.
458	(*E*)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide. The title compound (0.0195 g) was prepared from Compound **465** (0.10 g, 0.26 mmol) and trifluoroacetylimidazolide (0.047g, 0.29 mmol). ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm): 12.7-12.9 (bs, 1H) 11.0 (s, 1H) 7.90-7.94 (d, J=8.59Hz, 2H)) 7.78-7.81 (d, J=8.59Hz, 2H) 7.37-7.76 (m, 7H) 7.20 (d, J=9.34Hz, 1H) MS (ESI, pos. ion) m/z: 476.2 (M+1).

Cpd	Name and Data
459	(*E*)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide The title compound (0.0015 g) was prepared from Compound **465** (0.034 g, 0.09 mmol) and trifluoromethylsulfonylchloride (0.018g, 0.10 mmol). ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 12.75-12.82 (bs, 1H) 9.70-9.80 (bs, 1H) 7.90-7.96 (d, J=8.08Hz, 2H) 7.78-7.84 (m, 3H) 7.54-7.77 (m, 2H) 7.40-7.50 (m, 2H) 7.24-7.40 (m, 6H) 4.0 (bs, 2H)MS (ESI, pos. ion) *m/z*: 526.1 (M+1).
460	(*E*)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propionamide The title compound (0.0014 g) was prepared from Compound **465** (0.034 g, 0.09 mmol) and trimethylacetylchloride (0.012 mL, 0.036 mmol). ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.80-7.84 (m, 3H) 7.58-7.78 (m, 6H) 7.38-7.42 (m, 2H) 7.24-7.35 (m, 3H) 1.20 (s, 9H) MS (ESI, pos. ion) *m/z*: 464.3 (M+1).
461	(*E*)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide The title compound (0.0018 g) was prepared from Compound **465** (0.10 g, 0.26 mmol) and ethylsulfonyl chloride (0.027 mL, 0.29 mmol). ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 12.88 (d, J=9.1Hz, 1H) 8.92 (d, J=7.3Hz, 1H) 7.78 (d, J=8.08Hz, 2H)) 7.85 (d, J=8.08Hz, 2H) 7.72-7.82 (m, 3H) 7.63-7.68 (m, 1H) 7.30-7.53 (m, 6H) 2.78-2.92 (qq, J=7.33Hz, 2H) 1.00 (tt, J=7.33Hz, 3H). MS (ESI, pos. ion) *m/z*: 472.1 (M+1).
462	(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid methyl ester The title compound (0.0056 g) was prepared from Compound **465** (0.10 g, 0.26 mmol) and chloromethylformate (0.022 mL, 0.29 mmol). ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 7.82-7.84 (d, J=8.59Hz, 2H) 7.76-7.78 (d, J=8.59Hz, 2H) 7.62-7.70 (m, 3H) 7.59 (bs, 1H) 7.36-7.41 (m, 3H) 7.24-7.34 (m, 3H). MS (ESI, pos. ion) *m/z*: 438.4 (M+1).
463	(*E*)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 7.82-7.84 (m, 1H) 7.35-7.64 (m, 8H) 7.10-7.30 (m, 4H) 1.38 (s, 15H). MS (ESI, pos. ion) m/z: 411.3 (M+1).
465	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine The title compound was prepared from Compound **479** by stirring in TFA with heating. ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 12.78 (s, 0.5H) 12.75 (s, 0.5H) 7.91 (d, J=8.08Hz, 2H) 7.78-7.81 (m, 3H) 7.74 (d, J=4.55Hz, 1H) 7.68 (d, J=8.08Hz, 1H) 7.56-7.62 (m, 1H) 7.52 (bs, 1H) 7.41 (d, J=16.4Hz, 1H) 7.20-7.29 (m, 1H) 7.05 (t, J=7.6Hz, 2H) 6.78 (d, J=8.34Hz, 1H) 6.65 (t, J=6.8Hz, 1H) 4.81 (s, 1H) 4.74 (s, 1H)MS (ESI, pos. ion) m/z: 526.1 (M+1).

Cpd	Name and Data
466	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 7.82-7.84 (d, J=8.59Hz, 2H) 7.76-7.78 (d, J=8.59Hz, 2H) 7.62-7.70 (m, 3H) 7.59 (bs, 1H) 7.36-7.41 (m, 3H) 7.24-7.34 (m, 3H). MS (ESI, pos. ion) m/z: 438.4 (M+1).
468	(*E*)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 8.18 (bs, 2H) 7.70 (m, 3H) 7.44 (m, 3H) 7.30 (m, 3H) 7.22 (m, 2H) 7.19 (m, 1H) 1.28 (s, 9H). MS (ESI, pos. ion) m/z: 412.2 (M+1).
470	(*E*)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)sulfamide The title compound (0.0023 g) was prepared from Compound **465** (0.0175 g, 0.046 mmol) and sulfamide (0.5g, 5.2 mmol). ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 7.86 (d, J=8.61Hz, 2H) 7.62-7.78 (m, 6H) 7.31-7.41 (m, 4H) 7.21-7.25 (m, 1H). MS (ESI, pos. ion) *m/z*: 459.2 (M+1).
476	(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.83 (d, J=8.59Hz, 2H) 7.77 (d, J=8.34Hz, 2H)7.56-7.74 (m, 5H)7.24-7.42 (m, 5H) 4.56 (s, 2H)MS (ESI, pos. ion) m/z: 395.1 (M+1).
478	(*E*)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.80-7.84 (m, 3H) 7.56-7.78 (m, 5H) 7.30-7.44 (m, 5H) 1.97 (s, 3H). MS (ESI, pos. ion) m/z: 422.3 (M+1).
479	(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.76-8.00 (d, J=8.1Hz, 2H) 7.82-7.90 (d, J=8.8Hz, 2H) 7.68-7.79 (m, 4H) 7.36-7.48 (5H) 1.44 (s, 9H). MS (ESI, pos. ion) m/z: 480.2 (M+1).
480	(*E*)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.84-7.87 (d, J=8.1Hz, 2H) 7.56-7.78 (m, 5H) 7.20-7.40 (m, 6H). MS (ESI, pos. ion) m/z: 411.2 (M+1).

Cpd	Name and Data
481	(*E*)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl-phenyl)-1H-benzimidazole ^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 8.10 (d, 2H, J= 8.5 Hz, 1H), 8.02 (d, 2H, J= 8.5 Hz), 7.77 (d, 1H, J= 7.8 Hz, 1H), 7.73 (d, 1H, J= 16.5 Hz), 7.64 (d, 1H, J= 7.4 Hz), 7.60 (d, 1H, J= 8.4 Hz), 7.54 (d, 1H, J= 7.7 Hz), 7.50 (s, 1H), 7.46 (d, 1H, J= 16.5 Hz), 7.42 (d, 1H, J= 7.6 Hz), 7.22 (dd, 1H, J= 8.4, 1.0 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{23}H_{14}F_6N_2O_2S$: 497.1 (M + H), Found 497.1.
482	(*E*)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol ^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 8.00-7.94 (m, 2H), 7.79 (dd, 1H, J= 8.1, 1.1 Hz), 7.73 (d, 1H, J= 7.9 Hz), 7.66 (t, 1H, J= 7.7 Hz), 7.53 (br s, 1H), 7.50 (t, 1H, J= 7.67, 7.67 Hz), 7.41 (br s, 1H), 7.31 (m, 1H), 7.21-7.13 (m, 3H), 7.04 (dd, 1H, J= 7.5, 1.4 Hz), 1.31 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{25}H_{21}F_3N_2O$: 423.2 (M + H), Found 423.3.
483	(*E*)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzyl)-amine To a solution of Compound **484** (20.7 mg, 0.053 mmol) in DMF (10 mL) was added dimethylamine 2.0 M in THF (66 µL, 0.132 mmol). The mixture was stirred for 45 min and sodium triacetoxyborohydride (17 mg, 0.080 mmol) was added. The mixture was stirred at rt for 2.5 d and then concentrated under reduced pressure. The residue was purified using preparative TLC plates (silica gel, 20 X 20 cm, 2000 microns, EtOAc: hexanes: methanol 5: 5: 1) to give the title compound (18.2 mg, 81 %). ^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.81 (d, 2H, J= 8.2 Hz), 7.70 (d, 2H, J= 8.0 Hz), 7.67 (d, 1H, J= 16.3 Hz), 7.60 (d, 1H, J= 8.2 Hz), 7.55-7.47 (m, 2H), 7.40-7.26 (m, 4H), 7.19 (dd, 1H, J= 8.3, 1.5 Hz), 3.58 (s, 2H), 2.14 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{25}H_{22}F_3N_3$: 422.2 (M + H), Found 422.1.
484	(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzaldehyde ^{1}H NMR (400 MHz, DMSO-d6) δ (ppm): 12.93 (d, 1H, J= 12.5 Hz), 9.93 (s, 1H), 7.93 (d, 3H, J= 8.4 Hz), 7.82-7.56 (m, 8H), 7.44 (d, 1H, J= 16.5 Hz), 7.28 (dd, 1H, J= 10.1, 9.3 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{23}H_{15}F_3N_2O$: 393.1 (M + H), Found 393.3.
485	(E)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzyl)-amine The title compound was prepared according to the procedure used for Compound **483**, with the exception that methylamine was used. ^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.82 (d, 2H, J= 8.3 Hz, 1H), 7.71 (d, 2H, J= 8.3 Hz), 7.69 (d, 1H, J= 16.6 Hz), 7.63 (d, 1H, J= 8.1 Hz), 7.52-7.47 (m, 2H), 7.39 (tdd, 2H, J= 9.1, 7.2, 3.6, 3.6 Hz), 7.35-7.29 (m, 2H), 7.23 (dd, 1H, J= 8.3, 1.6 Hz), 3.86 (s, 2H), 2.30 (s, 3H). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{24}H_{20}F_3N_3$: 408.2 (M + H), Found 408.1.

Cpd	Name and Data
487	(*E*)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole ^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.80 (d, 2H, J= 8.2 Hz), 7.76 (d, 1H, J= 7.9 Hz), 7.70-7.60 (m, 4H), 7.57 (d, 1H, J= 8.3 Hz), 7.52 (t, 1H, J= 7.7 Hz), 7.47 (s, 1H), 7.40 (d, 1H, J= 7.6 Hz), 7.29 (d, 1H, J= 16.6 Hz), 7.19 (dd, 1H, J= 8.3, 1.0 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{23}H_{14}F_6N_2$: 433.1 (M + H), Found 433.3.
488	(*E*)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole ^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.78 (d, 2H, J= 8.3 Hz), 7.68-7.66 (m, 3H), 7.63-7.58 (m, 2H), 7.50 (m, 1H), 7.43-7.35 (m, 3H), 7.33 (dd, 1H, J= 8.4, 1.6 Hz), 7.27 (d, 1H, J= 16.6 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{23}H_{14}F_6N_2O$: 449.1 (M + H), Found 449.3.

Example 10.1

Scale Up Preparation of (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd **18**)

Step A. 3-(4-trifluoromethyl-phenyl)-acrylic acid

A 2-L 4-neck round bottom flask equipped with an air condenser/argon inlet, mechanical stirrer, thermocouple and a stopper was charged with 4-(trifluoromethyl)benzaldehyde (250 g, 196.2 mL, 1.44 mol), malonic acid (302.6 g, 2.87 mol), and pyridine (750 mL). An exotherm developed (about 38-40 °C), which was maintained for 30 min. Piperidine (14.202 mL, 143.58 mmol) was then added to the reaction and a second exotherm developed (T_{max} about 42 °C after about 10 min.). The reaction was stirred for 30 min and then heated to 60 °C for 18 h (overnight). The reaction appeared to be complete by TLC, and was cooled to about 40 °C, diluted into water (2 L; done to prevent reaction freezing), cooled to room temperature, and further diluted with water (4 L, 6 L total). The slurry was acidified to pH = 2.0 - 3.0 with concentrated hydrochloric acid (about 675 - 700 mL). The material was stirred for 30 min., and a white solid was collected by filtration. The filter cake was washed with water until the filtrate was neutral (pH about 5.5-6, 2.5 L), air-dried in a Buchner funnel for 2 h, and then further dried in a

vacuum oven at 60 °C overnight to provide 300.5 g (96%) of the title Compound **10a** as a white solid.

Step B. (*E*)-5-bromo-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole

To a 5-L 4-neck round bottom flask equipped with a magnetic stirrer, argon inlet-argon outlet to a carbonate scrub, two stoppers, and a room temperature water bath was charged with 4-(trifluoromethyl)cinnamic acid (315 g, 1.46 mol) and dichloromethane (3.15 L) to give a slurry. To the slurry was added oxalyl chloride (151.71 mL, 1.75 mol) and DMF (1.13 mL, 14.57 mmol). Upon addition of DMF, gas evolution commenced, and the reaction was continued for about 3 h during which time a solution developed. When the reaction was complete (LC-MS), it was concentrated to dryness to give 342.4 g of 3-(4-trifluoromethyl-phenyl)-acryloyl chloride Compound **10b** (>100%) as a yellow oily solid.

A 5-L 4-neck round bottom flask equipped with mechanical stirrer, thermocouple, air condenser with argon inlet, and a stopper was charged with 4-bromo-benzene-1,2-diamine (244 g, 1.27 mol) and acetic acid (2.13 L). To this solution was added a solution of Compound **10b** (327 g, 1.39 mol) in toluene (237 mL). After this addition, the temperature spiked to 45 °C in about 30 seconds and then subsided. The reaction was then heated to 90 °C for 16 h (overnight). The reaction was cooled to 40 °C, and poured into a mixed solution of EtOAc and heptane (about 1:3, 5.75 L) and a precipitate occurred. The resulting slurry was stirred for 3 h, and the solid was collected by filtration, washed with EtOAc: heptane (1: 3, 3 L), and then dried in a vacuum oven (60 °C) to give 324.3 g (65%) of the title Compound **10c** as a partial acetate salt.

Step C. 2-(2-bromo-phenyl)-propan-2-ol

A 12-Liter 4-neck flask equipped with a thermocouple, condenser, septum, addition funnel and overhead mechanical stirrer under argon was charged with methyl-2-bromobenzoate (226.5 g, 1.05 mol) and THF (1.6 L, 19.66 mol). The mixture was cooled to a temperature between 2 and 5 °C with stirring and held for 30 min. To the solution was slowly added methyl magnesium bromide in diethyl

ether (3M, 1.05 L; 3.15 mol) via the addition funnel at a rate to maintain the reaction temperature below 15 °C. An exotherm was observed during the addition, the reaction temperature warmed from 3 to 15 °C. The addition of 1.05 L Grignard was complete in 4 h (approximate feed rate was 4.17 mL/min). The reaction mixture appeared to be off-white/yellow slurry. The reaction was allowed to warm to room temperature and stirred overnight (15 h). The reaction was sampled by HPLC/TLC and showed no starting material present. The ice bath was again applied to the reaction flask and a 0.5 M HCl solution (4.5 L; 2.25 mol) was slowly added over a period of 2 h. The temperature increased dramatically from 0 to 15 °C. After the quench was complete, the reaction was stirred at room temperature for 30 min. Additional 2 N HCl (500 mL; 1.00 mol) was slowly added to maintain a pH less than 6. MTBE (1 L) was added to help with the phase split. The reaction was stirred at room temperature for 1 to 2 h to dissolve the solid material into the aqueous phase (most likely $Mg(OH)_2$ which is very basic). The pH must be checked and adjusted with additional acid when necessary. The phases were separated and the aqueous layer was washed with an additional 1 L MTBE (2 x 500 mL). The organic phases were combined, washed with $NaHCO_3$ solution (2 x 300 mL), dried over $MgSO_4$, filtered and the filtrate was concentrated under vacuum to yield the title Compound **10d** (220.83 g, 97.48% yield) as a clear yellow oil.

Step D. 3,3-dimethyl-3H-benzo[c][1,2] oxaborol-1-ol

A 12-Liter 4-neck round bottom flask equipped with a thermocouple, condenser, addition funnel and overhead mechanical stirrer under dry Argon was charged with anhydrous THF, (3 L) and chilled to -70 to -78 °C via a dry ice/acetone bath. n-Butyl lithium (2.5N in hexanes, 860 mL, 2.15 mol) was slowly added via addition funnel. An exotherm was observed as the temperature rose from -78 to -70 °C. To the addition funnel was added a solution of Compound **10d** (220 g, 979.97 mmol) in anhydrous THF (1 L). The 2-(2-bromophenyl)propan-2-ol solution was slowly added to the n-BuLi solution. The addition took 90 min in order to maintain a reaction temperature below -70 °C. After the addition was

complete, the reaction mixture was stirred at -70 to -75 °C for 30 min. The triethylborate (230 mL, 1.35 mol) was quickly added in 3 portions at -70 °C. An exotherm was observed, the batch temperature rose from -70 to -64 °C. The reaction was stirred at -70 °C and slowly warmed to room temperature over night. After the reaction was cooled to 0-5 °C, the reaction was slowly quenched with 2 M HCl (1 L, 2.00 mol) added via the addition funnel while maintaining the batch temperature 0-5 °C. The reaction mixture was stirred for 1 h. The aqueous phase pH was 9-10. The pH was then adjusted to acidic (4-5) with 2 M HCl (200 mL). The two phases were separated and the aqueous layer was extracted with MTBE (2 x 500 mL). The combined organic phases were dried with anhydrous magnesium sulfate. The solution was filtered and concentrated to yield a yellow oil. The yellow oil was diluted with MTBE (1.5 L) and washed with 1M NaOH (3 x 500 mL). The product containing basic aqueous phases were combined and acidified with 2 M HCl (800 mL) (the clear solution turns turbid with the addition of acid). After stirring the turbid solution for 15 min (pH = 4-5) (Note 1), it was extracted with MTBE (2 x 500 mL). The organic phases were combined and dried over $MgSO_4$. The solution was filtered and the filtrate was concentrated to yield the title Compound **10e** as a clear yellow oil (121.78 grams, 77% yield).

Step E. (*E*)-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol

A 5-L 4-neck flask equipped with a thermocouple controller, condenser, overhead mechanical stirrer, Firestone valve® and a nitrogen inlet/outlet was charged with dimethoxyethane (2 L), DI water (1 L) and sodium carbonate (230.9 g, 2.18 mol). The solution was degassed and purged with N_2 three times. Compound **10e** (71.7 g, 0.35 mol) and Compound **10c** (100.0 g, 0.27 mol) were added to the degassed solution. The solution was degassed and purged with N_2 three times. $PdCl_2$(dppf) (44.48 g, 54.4 mmol) was added to the solution, and the solution was degassed and purged with N_2 three times. The resulting two-phase suspension was heated to reflux for 18 h, and then cooled to room temperature. The reaction mixture was transferred to a 12-L separatory funnel, and the layers

were separated. The organic layer was washed with brine (1 L). The two aqueous layers were combined and extracted with EtOAc (1 L). The combined organic layers were dried (Na_2SO_4), filtered, and the filtrate was concentrated to an oil. Two separate 100 g coupling reactions were combined and purified by chromatography in 10 successive chromatography runs on an ISCO preparative chromatography system (10 x 1.5 Kg SiO2, 5 column volumes of EtOAc, 250 mL/min flow rate). The combined fractions were transferred to two 22 L 4-neck round bottom flasks, and Silicycle Si-thiol functionalized silica gel (2 g) was added to each solution. The solutions were warmed to 40 °C and aged for 1 h. The solutions were filtered thru a medium glass funnel and washed with EtOAc (4 L) and combined. The filtrate was evaporated to a semi solid, which was transferred to a 2 L round bottom flask, to which EtOAc (0.4 L) was added. The resulting white precipitate slurry was cooled to –5 °C and stirred for 1 h. The slurry was filtered and washed twice with cold EtOAc (100 mL). The solids were dried in a vacuum oven at 40 °C for 40 h to afford 84.0 g (36.5% yield, 98.8 area% purity) of the title Compound **18** as a white solid. Anal. Calcd for $C_{25}H_{21}N_2OF_3 \cdot 0.04\%$ $H_2O \cdot 0.15$ mol MeOH: C, 70.48; H, 5.14: N, 6.42; F, 13.06 Found: C, 70.54; H, 4.83: N, 6.18; F, 13.33

Example 10.2

(E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol monosodium salt (Cpd **18**)

A 5-L 4-neck flask equipped with a thermocouple controller, an overhead mechanical stirrer, and a nitrogen inlet/outlet was charged with (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol. Compound **18** (125.0 g, 0.510 mol) and MeOH (1.25 L). A solution of sodium methoxide in methanol (0.5 M, 592 mL, 0.3 mol) was added. The reaction was heated to 65 °C for 30 min and all solids dissolved. The solution was cooled and evaporated to dryness. The foam was collected by scraping it out of the flask. The solids were placed in vacuum oven for 24 h at 40 °C to afford 139 g (about

100% isolated yield) of the title Compound **18** monosodium salt as a yellowish solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 7.80-7.84 (m, 3H), 7.74 (d, 2H, J= 8.59 Hz), 7.65 (d, 1H, J= 16.4 Hz), 7.40-7.44 (m, 2H), 7.25-7.37 (m, 2H), 7.16-7.20 (m, 1H), 7.01-7.05 (m, 1H), 6.84-6.87 (m, 1H), 1.23 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{25}H_{21}F_3N_2O$: 423.2 (M + H), Found 423.3. m.p. (uncorr.) 258-259 °C.

Example 10.3

(E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol hydrochloride salt (Cpd **18**)

A 250-mL separatory funnel was charged with (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol. Compound **18** (1.0 g, 2.4 mmol) and EtOAc (20 mL). Aqueous HCl (1M, 20 mL) was added to the white slurry, and the separatory funnel was shaken. The solid product quickly dissolved, and a white precipitate started to form. The organic layer was transferred to a 100 mL round bottom flask equipped with a magnetic stir bar, and was stirred for 2 h. The thick slurry was filtered, rinsed with EtOAc (2 x 5 mL), and put into a vacuum oven at 40 °C for 36 h to afford 0.95 g (87.5%) of the title Compound **18** hydrochloride salt.

Example 11

(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol (Cpd **48**)

Step A. N-(4-bromo-2-nitro-5-trifluoromethyl-phenyl)-2,2,2-trifluoro-acetamide

4-bromo-3-trifluoromethyl aniline (4.8 g, 0.02 mol) was added in portions to a stirred ice-cold trifluoroacetic anhydride (50 mL). To the resulting solution was added KNO_3 (2.22 g, 0.022 mol, 1.1 eq) in portions. The reaction mixture was stirred at 0 °C for 1 h, and then allowed to warm to room temperature overnight. The reaction mixture was diluted with ice water (150 mL), and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried

in vacuo to provide the title Compound **11a** as a bright yellow solid (6.4 g). ^{1}H-NMR (400MHz, $CDCl_3$) δ (ppm): 9.19 (s, 1H) 8.64 (s, 1H) MS (ESI, pos. ion) *m/z*: 381.4 (M+1).

Step B. 4-bromo-2-nitro-5-trifluoromethyl-phenylamine

Compound **11a** (5.7 g, 0.015 mol) was dissolved in a mixture of methanol (25 mL) and saturated aqueous K_2CO_3 (15 mL). The reaction mixture was then stirred at room temperature for 10 h. The reaction mixture was diluted with water (25 mL) and the product was collected by vacuum filtration to provide the title Compound **11b** as a yellow solid (2.99 g). ^{1}H-NMR (400MHz, $CDCl_3$) δ (ppm): 8.44 (s, 1H) 7.21 (s, 1H), 6.21 (bs, 2H). MS (ESI, pos. ion) *m/z*: 285.0 (M+1).

Step C. 4-bromo-5-trifluoromethyl-benzene-1,2-diamine

Compound **11b** (2.85 g, 0.01 mol) was dissolved in 30 mL of ethanol. Zinc powder (5.9 g, 0.09 mol) was added in portions followed by the addition of ammonium chloride (1.07 g, 0.02 mol, 2 eq). The reaction mixture was stirred at room temperature overnight (16 h). The reaction mixture was filtered over a pad of celite and the solvent was evaporated *in vacuo*. The residue was taken up in ethyl acetate (40 mL), washed with 35 mL of brine, dried over Na_2SO_4, and evaporated *in vacuo*. The residue was purified by chromatography (silica gel, CH_2Cl_2: MeOH, 96:4-94:6)) to provide the title Compound **11c** as a bright yellow solid (1.53 g), which was used without further purification in the next step. ^{1}H-NMR (400MHz, CD_3OD) δ (ppm): 6.99 (s, 1H) 6.92 (s, 1H) MS (ESI, pos. ion) *m/z*: 254.7 (M+1).

Step D. (*E*)-5-bromo-2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazole

4-*t*-butyl acrylic acid (1.02 g, 0.0055, 1.1 eq) was dissolved in 30 mL of $POCl_3$. To this was added Compound **11c** (1.27 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h. (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and concentrated *in vacuo*. The

residue was taken up in 50 mL of ethyl acetate, washed with 50 mL of brine, dried over Na_2SO_4, filtered and the filtrate was concentrated *in vacuo*. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 1:3-2:3) to provide the title Compound **11d** as a light brown solid (0.84 g). ^{1}H-NMR (400MHz, $CDCl_3$) δ (ppm): 7.91 (d, 2H, J = 18.5 Hz) 7.69 (d, 1H, J=16.4 Hz), 7.32 (m, 4H) 7.09 (d, 1H, J = 16.5 Hz) 1.28 (s, 9H). MS (ESI, pos. ion) *m/z*: 423.7 (M+1).

Step E. (*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol

Compound **11d** (0.00026 mol, 0.10 g) was dissolved in 5 mL of dioxane. 2-hydroxyphenyl boronic acid (0.00052 mol, 0.072 g, 2.0 equiv) was added followed by aqueous Na_2CO_3 (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave synthesizer at 110 °C for 20 minutes. The reaction mixture was cooled and the solvent was concentrated *in vacuo*. The residue was taken up in 10 mL of CH_2Cl_2, and washed sequentially with 10 mL of saturated aqueous $NaHCO_3$ and 10 mL of brine. The organic fractions were dried over Na_2SO_4, filtered, and the filtrate was concentrated *in vacuo*. The residue purified by chromatography (silica gel, CH_2Cl_2: MeOH, 98:2-95:5) to provide the title Compound **48** as a white solid. ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm): 7.29-7.56 (m, 8H) 7.15 (d, 1H, J=6.7 Hz) 6.89-7.05 (m, 3H)) 1.34 (s, 9H). MS (ESI, pos. ion) *m/z*: 437.1 (M+1).

Using the procedures described in Example 11 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
49	(*E*)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol The title compound was prepared from 3-hydroxyphenyl boronic acid (0.00052 mol, 0.072g) and Compound **1a** (0.00026 mol, 0.10 g). ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm): 7.25-7.61 (m, 8H) 7.19 (d, 1H, J= 7.0 Hz) 6.90-7.11 (m, 3H)) 1.28 (s, 9H). MS (ESI, pos. ion) *m/z*: 437.1 (M+1).

Cpd	Name and Data
50	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-acetamide The title compound was prepared from 2-acetamidophenyl boronic acid (0.00052 mol, 0.093g) and Compound **1a** (0.00026 mol, 0.10 g) to give the product as an off-white solid. ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm): 8.15 (d, 2H, J = 8.1 Hz) 7.73-7.76 (m, 2H) 7.35-7.52 (m, 4H) 7.0-7.14 (m, 3H) 6.77 (s, 1 H) 1.45 (s, 9H) 1.35 (s, 3H). MS (ESI, pos. ion) *m/z*: 478.2 (M+1).
51	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanol The title compound was prepared from 2-hydroxymethyl phenylboronic acid (0.00052 mol, 0.070 g) and Compound **1a** (0.00026 mol, 0.10 g) to give the product as a white solid. ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm): 6.9-7.5 (m, 12H) 4.39 (m, 2 H) MS (ESI, pos. ion) *m/z*: 451.2 (M+1).
52	(*E*)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl-1H-benzimidazole The title compound was prepared from 2-fluorophenylboronic acid (0.00052 mol, 0.073 g) and Compound **1a** (0.00026 mol, 0.10 g) to give the product as a beige solid. ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm): 8.1 (m, 2H) 7.72 (d, 2H, J = 16 5 Hz) 7.42-7.53 (m, 4H) 7.05-7.20 (m, 4H) 1.34 (s, 9H). MS (ESI, pos. ion) *m/z*: 440.1 (M+1).
53	(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-benzamide The title compound was prepared from 2-aminocarbonyl phenylboronic acid (0.00052 mol, 0.086 g) and Compound **1a** (0.00026 mol, 0.10 g) to give the product as a yellow solid. ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm): 7.2-7.8 (m, 9H) 6.91 (d, 2H, J=5.4 Hz) 6.68 (d, 1H, J=19.5 Hz) 1.32 (s, 9H). MS (ESI, pos. ion) *m/z*: 465.25 (M+1).
54	(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester The title compound was prepared from t-butyl-N-[2-4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenylcarbamate (0.00052 mol, 0.166 g) and Compound **1a** (0.00026 mol, 0.10 g) to give the product as a beige solid. ^{1}H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.0 (s, 1H), 7.89 (s, 1H), 7.62-7.79 (m, 4H), 7.42-7.55 (m, 3H), 7.36-7.41 (m, 2H), 7.15-7.30 (m, 2H))) 1.32 (s, 18H) MS (ESI, pos. ion) *m/z*: 536.2 (M+1).

Cpd	Name and Data
55	(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide The title compound was prepared from 2-methylsulfonylaminophenyl boronic acid (0.00052 mol, 0.111 g) and Compound **1a** (0.00026 mol, 0.10 g) to give the product as a bright yellow solid. ^{1}H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.0 (s, 1H) 7.79 (d, 1H, J = 16.5 Hz) 7.65 (d, 2H, J = 8.4 Hz) 7.5 (m, 3H) 7.41 (t, 1H, J = 7.7 Hz) 7.23-7.28 (m, 3H) 7.10 (d, 1H, J = 12.1 Hz) 2.5 (s, 3H) 1.31 (s, 9H). MS (ESI, pos. ion) *m/z*: 514.2 (M+1).

Example 12

(*E*)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide (Cpd **56**)

Step A. (*E*)-5-bromo-6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole

Using the procedure of Example 11, Step D, 4-trifluoromethyl acrylic acid (1.19 g, 0.0055, 1.1 eq) was dissolved in 30 mL of $POCl_3$. To this solution was added Compound **11c** (1.27 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and then concentrated *in vacuo*. The residue was taken up in 50 mL of ethyl acetate, washed with 50 mL of brine, dried over Na_2SO_4, filtered, and the filtrate was concentrated *in vacuo*. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 3:1-3:2) to provide the title Compound **12a** as a light yellow solid (1.02 g). ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm): 7.92 (d, 2H, J = 14.1 Hz) 6.67-7.76 (m, 5H) 7.21 (d, 1H, J = 16.5 Hz) MS (ESI, pos. ion) *m/z*: 368.3 (M+1).

Step B. (*E*)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide

Compound **12a** (0.00025 mol, 0.10 g) was dissolved in 5 mL of dioxane. 2-acetamidophenyl boronic acid (0.0005 mol, 0.089 g, 2.0 equiv) was added followed by aqueous Na_2CO_3 (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction

mixture was heated in a microwave synthesizer at 110 °C for 20 minutes. The reaction mixture was cooled and the reaction mixture was concentrated *in vacuo*. The residue was taken up in 10 mL of CH_2Cl_2, and washed sequentially with 10 mL of saturated aqueous $NaHCO_3$ and 10 mL of brine. The organic fractions were dried over Na_2SO_4, filtered and the filtrate was concentrated *in vacuo*. The residue was purified by chromatography (silica gel CH_2Cl_2: MeOH, 98:2 – 95:5) to provide the title Compound **56** as a white solid. ^{1}H-NMR (400M Hz, DMSO-d6) δ (ppm): 8.68 (s, 1H) 8.03 (s, 1H) 7.80-7.96 (m, 6H) 7.35-7.50 (m, 3H) 7.20 (d, 2H, J = 4.1 Hz) 1.8 (s, 3H) MS (ESI, pos. ion) *m/z*: 490.0 (M+1).

Using the procedures described in Example 12 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
57	(*E*)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone The title compound was prepared from 2-acetylphenyl boronic acid (0.0005 mol, 0.082g) and Compound **12a** (0.00025 mol, 0.10 g) to give the product as a whitish-yellow solid. ^{1}H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.81-8.0 (m, 8H) 7.42-7.62 (m, 3H) 7.30 (d, 1H, J = 6.8 Hz) 2.49 (s, 3H) MS (ESI, pos. ion) *m/z*: 475.0 (M+1).
58	(*E*)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol The title compound was prepared from 2-hydroxymethyl phenylboronic acid (0.0005 mol, 0.067g) and Compound **12a** (0.00025 mol, 0.10 g) to give the product as a light yellow powder. ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm): 8.0 (d, 2H, J = 8.1 Hz) 7.8 (d, 2H, J = 8.2 Hz) 7.0-7.59 (m, 8H) 4.91-5.07 (m, 1H) 4.09-4.22 (m, 2H) (s, 9H). MS (ESI, pos. ion) *m/z*: 463.0 (M+1).

Example 13

(*E*)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol (Cpd **59**)

Step A. N-(4-bromo-5-fluoro-2-nitro-phenyl)-2,2,2-trifluoro-acetamide

4-bromo-3-fluoromethyl aniline (3.8 g, 0.02 mol) was added in portions to a stirred ice-cold trifluoroacetic anhydride (50 mL). To the solution was added KNO_3

(2.22 g, 0.022 mol, 1.1 eq) in portions. The reaction mixture was stirred at 0 °C for 1 h and then allowed to warm to room temperature overnight. The reaction mixture was diluted with ice water (150 mL) and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried *in vacuo* to provide the title Compound **13a** as a bright yellow solid (5.42 g). ^{1}H-NMR (400MHz, $CDCl_3$) δ (ppm): 8.66 (d, 1H, J = 10.0 Hz) 8.60 (d, 1H, J = 11.3 Hz). MS (ESI, pos. ion) *m/z*: 402.0 (M+Na).

Step B. 4-bromo-5-fluoro-2-nitro-phenylamine

Compound **13a** (5.0 g, 0.015 mol) was dissolved in a mixture of methanol (25 mL) and saturated aqueous K_2CO_3 (15 mL) and the mixture was stirred at room temperature for 10 h. The reaction mixture was diluted with water (25 mL) and the product was collected by vacuum filtration to provide the title Compound **13b** as a yellow solid (2.5 g). ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm): 8.39 (d, 1H, J = 7.1 Hz) 6.75 (d, 1H, J = 9.6 Hz) 6.19 (bs, 2H). MS (ESI, pos. ion) *m/z*: 236.9 (M+1).

Step C. 4-bromo-5-fluoro-benzene-1,2-diamine

Compound **13b** (1.88 g, 0.008 mol) was dissolved in 20 mL of ethanol. Zinc powder (4.71 g, 0.072 mol) was added in portions followed by the addition of the ammonium chloride (0.86 g, 0.016 mol). The reaction mixture was stirred at room temperature overnight (16 h). The reaction mixture was filtered over a pad of celite and the solvent was evaporated *in vacuo*. The residue was taken up in ethyl acetate (30 mL) and washed with 25 mL of brine. The organic fractions were dried over Na_2SO_4, filtered and the filtrate was concentrated *in vacuo*. The residue was purified by flash chromatography (silica gel, CH_2Cl_2: MeOH, 96:4-94:6)) to provide the title Compound **13c** as a dark yellow solid (1.02 g) that was used immediately in the next reaction. MS (ESI, pos. ion) *m/z*: 235.7 (M+1).

Step D. (*E*)-5-bromo-6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole

4-trifluoromethyl cinnamic acid (1.2 g, 0.0055, 1.1 eq) was dissolved in 30 mL of $POCl_3$. To the solution was added Compound **13c** (1.02 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h. The reaction mixture was cooled to room temperature and then evaporated *in vacuo*. The residue was taken up in 50 mL of ethyl acetate, and washed with 50 mL of brine. The organic fractions were dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 3:1-3:2) to provide the title Compound **13d** as a light brown solid (0.80 g). ^{1}H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.63-8.09 (m, 4 H) 7.4 (d, 1H, J = 20.7 Hz) 6.69 (d, 1H, J = 20.7 Hz) MS (ESI, pos. ion) *m/z*: 386.0 (M+1).

Step E. (*E*)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol

Compound **13d** (0.00025 mol, 0.096 g) was dissolved in 5 mL of dioxane. 2-hydroxyphenyl boronic acid (0.0005 mol, 0.069 g) was added followed by aqueous Na_2CO_3 (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave synthesizer at 110 °C for 20 minutes. The reaction mixture was cooled and the solvent was evaporated *in vacuo*. The residue was taken up in 10 mL of CH_2Cl_2, and washed sequentially with 10 mL of saturated aqueous $NaHCO_3$ and 10 mL of brine. The organic fractions were dried over Na_2SO_4, filtered and the filtrate was concentrated *in vacuo*. The residue was purified by chromatography (silica gel (CH_2Cl_2: MeOH, 98:2-95:5) to provide the title Compound **59** as a tan solid. ^{1}H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.90 (d, 2H, J = 8.0 Hz) 7.79 (d, 2H,J = 7.8 Hz) 7.22-7.53 (m, 4H) 6.88-6.96 (m, 4H) MS (ESI, pos. ion) *m/z*: 399.1 (M+1).

Using the procedures described in Example 13 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
60	(*E*)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol The title compound was prepared from 3-hydroxyphenyl boronic acid (0.0005 mol, 0.069 g) and Compound **13d** (0.00025 mol, 0.096 g) to give the product as an off-white solid. ^{1}H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.76-8.0 (m, 4H) 7.24-7.64 (m, 5H) 6.96-7.03 (m, 1H) 6.75-6.8 (m, 2H) MS (ESI, pos. ion) *m/z*: 399.3 (M+1).
61	(*E*)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol The title compound was prepared from 2-hydroxymethyl phenylboronic acid (0.0005 mol, 0.067 g) and Compound **13d** (0.00025 mol, 0.096 g) to give the product as a yellowish solid. ^{1}H-NMR (400 MHz, CD3OD) δ (ppm): 7.83 (d, 2H, J = 8.2 Hz) 7.70-7.73 (m, 2H) 7.64 (t, 2H, J = 7.9, 7.5 Hz)) 7.55 (d, 1H, J = 7.2 Hz) 7.25-7.46 (m, 4H) 7.10 (dd, 1H, J = 1.2 Hz) 4.29 (d, 2H, J = 0.85 Hz) MS (ESI, pos. ion) *m/z*: 413.1 (M+1).
62	(*E*)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone The title compound was prepared from 2-acetylphenyl boronic acid (0.0005 mol, 0.082g) and Compound **13d** (0.00025 mol, 0.096 g) to give the product as a bright yellow solid. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.75-7.91 (m, 5 H) 7.55-7.68 (m, 4H) 7.41-7.47 (m, 3 H) 2.46 (s, 3H) MS (ESI, pos. ion) *m/z*: 425.1 (M+1).
63	(*E*)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide The title compound was prepared from 2-aminocarbonyl phenylboronic acid (0.0005 mol, 0.083 g) and Compound **13d** (0.00025 mol, 0.096 g) to give the product as a sticky tan solid. ^{1}H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.93 (d, 2H, J = 8.6 Hz) 7.83 (d, 2H, J = 8.6 Hz) 7.40-7.71 (m, 8H) MS (ESI, pos. ion) *m/z*: 426.0 (M+1).
64	(*E*)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide The title compound was prepared from 2-acetamidophenyl boronic acid (0.0005 mol, 0.089 g) and Compound **13d** (0.00025 mol, 0.096 g) to give the product as an off-white solid. ^{1}H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.68 (s, 1H) 8.03 (s, 1H) 7.80-7.96 (m, 6H) 7.35-7.50 (m, 3H) 7.20 (d, 2H, J = 4.1 Hz) 1.8 (s, 3H) MS (ESI, pos. ion) *m/z*: 440.1 (M+1).

Cpd	Name and Data
65	(*E*)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide The title compound was prepared from 2 methylsulfonylaminophenyl boronic acid (0.0005 mol, 0.108 g) and Compound **13d** (0.00025 mol, 0.096 g) to give the product as an off-white solid. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.65 (s, 1 H) 7.59 (d, 1H, J = 6.7 Hz) 7.26-7.48 (m, 10 H) 2.95 (s, 3H) MS (ESI, pos. ion) *m/z*: 476.1 (M+1).

Example 14

(*E*)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol (Cpd **66**)

Step A. N-(4-bromo-5-chloro-2-nitro-phenyl)-2,2,2-trifluoro-acetamide

4-Bromo-3-chloromethyl aniline (4.1 g, 0.02 mol) was added in portions to a stirred ice cold trifluoroacetic anhydride (50 mL). To the resulting solution was added KNO_3 (2.22 g, 0.022 mol, 1.1 eq) in portions. The reaction mixture was stirred at 0 °C for 1 hour and then allowed to warm to room temperature overnight. The reaction mixture was diluted with ice water (150 mL) and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried *in vacuo* to provide the title Compound **14a** as a pale yellow solid (5.55 g).

Step B. 4-bromo-5-chloro-2-nitro-phenylamine

Compound **14a** (5.2 g, 0.015 mol) was dissolved in a mixture of methanol (25 mL) saturated aqueous K_2CO_3 (15 mL). The reaction mixture was stirred at room temperature for 10 hours. The reaction mixture was diluted with water (25 mL) and the product was collected by vacuum filtration to provide the title Compound **14b** as a yellow solid (2.71 g). ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm): 8.39 (s, 1H) 6.98 (s, 1H) 6.08 (bs, 2H). MS (ESI, pos. ion) *m/z*: 250.9 (Br, Cl pattern).

Step C. 4-bromo-5-chloro-benzene-1,2-diamine

Compound **14b** (2.0 g, 0.008 mol) was dissolved in 20 mL of ethanol. Zinc powder (4.7 g, 0.072 mol) was added in portions followed by the addition of the

ammonium chloride (0.88 g, 0.016 mol, 2 eq). The reaction mixture was stirred at room temperature overnight (16 hours). The reaction mixture was filtered over a pad of celite and the solvent was evaporated in vacuo. The residue was taken up in ethyl acetate (30 mL) and washed with 25 mL of brine. The organic fractions were dried over Na_2SO_4, filtered and the filtrate was concentrated *in vacuo*. The residue was purified by flash chromatography (silica gel, CH_2Cl_2: MeOH, 96:4-94:6) to provide the title Compound **14c** as a dark yellowish-brown solid (1.08 g) and was used immediately in the next reaction. MS (ESI, pos. ion) *m/z*: 220.9 (Br, Cl pattern).

Step D. (*E*)-5-bromo-6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole

4-trifluoromethyl cinnamic acid (1.2 g, 0.0055, 1.1 eq) was dissolved in 30 mL of $POCl_3$. To this solution was added Compound **14c** (1.08 g, 0.005 mol), and the reaction mixture was heated to reflux for 6 hours (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and the evaporated *in vacuo*. The residue was taken up in 50 mL of ethyl acetate, and washed with 50 mL of brine. The organic fractions were dried over Na_2SO_4, filtered and the filtrate was evaporated in vacuo. The residue was purified by chromatography (silica gel hexanes: EtOAc, 3:1-3:2) to provide the title Compound **14d** as a light brown solid (0.80 g). ^{1}H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.57-8.21 (m, 4 H) 7.35 (d, 1H, J = 19 Hz) 6.72 (d, 1H, J = 18.5 Hz). MS (ESI, pos. ion) *m/z*: 401.0.

Step E. (*E*)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol

Compound **14d** (0.00025 mol, 0.100 g) was dissolved in 5 mL of dioxane. 2-hydroxymethyl phenylboronic acid (0.0005 mol, 0.067 g, 2.0 equiv) was added followed by aqueous Na_2CO_3 (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine) -palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave at 110 °C for 20 minutes. The reaction

mixture was cooled and the solvent was evaporated in vacuo. The residue was taken up in 10 mL of CH_2Cl_2, and washed sequentially with 10 mL of saturated aqueous $NaHCO_3$ and 10 mL of brine. The organic fractions were dried over Na_2SO_4, filtered and the solvent was evaporated in vacuo. The residue was purified by chromatography (silica gel,CH_2Cl_2: MeOH, 98:2-95:5) to provide the title Compound **66** as a yellow sticky solid. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.82-7.85 (d, 2H, J = 8.4 Hz) 7.72-7.74 (d, 2H, J=8.3 Hz) 7.56-7.66 (m, 3H) 7.26-7.43 (m, 5H) 5.05 (s, 1H) 4.58 (s, 2H). MS (ESI, pos. ion) *m/z*: 395.3 (-CH_2OH).

Using the procedures described in Example 14 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
67	(*E*)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone The title compound was prepared from 2-acetylphenyl boronic acid (0.0005 mol, 0.082 g) and Compound **14d** (0.00025 mol, 0.100 g) to give the product as a pale yellow solid. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.80-7.84 (m, 2H) 7.70-7.74 (m, 2H) 7.67 (s, 1H), 7.50-7.7.64 (m, 2H) 7.27-7.43 (m, 5H), 1.36 (s, 9H). MS (ESI, pos. ion) *m/z*: 441.1 (M+1).
68	(*E*)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol The title compound was prepared from 2-hydroxyphenyl boronic acid (0.0005 mol, 0.108 g) and Compound **14d** (0.00025 mol, 0.069 g) to give the product as a dark yellow solid. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 6.2-6.6 (m, 5H) 5.99-6.05 (m, 5H) 5.59-5.66 (2H) 7.80-7.84 (m, 2H). MS (ESI, pos. ion) *m/z*: 415.0 (M+1).

Example 15

(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd **70**)

(*E*)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd **309**)

Step A. (*E*)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide

A mixture of 2-(t-butylamino)sulfonylphenyl boronic acid (12.4 g, 0.048 mol), Compound **10c** (13.6 g, 0.037 mol), $Pd(dppf)Cl_2CH_2Cl_2$ (3.00 g, 3.70 mmol), TBAB (11.9 g, 0.037 mmol), and Na_2CO_3 (31.4 , 0.296 mol) in 750 mL of mixed solvent (DME: water, 4: 1) was heated at 90 °C for 12 hours. The reaction mixture was concentrated, and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 1: 1) to provide the title Compound **309** as a yellow oil. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.6 and 7.6 Hz) 7.84 (d, 2H, J = 8.4 Hz) 7.73 (d, 2H, J = 8.4 Hz) 7.70-7.62 (m, 4H) 7.54 (dt, 1H, J = 1.6 and 8.6 Hz) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.37-7.31 (m, 2H) 1.00 (s, 9H) MS (ESI, pos. ion) *m/z*: 490.3 (M+1).

Step B. (*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide

A solution of Compound **309** in 60 mL TFA was heated at 70 °C for 2 hours. The reaction was concentrated, the residue was dissolved in EtOAc, and washed with sat'd $NaHCO_3$. The organic layer was dried over Na_2SO_4, filtered, and the residue was concentrated. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 1:2) to provide the title Compound **70** as a light brown solid. M.p. 168-170 °C. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.16 (dd, 1H, J = 1.2 and 8.0 Hz) 7.95-7.91 (m, 3H) 7.82-7.76 (m, 4H) 7.70-7.56 (m, 3H) 7.44 (s, 1H) 7.16 (d, 1H, J = 9.6 Hz) MS (ESI, pos. ion) *m/z*: 444.3 (M+1).

Using the procedures described in Example 15 and reagents, starting materials and conditions known to those skilled in the art, the following compound representative of the present invention was prepared:

Cpd	Name and Data
71	(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 8.10 (d, 2H, J = 8.4 Hz) 8.01 (d, 2H, J = 8.4 Hz) 7.71-7.53 (m, 5H) 7.44 (d, 1H, J = 16.4 Hz) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) **7**.35 (dd, 1H, J = 1.2 and 8.4 Hz) MS (ESI, pos. ion) *m/z*: 508.3 (M+1).
398	(*E*)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared from 2-N,N-dimethylaminosulfonylphenyl boronic acid and Compound **10c**. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.08 (dd, 1H, J = 1.2 and 8.4 Hz) **7**.84 (d, 2H, J = 8.4 Hz) 7.73 (d, 2H, J = 8.8 Hz) 7.69-7.56 (m, 5H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.33 (d, 1H, J = 16.4 Hz) 7.28 (dd, 1H, J = 1.6 and 8.4 Hz) 2.34 (s, 6H) MS (ESI, pos. ion) *m/z*: 472.5 (M+1).
441	(*E*)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared from 2-tert-butylaminosulfonyl-5-fluorophenylboronic acid and Compound **10c**. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.18 (dd, J=5.6, 8 Hz, 1H), 7.94 (d, J=5.6, 8 Hz, 1H), 7.84 (d, J=8 Hz, 2H), 7.73 (s, 1H), 7.71-7.69 (m, 2H), 7.63 (d, J=8 Hz, 1H), 7.35-7.32 (m, 1H), 7.28-7.22 (m, 2H), 7.14 (dd, J=2, 9 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{22}H_{15}F_4N_3O_2S$: 462.4 (M + H), Found 462.2.
444	(*E*)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared from 2-tert-butylaminosulfonyl-5-trifluoromethylphenyl boronic acid and Compound **10c**. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.33 (d, J=8 Hz, 1H), 7.88 (s, 1H), 7.85 (d, J=8 Hz, 2H), 7.74-7.68 (m, 6H), 7.36-**7**.32 (m, 1H), 7.34 (d, J=16.4 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{23}H_{15}F_6N_3O_2S$: 512.5 (M + H), Found 512.3.

Cpd	Name and Data
446	(*E*)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared from 2-tert-butylaminosulfonyl-4-trifluoromethylphenyl boronic acid and Compound **10c**. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.42 (s, 1H), 7.94 (d, J=8 Hz, 1H), 7.85 (d, J=8 Hz, 2H), 7.73 (d, J=8 Hz, 2H), 7.71 (d, J=8 Hz, 2H), 7.64 (d, J=8 Hz, 2H), 7.34 (d, J=16.4 Hz, 2H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{23}H_{15}F_6N_3O_2S$: 512.1 (M + H), Found 512.2.

Example 16

(*E*)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd **69**)

Step A. (5-bromo-2-tert-butoxycarbonylamino-phenyl)-carbamic acid tert-butyl ester

4-bromo-phenylenediamine (25 g, 0.134 mol) was added portionwise to di-t-butyl dicarbonate (175 g, 0.802 mol) at 25 °C, and the reaction mixture was stirred for 10 hours. The mixture was purified by chromatography (silica gel, hexanes to hexanes: EtOAc, 1: 1) to provide the title Compound **16a** as a light brown solid. ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm): 7.76 (brs, 1H) 7.32 (brs, 1H) 7.22 (dd, 1H, J = 2.0 and 8.8 Hz) 6.72 (brs, 1H) 6.53 (brs, 1H).

Step B. (3-tert-butoxycarbonylamino-2'-tert-butylsulfamoyl-biphenyl-4-yl)-carbamic acid tert-butyl ester

A mixture of 2-(t-butylamino)sulfonylphenyl boronic acid (4.7 g, 0.018 mmol), Compound **16a** (4.7 g, 0.012 mmol), $Pd(dppf)Cl_2 \cdot CH_2Cl_2$ (0.99 g, 0.0012 mmol), TBAB (3.90 g, 0.012 mmol), and 20 mL of 1M Na_2CO_3 (aq) in 100 mL of DME was heated at 100 °C for 12 hours. The reaction mixture was concentrated, and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 2: 1) to provide the title Compound **16b** as a yellow oil.

Step C. 3',4'-diamino-biphenyl-2-sulfonic acid tert-butylamide

A mixture of Compound **16b** in 20 mL of 4M HCl in dioxane was stirred for 3 hours. The reaction mixture was concentrated, diluted with EtOAc and washed with sat'd $NaHCO_3$ (aq), then dried over Na_2SO_4 and filtered. The filtrate was concentrated to provide the title Compound **16c** as a brown oil. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.04 (dd, 1H, J = 1.2 and 7.6 Hz) 7.56 (dt, 1H, J = 1.2 and 8.2 Hz) 7.44 (dt, 1H, J = 1.2 and 8.4 Hz) 7.33 (dd, 1H, J = 1.2 and 7.6 Hz) 6.86 (d, 1H, J = 1.6 Hz) 6.77 (d, 1H, J = 7.6 Hz) 6.73 (dd, 1H, J = 2.0 and 8.0 Hz) 0.97 (s, 9H). MS (ESI, pos. ion) *m/z*: 319.9 (M+1).

Step D. (*E*)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide

A mixture of Compound **16c** (0.120 g, 0.376 mmol), trans 4-(trifluoromethoxy)-cinnamic acid (0.105 g, 0.451 mmol), and 0.4 mL of 4N HCl (aq) in 4 mL of ethylene glycol was heated at 180 °C for 1 hour. The reaction mixture was purified directly by HPLC (YMC ODS-A, H_2O: MeCN, 90: 10 to 40: 60, over 10 min) to provide the title Compound **69** as an off-white solid. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.75 (d, 2H, J = 8.4 Hz) 7.68-7.53 (m, 5H) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.37-7.33 (m, 3H) 7.19 (d, 1H, J = 16.8 Hz) MS (ESI, pos. ion) *m/z*: 460.3 (M+1).

Using the procedures described in Example 16 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
79	(*E*)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.68-7.54 (m, 7H) 7.46-7.40 (m, 3H) 7.38 (dd, 1H, J = 1.2 and 8.4 Hz) 7.19 (d, 1H, J = 16.8 Hz) MS (ESI, pos. ion) *m/z*: 410.4 (M+1).

Cpd	Name and Data
85	(*E*)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.99 (d, 2H, J = 8.4 Hz) 7.89 (d, 2H, J = 8.4 Hz) 7.71-7.53 (m, 5H) 7.41 (dd, 1H, J = 1.6 and 7.6 Hz) 7.36 (d, 1H, J = 16.4 Hz) 7.34 (dd, 1H, J = 1.6 and 8.4 Hz) MS (ESI, pos. ion) *m/z*: 453.4 (M+1).
357	(*E*)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (d, 1H, J = 8.0 Hz) 7.83-7.75 (m, 2H) 7.67-7.53 (m, 4H) 7.38 (t, 2H, J = 9.2 Hz) 7.22 (d, 1H, J = 16.8 Hz) 7.08-7.03 (m, 2H) MS (ESI, pos. ion) *m/z*: 412.4 (M+1).
358	(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.72-7.55 (m, 6H) 7.48-7.35 (m, 4H) 7.20 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) *m/z*: 412.4 (M+1).
359	(*E*)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.84 (d, 1H, J = 16.8 Hz) 7.70-7.54 (m, 5H) 7.41 (dd, 2H, J = 1.6 and 8.4 Hz) 7.33 (d, 1H, J = 16.8 Hz) 7.29-7.23 (m, 2H) MS (ESI, pos. ion) *m/z*: 412.4 (M+1).
360	(*E*)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.81 (d, 1H, J = 16.8 Hz) 7.69-7.54 (m, 5H) 7.46-7.38 (m, 2H) 7.33 (d, 1H, J = 16.8 Hz) 7.26-7.14 (m, 2H) MS (ESI, pos. ion) *m/z*: 412.4 (M+1).
361	(*E*)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.6 and 8.0 Hz) 7.71-7.55 (m, 5H) 7.42 (td, 2H, J = 1.4 and 8.4 Hz) 7.34-7.28 (m, 3H) 7.04-6.99 (m, 1H) MS (ESI, pos. ion) *m/z*: 412.4 (M+1).
362	(*E*)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.37-7.51 (m, 8H) 7.41 (dd, 1H, J = 1.2 and 8.0 Hz) 7.35 (dd, 1H, J = 1.6 and 8.0 Hz) 7.29 (d, 1H, J = 8.8 Hz) 7.25 (d, 1H, J = 16.8 Hz) 7.34 (dd, 1H, J = 1.6 and 8.4 Hz) MS (ESI, pos. ion) *m/z*: 460.4 (M+1).

Cpd	Name and Data
363	(*E*)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, 1H, J = 1.2 and 7.6 Hz) 7.93 (d, 1H, J = 1.2 and 7.6 Hz) 7.65-7.47 (m, 6H) 7.42-7.29 (m, 4H) 7.22 (d, 1H, J = 16.8 Hz) MS (ESI, pos. ion) *m/z*: 454.3 (M+1).
364	(*E*)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 8.10 (dd, 1H, J = 2.0 and 16.4 Hz) 8.01 (d, 1H, J = 7.6 Hz) 7.80 (d, 1H, J = 7.6 Hz) 7.75-7.55 (m, 6H) 7.42 (dd, 2H, J = 1.2 and 8.4 Hz) 7.25 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) *m/z*: 444.3 (M+1).
365	(*E*)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.16 (d, 1H, J = 7.6 Hz) 8.13 (s, 1H) 7.90 (d, 1H, J = 9.2 Hz) 7.68 (d, 1H, J = 14.4 Hz) 7.65-7.49 (m, 4H) 7.43-7.38 (m, 4H) 7.25 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) *m/z*: 410.3 (M+1).
366	(*E*)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.35 (d, 1H, J = 16.4 Hz) 8.16 (dd, 1H, J = 1.6 and 8.0 Hz) 7.97 (dd, 1H, J = 1.6 and 7.6 Hz) 7.84 (s, 1H) 7.80 (d, 1H, J = 9.2 Hz) 7.76 (dd, 1H, J = 1.2 and 8.0 Hz) 7.70-7.60 (m, 3H) 7.52 (dt, 1H, J = 1.2 and 8.2 Hz) 7.45-7.39 (m, 2H) 7.32 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) *m/z*: 454.3 (M+1).
367	(*E*)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 7.6 Hz) 8.12-8.08 (m, 2H) 7.76-7.41 (m, 8H) 7.25 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) *m/z*: 461.4 (M+1).
368	(*E*)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 8.10 (t, 1H, 7.0 Hz) 7.91 (d, 1H, J = 16.4 Hz) 7.75-7.54 (m, 5H) 7.46-7.34 (m, 4H) MS (ESI, pos. ion) *m/z*: 461.4 (M+1).
369	(*E*)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.16 (dd, 1H, J = 1.6 and 8.0 Hz) 8.12-8.10 (m, 2H) 7.94 (d, 1H, J = 16.8 Hz) 7.85 (dd, 1H, J = 0.8 and 1.6 Hz) 7.80 (dd, 1H, J = 0.8 and 8.8 Hz) 7.70-7.59 (m, 3H) 7.52 (t, 1H, J = 9.8 Hz) 7.43 (dd, 1H, J = 1.6 and 7.6 Hz) 7.39 (d, 1H, J = 16.8 Hz) MS (ESI, pos. ion) *m/z*: 462.3 (M+1).

Cpd	Name and Data
370	(*E*)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (d, 1H, J = 8.0 Hz) 7.79 (d, 1H, J = 16.8 Hz) 7.68 (d, 1H, J = 16.0 Hz) 7.64-7.55 (m, 4H) 7.43-7.40 (m, 2H) 7.31 (d, 1H, J = 16.8 Hz) 7.23 (q, 1H, J = 8.1 Hz) MS (ESI, pos. ion) *m/z*: 430.4 (M+1).
371	(*E*)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.84-7.79 (m, 1H) 7.75 (d, 1H, J = 15.6 Hz) 7.68-7.53 (m, 4H) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.37 (dd, 1H, J = 1.6 and 8.4 Hz) 7.33-7.25 (m, 2H) MS (ESI, pos. ion) *m/z*: 430.3 (M+1).
372	(*E*)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 0.8 and 7.6 Hz) 7.85 (d, 1H, J = 16.8 Hz) 7.70-7.54 (m, 4H) 7.49 (d, 1H, J = 16.8 Hz) 7.46-7.40 (m, 3H) 7.10 (t, 2H, J = 8.8 Hz) MS (ESI, pos. ion) *m/z*: 412.3 (M+1).
373	(*E*)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.25 (s, 2H) 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.95 (s, 1H) 7.71 (d, 1H, J = 16.8 Hz) 7.68-7.53 (m, 4H) 7.44 (d, 1H, J = 16.8 Hz) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.35 (dd, 1H, J = 1.6 and 8.0 Hz) MS (ESI, pos. ion) *m/z*: 512.4 (M+1).
374	(*E*)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.36 (s, 1H) 8.24 (dd, 1H, J = 2.0 and 16.4 Hz) 8.16 (dd, 1H, J = 1.2 and 8.0 Hz) 8.06 (d, 1H, J = 8.4 Hz) 7.84 (d, 1H, J = 8.4 Hz) 7.83 (s, 1H) 7.79 (d, 1H, J = 8.8 Hz) 7.69-7.57 (m, 3H) 7.48-7.42 (m, 2H) MS (ESI, pos. ion) *m/z*: 512.4 (M+1).
375	(*E*)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.51 (d, 1H, J = 16.0 Hz) 8.16-8.10 (m, 2H) 8.03 (d, 1H, J = 8.4 Hz) 7.82 (dd, 1H, J = 1.6 and 8.0 Hz) 7.75-7.55 (m, 4H) 7.49-7.36 (m, 2H) 7.28 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) *m/z*: 488.1 (M+1).
376	(*E*)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.15 (d, 1H, J = 7.6 Hz) 7.89 (s, 1H) 7.74-7.58 (m, 7H) 7.48-7.37 (m, 3H) 7.27 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) *m/z*: 454.3 (M).

Cpd	Name and Data
378	(*E*)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.6 and 8.0 Hz) 8.04 (d, 1H, J = 2.0 Hz) 7.93 (dd, 1H, J = 2.0 and 8.4 Hz) 7.71-7.54 (m, 6H) 7.43-7.38 (m, 2H) 7.32 (d, 1H, J = 16.8 Hz) MS (ESI, pos. ion) *m/z*: 478.4 (M+1).
379	(*E*)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 8.0 Hz) 8.00 (dd, 1H, J = 2.4 and 6.4 Hz) 7.88 (d, 1H, J = 16.4 Hz) 7.76-7.57 (m, 5H) 7.51 (dd, 1H, J = 1.6 and 8.8 Hz) 7.42 (dd, 1H, J = 1.2 and 8.0 Hz) 7.38 (d, 1H, J = 16.4 Hz) 7.20 (dd, 1H, J = 8.8 and 10.4 Hz) MS (ESI, pos. ion) *m/z*: 472.3 (M+1).
423	(*E*)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, J=1.2, 8.2 Hz, 1H), 7.74-7.62 (m, 7H), 7.43- 7.34 (m, 3H), 6.64 (d, J=16.0 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{22}H_{15}F_4N_3O_2S$: 462.1 (M + H), Found 462.2.
424	(*E*)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm); 8.13 (dd, J=1.6, 8.0 Hz, 1H), 7.99 (t, J=7.2 Hz, 1H), 7.83 (d, J=16.8 Hz, 1H), 7.67-7.52 (m, 4H), 7.45 (s, 1H), 7.43-7.40 (m, 3H), 7.34 (dd, J=1.6, 7.6 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{22}H_{15}F_4N_3O_2S$: 462.1 (M + H), Found 462.2.
425	(*E*)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 8.0 Hz, 1H), 7.99 (t, J=7.2 Hz, 1H), 7.57 (d, J=16 Hz, 1H), 7.67-7.60 (m, 2H), 7.45 (s, 1H), 7.43-7.40 (m, 2H), 7.25 (t, J=4 Hz, 1H), 7.11 (d, J=8 Hz, 1H), 7.07-7.08 (m, 1H), 6.92-6.89 (m, 1H), 6.45 (d, J=16 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{23}H_{21}N_3O_3S$: 420.1 (M + H), Found 420.2.
426	(*E*)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide 1H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 7.8 Hz, 1H), 7.66-7.58 (m, 6H), 7.54 (dt, J=1.6, 7.6 Hz, 1H), 7.44-7.40 (m, 3H), 7.38-7.34 (m, 1H), 7.31 (dd, J=1.6, 8 Hz, 1H), 7.18 (d, J=16.4 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{21}H_{17}N_3O_2S$: 376.1 (M + H), Found 376.3.
427	(*E*)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 8 Hz, 1H), 7.82 (s, 1H), 7.65-7.61 (m, 3H), 7.60-7.54 (m, 3H), 7.52 (s, 1H), 7.41 (dd, J=1.6, 8 Hz, 1H), 7.32 (dd, J=1.6, 8 Hz, 1H), 7.22 (d, J=16.4 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{21}H_{15}Cl_2N_3O_2S$: 444.0 (M + H), Found 444.1.

Cpd	Name and Data
428	(*E*)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 8 Hz, 1H), 7.78 (d, J=8 Hz, 1H), 7.75 (d, J=8 Hz, 1H), 7.72 (s, 1H), 7.55-7.54 (m, 1H), 7.62 (dd, J=1.6, 8 Hz, 1H), 7.54 (dt, J=1.6, 8 Hz, 1H), 7.41 (dd, J=1.6, 8 Hz, 1H), 7.34-7.26 (m, 4H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{21}H_{15}ClFN_3O_2S$: 428.9 (M + H), Found 430.2.
429	(*E*)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 8 Hz, 1H), 7.65-7.60 (m, 4H), 7.58-7.52 (m, 3H), 7.41 (dd, J=1.6, 8 Hz, 1H), 7.32-7.29 (m, 3H), 7.13 (d, J=16.8 Hz, 1H), 2.94 (h, J=2.4 Hz, 1H), 1.27 (d, J=8 Hz, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{24}H_{23}N_3O_2S$: 418.1 (M + H), Found 418.4.
430	(*E*)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 8 Hz, 1H), 7.65-7.58 (m, 5H), 7.53 (d, J=7.6 Hz, 2H), 7.41 (dd, J=1.6, 8 Hz, 1H), 7.30 (dd, J=1.6, 8 Hz, 1H), 7.23 (d, J=8 Hz, 2H), 7.11 (d, J=16.8 Hz, 1H), 2.36 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{22}H_{19}N_3O_2S$: 390.1 (M + H), Found 390.5.
431	(*E*)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 8 Hz, 1H), 7.80 (d, J=16 Hz, 1H), 7.73 (t, J=7.2 Hz, 1H), 7.66-7.60 (m, 4H), 7.57-7.52 (m, 1H), 7.51-7.46 (m, 1H), 7.42 (dd, J=1.6, 8 Hz, 1H), 7.33 (dd, J=1.6, 8 Hz, 1H), 7.22 (d, J=16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{21}H_{15}ClFN_3O_2S$: 428.9 (M + H), Found 428.3.
432	(*E*)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 8 Hz, 1H), 7.80 (dd, J=2, 7.2 Hz, 1H), 7.65-7.52 (m, 6H), 7.41 (dd, J=1.6, 8 Hz, 1H), 7.33-7.28 (m, 2H), 7.16 (d, J=16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{21}H_{15}ClFN_3O_2S$: 428.9 (M + H), Found 428.3.
433	(*E*)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-benzene sulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 8 Hz, 1H), 8.01 (s, 1H), 7.91-7.82 (m, 4H), 7.80 (d, J=16.8 Hz, 1H), 7.66-7.59 (m, 3H), 7.55 (dd, J=1.6, 8 Hz, 1H), 7.52-7.48 (m, 2H), 7.42 (dd, J=2, 7.6 Hz, 1H), 7.32 (dd, J=1.6, 8 Hz, 1H), 7.30 (d, J=16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{25}H_{19}N_3O_2S$: 426.5 (M + H), Found 426.3.

Cpd	Name and Data
434	(*E*)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 8 Hz, 1H), 7.69-7.66 (m, 2H), 7.65-7.52 (m, 5H), 7.41 (dd, J=1.6, 8 Hz, 1H), 7.31 (dd, J=1.6, 8 Hz, 1H), 7.18-7.10 (m, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{21}H_{16}FN_3O_2S$: 394.4 (M + H), Found 394.3.
435	(*E*)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 8 Hz, 1H), 7.70 (d, J=8 Hz, 2H), 7.66-7.61 (m, 4H), 7.54 (dt, J=1.6, 8 Hz, 1H), 7.42 (dd, J=1.6, 8 Hz, 1H), 7.32 (d, J=8 Hz, 1H), 7.20 (d, J=8 Hz, 2H), 7.15 (d, J=16 Hz, 1H), 6.89 (s, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{22}H_{17}F_2N_3O_2S$: 426.5 (M + H), Found 426.3.
436	(*E*)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 8 Hz, 1H), 7.78 (s, 1H), 7.73 (dd, J=1.6, 8 Hz, 1H), 7.66-7.61 (m, 4H), 7.54 (dt, J=1.6, 8 Hz, 1H), 7.44 (d, J=8 Hz, 1H), 7.41 (dd, J=1.6, 8 Hz, 1H), 7.33 (d, J=8 Hz, 1H), 7.34 (d, J=16 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{22}H_{15}F_4N_3O_2S$: 461.4 (M + H), Found 462.2.
437	(*E*)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 8 Hz, 1H), 7.97 (d, J=16.8 Hz, 1H), 7.84 (d, J=8 Hz, 1H), 7.66-7.51 (m, 5H), 7.41-7.37 (m, 2H), 7.32 (dd, J=1.6, 8 Hz, 1H), 7.20 (d, J=16 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{21}H_{15}Cl_2N_3O_2S$: 445.3 (M + H), Found 446.1.
438	(*E*)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 8 Hz, 1H), 7.89 (d, J=16.8 Hz, 1H), 7.66-7.60 (m, 3H), 7.54 (dt, J=1.6, 8 Hz, 1H), 7.45 (d, J=16 Hz, 1H), 7.43 (s, 1H), 7.41-7.32 (m, 3H), 7.24-7.18 (m, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{21}H_{15}ClFN_3O_2S$: 428.9 (M + H), Found 428.3.
439	(*E*)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 8 Hz, 1H), 7.94 (dd, J=1.6, 8 Hz, 1H), 7.68-7.62 (m, 6H), 7.41 (dd, J=1.6, 8 Hz, 1H), 7.32 (d, J=1.6, 8 Hz, 1H), 7.28 (t, J=8 Hz, 1H), 7.16 (d, J=16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{21}H_{15}BrFN_3O_2S$: 473.3 (M + H), Found 473.2.

Cpd	Name and Data
440	(*E*)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, J=1.6, 8 Hz, 1H), 7.94 (dd, J=1.6, 8 Hz, 1H), 7.68-7.62 (m, 6H), 7.41 (dd, J=1.6, 8 Hz, 1H), 7.32 (d, J=1.6, 8 Hz, 1H), 7.28 (t, J=8 Hz, 1H), 7.16 (d, J=16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{21}H_{15}BrFN_3O_2S$: 473.3 (M + H), Found 473.2.

Prophetic Example 17

Using the procedures described in Example 15 or 16 and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:

Cpd	Name and Data
91	(*E*)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
97	(*E*)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
103	(*E*)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
109	(*E*)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
115	(*E*)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
121	(*E*)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide, and
127	(*E*)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide.

Example 18

(*E*)-N-Methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd **310**)

Step A. N-methylbenzenesulfonamide-2-boronic acid

To a solution of N-methylbenzenesulfonamide (2.00 g, 0.0117 mmol) in 20 mL THF at 0 °C was added dropwise n-butyl lithium (1.6 M in hexanes, 14.6 mL, 0.0234 mmol). After 30 min., triisopropyl borate (3.1 mL, 0.0164 mmol) was

added, and the mixture was stirred at 0 °C for 2 hours. The reaction was quenched by addition of 20 mL of 1M HCl (aq). The mixture was extracted with EtOAc, and the organic fractions were washed with brine, dried over Na_2SO_4, filtered, and the filtrate was concentrated to provide the title Compound **18a** as a yellow oil. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.81 (d, 1H) 7.62-7.56 (m, 2H) 2.52 (s, 3H).

Step B. (3-tert-butoxycarbonylamino-2'-methylsulfamoyl-biphenyl-4-yl)-carbamic acid tert-butyl ester

A mixture of the freshly prepared Compound **18a** (9.3 g, 0.0434 mol), Compound **16a** (11.2 g, 0.289 mol), $Pd(dppf)Cl_2CH_2Cl_2$ (4.7 g, 6.42 mmol), TBAB (9.3 g, 0.0289 mol), in 120 mL of 1M Na_2CO_3 (aq) and 600 mL DME was heated at 85 °C for 10 hours. The reaction mixture was cooled, and concentrated. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 2: 1) to provide the title Compound **18b** as a yellow oil. ^{1}H-NMR (400 MHz, CDCl3) δ (ppm): 8.12 (d, 1H) 7.86 (d, 1H) 7.62-7.46 (m, 3H) 7.22 (d, 1H) 7.14 (d, 1H) 2.62 (d, 3H) 1.55 (s, 9H) 1.44 (s, 9H).

Step C. 3',4'-diamino-biphenyl-2-sulfonic acid methylamide

A solution of Compound **18b** (21.4 g, 0.0995 mol) in 210 mL of 4M HCl in dioxane was stirred for 4 hours. The reaction mixture was concentrated, made basic with 1M NaOH (aq), and extracted with EtOAc. The organic fraction was dried over Na_2SO_4, filtered, and the filtrate was concentrated to provide the title Compound **18c** as a brown oil. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.00 (dd, 1H, J = 1.6 and 8.0 Hz) 7.59 (dt, 1H, J = 1.6 and 8.4 Hz) 7.48 (dt, 1H, J = 1.2 and 8.4 Hz) 7.33 (dd, 1H, J = 1.2 and 8.0 Hz) 6.79 (d, 1H, J = 2.0 Hz) 6.75 (d, 1H, J = 8.4 Hz) 6.68 (d, 1H, J = 2.0 and 7.6 Hz) 2.93 (s, 3H) MS (ESI, pos. ion) *m/z*: 277.9 (M+1).

Step D. (*E*)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide

A mixture of Compound **18c** (0.100 g, 0.361 mmol) and 4-trifluoromethyl cinnamic acid (0.324 mmol) in 2 mL of $POCl_3$ was heated to 100 °C for 14 hours. Evaporation of the reaction mixture provided a residue, which was then purified by HPLC (H_2O:MeCN, 90:10 to 30:70, over 15 min) to provide the title Compound **310** as a white solid. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.4 Hz) 7.85 (d, 2H, J = 8.4 Hz) 7.73 (d, 2H, J = 8 Hz) 7.69-7.63 (m, 3H) 7.58 (dt, 2H, J = 1.6 and 7.2 Hz) 7.44 (dd, 1H, J = 1.2 and 7.2 Hz) 7.34 (d, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 499.2 (M+MeCN+1).

Using the procedures described in Example 18 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
312	(*E*)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.68-7.60 (m, 3H) 7.59-7.55 (m, 6H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.30 (dd, 1H, J = 1.6 and 8.0 Hz) 7.21 (d, 1H, J = 16.4 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) *m/z*: 509.2 (M+MeCN).
314	(*E*)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzene sulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.04 (dd, 1H, J = 1.2 and 8.0 Hz) 7.77 (d, 1H, J = 16.4 Hz) 7.70 (d, 1H, J = 15.2 Hz) 7.66-7.64 (m, 2H) 7.61-7.55 (m, 3H) 7.46 (dd, 1H, J = 1.6 and 8.4 Hz) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.26 (d, 2H, J = 7.6 Hz) 7.15 (d, 1H, J = 16.8 Hz) 2.42 (s, 3H) 2.36 (s, 3H) MS (ESI, pos. ion) *m/z*: 404.2 (M+1).
315	(*E*)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 7.6 Hz) 7.82-7.73 (m, 4H) 7.70-7.66 (m, 2H) 7.61 (dd, 1H, J = 1.2 and 7.6 Hz) 7.45 (dd, 1H, J = 1.2 and 8.0 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.22 (d, 1H, J = 8.4 Hz) 7.21 (s, 2H) 7.18 (d, 1H, J = 7.6 Hz) 2.42 (s, 3H) MS (ESI, pos. ion) *m/z*: 408.3 (M+1).

Cpd	Name and Data
316	(*E*)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 7.6 Hz) 7.84 (s, 1H) 7.70-7.66 (m, 2H) 7.64 (d, 1H) 7.60 (d, 2H, J = 7.6 Hz) 7.59 (s, 2H) 7.42 (dt, 2H, J = 1.6 and 9.2 Hz) 7.25 (d, 1H, J = 16.4 Hz) 2.42 (s, 3H) MS (ESI, pos. ion) *m/z*: 408.3 (M+1).
317	(*E*)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 7.6 Hz) 7.96 (dd, 1H, J = 2 and 5 Hz) 7.69-7.62 (m, 4H) 7.61-7.57 (m, 2H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.39 (dd, 1H, J = 1.6 and 8.0 Hz) 7.29 (t, 1H, J = 8.4 Hz) 7.18 (d, 1H, J = 16.4 Hz) 2.40 (s, 3H) MS (ESI, pos. ion) *m/z*: 486.2 (M).
318	(*E*)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 7.6 Hz) 7.96 (d, 1H, J = 16.4 Hz) 7.73-7.67 (m, 3H) 7.63 (dd, 1H, J = 1.2 and 8.0 Hz) 7.59 (d, 2H, J = 9.2 Hz) 7.52 (dd, 1H, J = 1.6 and 8.4 Hz) 7.44 (dd, 1H, J = 1.6 and 7.6 Hz) 6.90 (d, 1H, J = 16 Hz) 6.81 (d, 2H, J = 8.8 Hz) 3.06 (s, 6H) 2.45 (s, 3H) MS (ESI, pos. ion) *m/z*: 433.4 (M+1).
319	(*E*)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 6.4 Hz) 7.77 (q, 1H, J = 5.3 Hz) 7.73-7.63 (m, 5H) 7.60 (dt, 1H, J = 1.6 and 8.4 Hz) 7.51 (dd, 1H, J = 1.6 and 6.4 Hz) 7.43 (d, 2H, J = 8.4 Hz) 7.39 (d, 1H, J = 16.8 Hz) 2.41 (s, 3H) MS (ESI, pos. ion) *m/z*: 476.3 (M+1).
320	(*E*)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 6.4 Hz) 8.01 (t, 1H, J = 7.8 Hz) 7.90 (d, 1H, J = 16.4 Hz) 7.70-7.65 (m, 3H) 7.61-7.56 (m, 3H) 7.45 (d, 1H, J = 16.8 Hz) 7.28 (dd, 1H, J = 1.2 and 7.2 Hz) 7.40 (d, 1H, J = 1.2 and 7.2 Hz) 2.40 (s, 3H) MS (ESI, pos. ion) *m/z*: 476.3 (M+1).
321	(*E*)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 6.0 Hz) 7.86 (t, 1H, J = 2.0 and 6.2 Hz) 7.73-7.65 (m, 5H) 7.61 (dd, 1H, J = 1.6 and 7.6 Hz) 7.46 (dd, 1H, J = 1.6 and 8.8 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.34 (t, 1H, J = 8.8 Hz) 7.22 (d, 1H, J = 16.4 Hz) 2.42 (s, 3H) MS (ESI, pos. ion) *m/z*: 442.3 (M+1).

Cpd	Name and Data
322	(*E*)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 6.0 Hz) 7.86 (t, 1H, J = 2.0 and 6.2 Hz) 7.73-7.65 (m, 5H) 7.61 (dd, 1H, J = 1.6 and 7.6 Hz) 7.46 (dd, 1H, J = 1.6 and 8.8 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.34 (t, 1H, J = 8.8 Hz) 7.22 (d, 1H, J = 16.4 Hz) 2.42 (s, 3H) MS (ESI, pos. ion) *m/z*: 442.3 (M+1).
323	(*E*)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (d, 1H, J = 7.6 Hz) 7.75 (d, 1H, J = 16.8 Hz) 7.68-7.56 (m, 5H) 7.43 (d, 1H, J = 3.2 Hz) 7.34 (d, 1H, J = 1.2 and 8.0 Hz) 7.33 (d, 1H, J = 4.0 Hz) 7.22 (q, 1H, J = 8.8 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) *m/z*: 444.4 (M+1).
324	(*E*)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 8.0 Hz) 7.87-7.82 (m, 2H) 7.72-7.58 (m, 5H) 7.46-7.42 (m, 2H) 7.31 (d, 1H, J = 16.4 Hz) 2.41 (s, 3H) MS (ESI, pos. ion) *m/z*: 444.4 (M+1).
325	(*E*)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.95 (d, 1H, J = 16.8 Hz) 7.74-7.66 (m, 3H) 7.63-7.59 (m, 2H) 7.47 (dd, 1H, J = 1.6 and 8.0 Hz) 7.44 (dd, 1H, J = 1.6 and 8.0 Hz) 7.39 (d, 1H, J = 16.8 Hz) 7.34-7.70 (m, 2H) 2.42 (s, 3H) MS (ESI, pos. ion) *m/z*: 426.4 (M+1).
326	(*E*)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.82 (d, 1H, J = 16.4 Hz) 7.69-7.64 (m, 3H) 7.61-7.55 (m, 2H) 7.43 (dd, 1H, J = 1.6 and 7.6 Hz) 7.37 (dd, 1H, J = 1.6 and 8.8 Hz) 7.33 (d, 1H, J = 16.8 Hz) 7.26-7.15 (m, 2H) 2.39 (s, 3H) MS (ESI, pos. ion) *m/z*: 426.4 (M+1).
327	(*E*)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.90 (d, 1H, J = 16.8 Hz) 7.71-7.58 (m, 4H) 7.51 (d, 1H, J = 16.8 Hz) 7.46-7.43 (m, 3H) 7.12 (t, 2H, J = 9.0 Hz) 2.41 (s, 3H) MS (ESI, pos. ion) *m/z*: 426.4 (M+1).
328	(*E*)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 8.0 Hz) 7.68-7.56 (m, 5H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.36 (dd, 1H, J = 1.6 and 8.8 Hz) 7.31-7.25 (m, 3H) 6.99-6.96 (m, 1H) 2.39 (s, 3H) MS (ESI, pos. ion) *m/z*: 426.3 (M+1).

Cpd	Name and Data
329	(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.66-7.56 (m, 6H) 7.48-7.42 (m, 2H) 7.36-7.32 (m, 2H) 7.17 (d, 1H, J = 16.8 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) *m/z*: 426.4 (M+1).
330	(*E*)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.25 (dd, 1H, J = 1.6 and 16.4 Hz) 8.16 (dd, 1H, J = 1.2 and 9.2 Hz) 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 8.4 (d, 1H, J = 1.2 Hz) 8.25 (dd, 1H, J = 0.8 and 8.0 Hz) 7.73-7.56 (m, 5H) 7.46 (dd, 1H, J = 1.6 and 8.0 Hz) 7.65 (d, 1H, J = 16.4 Hz) 2.46 (s, 3H) MS (ESI, pos. ion) *m/z*: 476.4 (M+1).
331	(*E*)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 8.02-7.98 (m, 2H) 7.18-7.56 (m, 4H) 7.45-7.40 (m, 2H) 7.38 (dd, 1H, J = 1.6 and 8.4 Hz) 7.26 (d, 1H, J = 16.8 Hz) 2.39 (s, 3H) MS (ESI, pos. ion) *m/z*: 476.4 (M+1).
332	(*E*)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.10-8.05 (m, 2H) 7.84 (d, 1H, J = 16.8 Hz) 7.71-7.55 (m, 5H) 7.43 (dd, 1H, J = 1.6 and 7.2 Hz) 7.37 (d, 1H, J = 16.8 Hz) 7.32 (dd, 1H, J = 1.2 and 8.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 476.5 (M+1).
333	(*E*)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.24 (s, 2H) 7.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.94 (s, 1H) 7.73-7.55 (m, 5H) 7.45-7.40 (m, 2H) 7.32 (dd, 1H, J = 1.6 and 8.4 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) *m/z*: 526.4 (M+1).
334	(*E*)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.27 (s, 1H) 8.08-7.92 (m, 3H) 8.87 (d, 1H, J = 8.4 Hz) 7.69-7.56 (m, 4H) 7.44 (dd, 1H, J = 1.6 and 8.0 Hz) 7.36-7.32 (m, 2H) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 526.4 (M+1).
335	(*E*)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (d, 1H, J = 8.4 Hz) 7.93 (d, 1H, J = 8.0 Hz) 7.81 (d, 1H, J = 16.4 Hz) 7.74-7.56 (m, 4H) 7.50-7.23 (m, 5H) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 442.4 (M+1).

Cpd	Name and Data
336	(*E*)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.89 (d, 1H, J = 16.8 Hz) 7.68-7.55 (m, 4H) 7.45 (d, 1H, J = 16.8 Hz) 7.43 (dd, 1H, J = 1.2 and 7.6 Hz) 7.38-7.31 (m, 3H) 7.23-7.18 (m, 1H) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 442.4 (M+1).
337	(*E*)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 8.0 Hz) 8.51 (d, 1H, J = 16.8 Hz) 7.88 (d, 1H, J = 8.0 Hz) 7.68-7.56 (m, 5H) 7.45-7.41 (m, 2H) 7.32 (dd, 1H, J = 1.6 and 8.4 Hz) 7.24 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 458.3 (M+1).
338	(*E*)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.82 (t, 1H, J = 1.8 Hz) 7.68-7.49 (m, 7H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.35 (d, 1H, J = 7.6 Hz) 7.30 (dd, 1H, J = 0.8 and 8.0 Hz) 7.21 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 468.3 (M+1).
339	(*E*)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.40 (d, 1H, J = 16.4 Hz) 8.08-8.06 (m, 2H) 8.01 (d, 1H, J = 8.4 Hz) 7.89 (dd, 1H, J = 2.4 and 8.4 Hz) 7.80-7.56 (m, 4H) 7.44 (dd, 1H, J = 1.2 and 7.2 Hz) 7.33 (dd, 1H, J = 1.6 and 7.2 Hz) 7.26 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 442.3 (M+1).
340	(*E*)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.76-7.72 (m, 2H) 7.66-7.54 (m, 4H) 7.42 (dd, 1H, J = 0.8 and 7.2 Hz) 7.32-7.26 (m, 4H) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 502.3 (M+1).
341	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethylthio-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.12 (d, 2H, J = 8.8 Hz) 8.06 (dd, 1H, J = 1.2 and 8.4 Hz) 8.06 (d, 2H, J = 8.8 Hz) 7.75-7.56 (m, 5H) 7.47 (d, 1H, J = 16.4 Hz) 7.44 (dd, 1H, J = 1.2 and 7.2 Hz) 7.34 (dd, 1H, J = 1.2 and 8.4 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) *m/z*: 522.3 (M+1).
342	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.4 Hz) 7.75 (q, 4H, J = 10.6 Hz) 7.44-7.55 (m, 5H) 7.43 (dd, 1H, J = 1.2 and 7.6 Hz) 7.33-7.28 (m, 2H) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 490.3 (M+1).

Cpd	Name and Data
343	(*E*)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 8.02 (dd, 1H, J = 12.0 and 16.0 Hz) 7.98 (d, 1H, J = 8.0 Hz) 7.77 (d, 1H, J = 8.4 Hz) 7.72-7.62 (m, 4H) 7.57 (dt, 1H, J = 1.6 and 8.4 Hz) 7.54 (t, 1H, J = 7.6 Hz) 7.44 (dd, 1H, J = 1.2 and 7.2 Hz) 7.32 (dd, 1H, J = 1.6 and 8.4 Hz) 7.21 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 458.4 (M+1).
344	(*E*)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.66-7.62 (m, 4H) 7.60-7.54 (m, 3H) 7.51 (d, 1H, J = 8.0 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.31 (dd, 1H, J = 1.2 and 8.0 Hz) 7.28 (d, 1H, J = 8.4 Hz) 7.25 (d, 1H, J = 16.8 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 474.4 (M+1).
345	(*E*)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.75 (d, 2H, J = 8.4 Hz) 7.69-7.64 (m, 3H) 7.61 (d, 1H, J = 8.0 Hz) 7.57 (dt, 1H, J = 1.2 and 8.4 Hz) 7.42 (dd, 1H, J = 1.6 and 8.4 Hz) 7.33 (d, 3H, J = 10.0 Hz) 7.20 (d, 1H, J = 16.4 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) *m/z*: 474.4 (M+1).
346	(*E*)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.03-8.05 (m, 2H) 7.87 (dd, 2H, J = 1.68 and 7.6 Hz) 7.66-7.55 (m, 4H) 7.45 (dd, 1H, J = 1.6 and 7.6 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.38-7.30 (m, 3H) 7.22 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 425.3 (M+1).
347	(*E*)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.36-7.63 (m, 4H) 7.62-7.55 (m, 3H) 7.44 (d, 3H, J = 8.0 Hz) 7.31 (dd, 1H, J = 1.6 and 8.0 Hz) 7.19 (d, 1H, J = 16.4 Hz) 2.36 (s, 3H) MS (ESI, pos. ion) *m/z*: 425.3 (M+1).
348	(*E*)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 8.02 (d, 1H, J = 16.4 Hz) 7.84 (dd, 1H, J = 1.6 and 8.4 Hz) 7.68-7.55 (m, 5H) 7.44-7.40 (m, 2H) 7.31 (dd, 1H, J = 1.2 and 6.8 Hz) 7.02 (dt, 1H, J = 1.6 and 8.4 Hz) 7.17 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 469.5 (M+1).

Cpd	Name and Data
349	(*E*)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.80 (q, 1H, J = 8.0 Hz) 7.74 (d, 1H, J = 16.8 Hz) 7.67-7.54 (m, 5H) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.30 (dd, 1H, J = 1.6 and 8.4 Hz) 7.23 (d, 1H, J = 16.8 Hz) 7.05 (t, 1H, J = 8.8 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 426.4 (M+1).
351	(*E*)-2-{2-[2-(**4**-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 8.01 (d, 2H, J = 8.4 Hz) 7.90 (d, 2H, J = 8.8 Hz) 7.72 (d, 1H, J = 16.4 Hz) 7.67-7.56 (m, 4H) 7.44 (dd, 1H, J = 1.6 and 7.2 Hz) 7.38 (d, 1H, J = 16.4 Hz) 7.33 (dd, 1H, J = 1.6 and 8.4 Hz) 3.15 (s, 3H) 2.37 (s, 3H) MS (ESI, pos. ion) *m/z*: 468.4 (M+1).

Example 19

(*E*)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide (Cpd **414**)

Step A. (3-tert-butoxycarbonylamino-2'-methanesulfonylamino-biphenyl-4-yl)-carbamic acid tert-butyl ester

To a solution of Compound **16a** (2.0 g, 5.1 mmol), 2-methylsulfonylphenyl boronic acid (1.1 g, 5.1 mmol), and K_2CO_3 (2.1g, 15.3 mmol) in 1,4-dioxane: water (4:1, 120 mL), was added $Pd(dppf)Cl_2CH_2Cl_2$ (0.42 g, 0.51 mmol) under an argon atmosphere. The mixture was heated at 95 °C for 12 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by chromatography (silica, EtOAc: hexanes, 3: 7) to provide the title Compound **19a** as a yellow solid (1.7 g, 70 % yield). ^{1}H NMR (400MHz, $CDCl_3$) δ (ppm): 7.64 (d, J=8.4 Hz, 1H), 7.57 (d, J=14.4 Hz, 1H), 7.34 (t, J=8.4 Hz, 1H), 7.26-7.15 (m, 3H), 7.07 (s, 1H), 7.04 (d, J=8 Hz, 1H), 6.87 (s, 1H), 6.63 (s, 1H), 2.90 (s, 3H), 1.51 (s, 9H), 1.49 (s, 9H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{23}H_{31}N_3O_6S$: 478.19 (M + H), Found 478.0.

Step B. N-(3',4'-diamino-biphenyl-2-yl)-methanesulfonamide

A solution of Compound **19a** (1.0 g, 2.1 mmol) in a mixture of **4**M HCl in 1,4-dioxane (10 mL) was heated at 70 °C for 2 h. After concentration of the

reaction, the residue was dissolved in dichloromethane (20 mL), and to the solution was added K_2CO_3 (0.5 g) and the mixture was stirred at room temperature for 20 min. After filtration and removal of solvents, the residue was dried to provide the title Compound **19b** as a brown solid (0.58 g, quantitative yield). ^1H NMR (400MHz, CD_3OD) δ (ppm): 7.47 (d, J=8.4 Hz, 1H), 7.40-7.35 (m, 1H), 7.32-7.29 (m, 2H), 7.16-7.09 (m, 3H), 2.80 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{13}H_{15}N_3O_2S$: 278.09 (M + H), Found 278.1.

Step C. (*E*)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide

A solution of Compound **19b** (50 mg, 0.18 mmol) and commercially available 3-(4-ethoxy-phenyl)-acrylic acid (34.6 mg, 0.18 mmol) in $POCl_3$ (1.5 mL) was heated to 100 ^0C for 12 h. The reaction was cooled, the excess $POCl_3$ was removed under reduced pressure, and the residue was purified by HPLC (Gilson, C-18 column, CH_3CN: H_2O (gradient of CH_3CN: 5%-80%)) to provide the title Compound **414** as an off-white solid (25 mg, 32% yield). ^1H NMR (400 MHz, CD_3OD) δ (ppm):7.62-7.59 (m, 4H), 7.54-7.52 (m, 1H), 7.41-7.37 (m, 2H), 7.35-7.30 (m, 2H), 7.03 (d, J=16.8 Hz, 2H), 6.97 (d, J=12 Hz, 2H), 4.09 (q, J=7.2 Hz, 2H), 2.72 (s, 3H), 1.41 (t, J=7.2 Hz, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{24}H_{23}N_3O_3S$: 434.1 (M + H), Found 434.1.

Using the procedures described in Example 19 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
77	(*E*)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide ^1H-NMR (400 MHz, CD_3OD) δ (ppm) 7.40-7.56 (m, 6H) 7.24-7.33 (m, 4H) 7.19-7.22 (m, 2H) 7.05 (d, J=16.4Hz, 1H) 2.61 (s, 3H). MS (ESI, pos. ion) m/z: 424.1 (M+1).,

Cpd	Name and Data
83	(*E*)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.99-7.96 (m, 2H), 7.89-7.86 (m, 4H), 7.78 (dd, J=6.4, 15.8 Hz, 2H), 7.60 (dd, J=1.2, 8.2 Hz, 1H), 7.46-7.39 (m, 2H), 7.33 (dt, J=1.6, 8.2 Hz, 2H), 6.99 (dd, J=6.4, 15.8 Hz, 2H), 3.10 (s, 3H), 3.09 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{23}H_{21}N_3O_4S_2$: 468.1 (M + H), Found 468.0.,
95	(*E*)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide ^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.67-7.62 (m, 5H), 7.54-7.52, (m,1H), 7.42-7.33 (m, 4H), 7.09 (d, J=16.4 Hz, 2H), 7.08 (d, J=12 Hz, 1H), 4.60 (q, J=8.4 Hz, 2H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{24}H_{20}F_3N_3O_3S$: 488.1 (M + H), Found 488.3,
101	(*E*)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.65-7.60 (m, 5H), 7.54-7.52 (m, 1H), 7.41-7.37 (m, 2H), 7.34-7.30 (m, 2H), 7.10-7.06 (m, 3H), 4.68 (t, *J*=12.8 Hz, 2H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{25}H_{20}F_5N_3O_3S$: 538.1 (M + H), Found 538.2.,
113	(*E*)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide ^{1}H-NMR (400 MHz, CD3OD) δ (ppm) 7.90-7.96 (m, 2H) 7.54-7.76 (m, 6H) 7.26-7.42 (m, 5H) 2.76 (s, 3H). MS (ESI, pos. ion) m/z: 458.1 (M+1).,
406	(*E*)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.87-7.80 (m, 2H), 7.58-7.30 (m, 9H), 2.85 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{22}H_{18}BrN_3O_2S$: 468.0 (M + H), Found 469.1.,
407	(*E*)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.67-7.52) (m, 6H), 7.14 (d,J=16.4 Hz, 1H), 3.13-3.12 (m, 1H), 2.72 (s, 3H), 1.27 (d, J=6.8 Hz, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{25}H_{25}N_3O_2S$: 432.2 (M + H), Found 432.2.,
408	(*E*)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.82 (dd, J=2.4, 7.2 Hz, 1H) 7.66-7.60 (m, 4H), 7.56-7.52 (m, 2H), 7.41-7.39 (m, 6H), 7.18 (d, J=16.4 Hz, 1H), 2.73 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{22}H_{17}ClFN_3O_2S$: 442.1 (M + H), Found 442.3.,

Cpd	Name and Data
409	(*E*)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.95 (dd, J-2.4, 6.8 Hz, 1H),7.69-7.68 (m, 1H), 7.67-7.63 (m, 2H), 7.58 (d, J=16.4 Hz, 1H), 7.53-7.51 (m, 1H), 7.40-7.26 (m, 5H), 7.18 (d, J=16.4 Hz, 1H), 2.72 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{22}H_{17}BrFN_3O_2S$: 486.0 (M + H), Found 486.3.,
410	(*E*)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.73 (d, J=12.8 Hz, 2H), 7.54-7.52 (m, 1H), 7.48-7.45 (m, 1H), 7.41-7.39 (m, 2H), 7.34-7.30 (m, 2H), 7.21 (d, J=8.8 Hz, 2H), 7.16 (d, J=17.2 Hz, 1H), 6.90 (s, 1H), 2.73 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{23}H_{19}F_2N_3O_3S$: 456.1 (M + H), Found 456.1.,
411	(*E*)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.77 (s, 1H), 7.75 (d, *J*=12 Hz, 1H), 7.68 (s, 1H), 7.67-7.64 (m, 2H), 7.52 (d, *J*=12 Hz, 1H), 7.46 (d, J=12 Hz, 1H), 7.40-7.25 (m, 5H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{23}H_{17}F_4N_3O_2S$: 476.1 (M + H), Found 476.2,
412	(*E*)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.65-7.60 (m, 3H), 7.41-7.36 (m, 3H), 7.41-7.36 (m, 2H), 7.33-7.30 (m, 2H), 7.26 (d, J=10 Hz, 2H), 7.18 (d, J=20 Hz, 1H), 2.74 (s, 3H), 2.39 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{23}H_{21}N_3O_2S$: 404.1 (M + H), Found 404.3,
413	(*E*)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.69-7.61 (m, 2H) 7.57-7.51 (m, 2H), 7.46-7.39 (m, 3H), 7.29 (d, J=16.2 Hz, 2H), 7.05 (d, J=12 Hz, 1H), 6.67 (d, J=16.2 Hz, 2H), 6.33 (d, J=12 Hz, 1H), 3.01 (s, 3H), 2.97 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{24}H_{24}N_4O_2S$: 433.2 (M + H), Found 433.3,
415	(*E*)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.09 (s, 1H), 7.96-7.88, (m, 4H), 7.74-7.72 (m, 2H), 7.57-7.52 (m, 3H), 7.51-7.33 (m, 6H), 2.80 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{26}H_{21}N_3O_2S$: 440.1 (M + H), Found 440.3,

Cpd	Name and Data
416	(*E*)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.03-8.00 (m, 1H), 7.93 (s, 1H), 7.77 (s, 1H), 7.74 (d, J=11.2 Hz, 1H), 7.69 (s, 1H), 7.57-7.52 (m, 2H), 7.47 (d, J=8 Hz, 1H), 7.44 (d, J= 7.6 Hz, 2H), 7.40-7.36 (m, 1H), 7.32 (d, J=17.2 Hz, 1H), 2.84 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{22}H_{17}Cl_2N_3O_2S$: 458.0 (M + H), Found 458.2.,
417	(*E*)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.03-8.00 (m, 1H), 7.76 (t, J=8.0 Hz, 1H), 7.71-7.67 (m, 3H), 7.63 (d, J=8.4 Hz, 1H), 7.54-7.52 (m, 1H), 7.78-7.44 (m, 1H), 7.43-7.38 (m, 3H), 7.38-7.32 (m, 1H), 2.77 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{23}H_{17}F_4N_3O_2S$: 476.1 (M + H), Found 476.2.,
418	(*E*)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.00 (t, J=8.4 Hz, 1H), 7.84 (d, J=17.2 Hz, 1H), 7.62-7.58 (m, 2H), 7.55-7.52 (m, 2H), 7.46 (s, 1H), 7.44-7.38 (m, 3H), 7.38-7.32 (m, 2H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{23}H_{17}F_4N_3O_2S$: 476.1 (M + H), Found 476.2,
475	(*E*)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm) 7.44-7.65 (m, 10H) 7.22-7.40 (m, 5H) 7.10-7.20 (m, 3H) 2.76 (s, 3H). MS (ESI, pos. ion) m/z: 466.2 (M+1).,

Prophetic Example 20

Using the procedures described in Example 19, or using the procedures in Example 1 and the corresponding bromobenzimidazole and boronic acid or boronate ester, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:

Cpd	Name and Data
89	(*E*)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
107	(*E*)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
119	(*E*)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

Cpd	Name and Data
125	(*E*)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,

Prophetic Example 21

Using the procedures described in Example 1 or Example 19 and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:

Cpd	Name and Data
72	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
73	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
74	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide.
75	(*E*)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
76	(*E*)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
80	(*E*)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide.
81	(*E*)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
82	(*E*)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
87	(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
88	(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
90	(*E*)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
92	(*E*)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
93	(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,

Cpd	Name and Data
94	(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
96	(*E*)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
98	(*E*)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
99	(*E*)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
100	(*E*)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
102	(*E*)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, and
104	(*E*)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide.
105	(*E*)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
106	(*E*)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
108	(*E*)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
110	(*E*)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
111	(*E*)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
112	(*E*)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
116	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide.
117	(*E*)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,
118	(*E*)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
120	(*E*)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
122	(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

Cpd	Name and Data
123	(*E*)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
124	(*E*)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
126	(*E*)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide, and
128	(*E*)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide.

Example 22

2-{2-[2-(2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd **401**)

A mixture of (*E*)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide Cpd **364** (0.020 g, 0.045 mmol) and 10 % palladium on charcoal (0.005 g, 0.0045 mmol) in 2 mL MeOH was hydrogenated under H_2 gas (1 atm) for 1 hour. The catalyst was removed by filtration, the filtrate was concentrated to dryness, and the residue was purified by chromatography (silica gel, MeOH: CH_2Cl_2=10: 1) to give the title compound as a white solid. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.74-7.53 (m, 4H) 7.60-7.56 (m, 2H) 7.51-7.40 (m, 4H) 3.41 (m, 4H) MS (ESI, pos. ion) *m/z*: 446.5 (M+1).

Using the procedures described in Example 22 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:

Cpd	Name and Data
129	2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, 1.2 and 8.0 Hz) 7.65-7.54 (m, 4H) 7.44-7.31 (m, 4H) 7.20 (d, 2H, J = 8.8 Hz) 3.26-3.23 (m, 4H) MS (ESI, pos. ion) *m/z*: 462.4 (M+1).

Cpd	Name and Data
130	2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.12 (dd, 1H, J = 1.2 and 8.4 Hz) 7.64-7.51 (m, 6H) 7.42 (d, 2H, J = 8.0 Hz) 7.39 (dd, 1H, J = 1.2 and 7.6 Hz) 7.27 (dd, 1H, J = 1.6 and 8.4 Hz) 3.24 (m, 4H) MS (ESI, pos. ion) *m/z*: 446.4 (M+1).
131	2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 8.0 Hz) 8.02 (d, 2H, J = 8.8 Hz) 7.70-7.55 (m, 7H) 7.42 (dd, 1H, J = 1.6 and 7.2 Hz) 7.36 (dd, 1H, J = 1.6 and 8.4 Hz) 3.41-3.48 (m, 4H) MS (ESI, pos. ion) *m/z*: 510.2 (M+1).
139	2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.12 (dd, 1H, 1.6 and 8.0 Hz) 7.64-7.59 (m, 2H) 7.55-7.51 (m, 2H) 7.39 (dd, 1H, J = 0.8 and 7.6 Hz) 7.32-7.14 (m, 5H) 3.20-3.13 (m, 4H) MS (ESI, pos. ion) *m/z*: 412.3 (M+1).
145	2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, 1.2 and 7.6 Hz) 7.87 (d, 2H, J = 8.4 Hz) 7.66-7.50 (m, 6H) 7.41 (dd, 1H, J = 1.2 and 8.0 Hz) 7.30 (dd, 1H, J = 1.6 and 8.4 Hz) 3.10 (m, 4H) MS (ESI, pos. ion) *m/z*: 456.3 (M+1).
175	2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.13 (dd, 1H, J = 1.2 and 7.6 Hz) 7.70-7.48 (m, 8H) 7.44 (dd, 1H, J = 1.6 and 8.0 Hz) 7.39 (dd, 1H, J = 1.2 and 7.2 Hz) 3.40-3.30 (m, 4H) MS (ESI, pos. ion) *m/z*: 446.4 (M+1).
383	2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.02 (dd, 1H, J = 1.2 and 8.0 Hz) 7.52-7.49 (m, 2H) 7.45-7.41 (m, 4H) 7.31-7.26 (m, 1H) 7.18 (dd, 1H, J = 1.2 and 8.0 Hz) 7.13 (t, 1H, J = 7.2 Hz) 3.20-3.15 (m, 4H) MS (ESI, pos. ion) *m/z*: 446.4 (M+1).
384	2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.66-7.53 (m, 4H) 7.42 (dd, 1H, J = 1.6 and 7.6 Hz) 7.29 (dd, 1H, J = 1.6 and 8.4 Hz) 7.04-6.99 (m, 2H) 3.24 (m, 4H) MS (ESI, pos. ion) *m/z*: 432.5 (M+1).

Cpd	Name and Data
385	2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.4 Hz) 7.67-7.53 (m, 4H) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.30 (dd, 1H, J = 1.6 and 8.4 Hz) 7.26-7.10 (m, 2H) 3.23-3.20 (m, 4H) MS (ESI, pos. ion) *m/z*: 432.3 (M+1).
386	2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.67-7.53 (m, 4H) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.31-7.25 (m, 2H) 6.97-6.93 (m, 2H) 3.26-3.19 (m, 4H) MS (ESI, pos. ion) *m/z*: 414.3 (M+1).
387	2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.12 (dd, 1H, 1.6 and 8.0 Hz) 7.92 (dd, 1H, 1.2 and 8.4 Hz) 7.80 (s, 1H) 7.64-7.51 (m, 4H) 7.40-7.33 (m, 2H) 7.28 (dd, 1H, J = 1.6 and 8.0 Hz) 3.38-3.25 (m, 4H) MS (ESI, pos. ion) *m/z*: 514.4 (M+1).
388	2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 7.6 Hz) 7.94 (d, 1H, J = 8.0 Hz) 7.76-7.72 (m, 2H) 7.67-7.54 (m, 4H) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.33 (dd, 1H, J = 1.6 and 8.4 Hz) 3.50-3.45 (m, 2H) 3.31-3.26 (m, 2H) MS (ESI, pos. ion) *m/z*: 514.5 (M+1).
390	2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.12 (dd, 1H, 1.6 and 8.0 Hz) 7.54-7.60 (m, 3H) 7.54 (dd, 1H, J = 1.2 and 8.0 Hz) 7.52-7.48 (m, 2H) 7.43 (dd, 1H, J = 2.0 and 8.4 Hz) 7.39 (dd, 1H, J = 1.6 and 7.2 Hz) 7.27 (d, 1H, J = 8.0 Hz) 3.23 (m, 4H) MS (ESI, pos. ion) *m/z*: 480.4 (M+1).
391	2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.15 (dd, 1H, 1.2 and 8.0 Hz) 7.65-7.54 (m, 4H) 7.43-7.37 (m, 2H) 7.33 (dd, 1H, J = 2.0 and 8.0 Hz) 7.26 (d, 1H, J = 8.8 Hz) 7.17 (s, 1H) 7.13 (d, 1H, J = 9.6 Hz) 3.26 (m, 4H) MS (ESI, pos. ion) *m/z*: 462.4 (M+1).
392	2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.15 (dd, 1H, 1.6 and 6.4 Hz) 7.67-7.53 (m, 4H) 7.42 (dd, 1H, 1.6 and 8.0 Hz) 7.30 (dd, 1H, J = 1.2 and 6.8 Hz) 7.28-7.23 (m, 1H) 6.96-6.85 (m, 2H) 3.22 (m, 4H) MS (ESI, pos. ion) *m/z*: 414.2 (M+1).

Cpd	Name and Data
393	2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.15 (dd, 1H, 1.2 and 7.6 Hz) 7.65-7.53 (m, 4H) 7.42 (dd, 1H, 1.2 and 7.2 Hz) 7.32 (dd, 1H, J = 1.2 and 8.4 Hz) 7.22-7.13 (m, 2H) 7.04-7.01 (m, 1H) 3.22 (m, 4H) MS (ESI, pos. ion) *m/z*: 414.4 (M+1).
394	2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, 1.6 and 8.0 Hz) 7.68-7.53 (m, 4H) 7.42 (dd, 1H, 1.6 and 7.6 Hz) 7.32 (dd, 1H, J = 1.6 and 8.0 Hz) 7.15-7.01 (m, 3H) 3.28 (m, 4H) MS (ESI, pos. ion) *m/z*: 414.3 (M+1).
395	2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.15 (dd, 1H, 2.4 and 7.6 Hz) 7.67-7.53 (m, 4H) 7.43-7.39 (m, 1H) 7.33-7.29 (m, 1H) 7.12-6.94 (m, 3H) 3.26 (m, 4H) MS (ESI, pos. ion) *m/z*: 414.4 (M+1).
396	2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.15 (dd, 1H, 2.0 and 8.0 Hz) 7.67-7.54 (m, 4H) 7.42 (dd, 1H, 1.6 and 7.6 Hz) 7.36 (dd, 1H, 1.6 and 8.4 Hz) 6.91-6.77 (m, 3H) 3.26-3.20 (m, 4H) MS (ESI, pos. ion) *m/z*: 414.6 (M+1).
397	2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, 1.6 and 7.6 Hz) 7.67-7.54 (m, 4H) 7.42 (dd, 1H, 1.6 and 7.6 Hz) 7.30-7.17 (m, 7H) 3.25-3.06 (m, 4H) MS (ESI, pos. ion) *m/z*: 378.3 (M+1).
399	N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared by hydrogenation using Compound **398**. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 7.65 (dt, 1H, J = 1.6 and 8.2 Hz) 7.58-7.53 (m, 5H) 7.41-7.38 (m, 3H) 7.20 (dd, 1H, J = 1.6 and 8.4 Hz) 3.25 (m, 4H) 2.27 (s, 6H) MS (ESI, pos. ion) *m/z*: 474.4 (M+1).
402	2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.12 (d, 1H) 7.64-7.52 (m, 4H) 7.41-7.38 (m, 2H) 7.26-7.19 (m, 4H) 3.22-3.18 (m, 4H) MS (ESI, pos. ion) *m/z*: 412.3 (M+1).

Cpd	Name and Data
404	2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.12 (dd, 1H, J = 1.6 and 8.0 Hz) 7.64-7.60 (m, 2H) 7.56-7.51 (m, 2H) 7.46-7.38 (m, 3H) 7.30-7.27 (m, 2H) 3.33-3.30 (m, 2H) 3.35-3.32 (m, 2H) MS (ESI, pos. ion) *m/z*: 464.4 (M+1).
405	2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 8.0 Hz) 7.66-7.62 (m, 2H) 7.59-7.50 (m, 4H) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.31 (dd, 1H, J = 1.6 and 8.0 Hz) 7.26-7.21 (m, 1H) 3.26 (m, 4H) MS (ESI, pos. ion) *m/z*: 464.3 (M+1).
419	2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzene sulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (d, J=8.0 Hz, 1H), 7.71 (s, 1H), 7.68-7.64 (m, 2H), 7.60-7.57 (m, 1H), 7.40 (d, J=8.0 Hz, 1H), 7.48 (d, J=8.0 Hz, 1H), 7.29-7.24 (m, 2H), 7.12-7.06 (m, 2H), 3.41 (t, J= 8.0 Hz, 2H), 3.28 (t, J=8.0 Hz, 2H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{21}H_{18}FN_3O_2S$: 396.1 (M + H), Found 396.3.
420	2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, J=1.6, 8.0 Hz, 1H), 7.73 (s, 1H), 7.69 (d, J=8.0 Hz, 1H), 7.65 (dd, J=1.6, 8.0 Hz, 1H), 7.58 (dt, J=1.6, 8.0 Hz, 1H), 7.51 (d, J=1.6, 8.0 Hz, 1H), 7.40 (dd, J=1.2, 7.2 Hz, 1H), 7.27-7.24 (m, 2H), 7.04-7.00 (m, 2H), 3.42 (t, J= 8.0 Hz, 2H), 3.23 (t, J=8.0 Hz, 2H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{21}H_{18}FN_3O_2S$: 396.1 (M + H), Found 396.3.
421	2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.12 (d, J=8.0 Hz, 1H), 7.64-7.60 (m, 2H), 7.56-7.51 (m, 2H), 7.40-7.36 (m, 2H), 7.32-7.29 (m, 3H), 3.27-3.25 (m, 4H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{22}H_{17}F_4N_3O_2S$: 464.1 (M + H), Found 464.3.
442	2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.12 (dd, J=1.6, 8 Hz, 1H), 8.01 (d, J=1.6, 8 Hz, 1H), 7.65-7.60 (m, 3H), 7.58-7.53 (m, 3H), 7.48-7.44 (m, 1H), 7.40 (dd, J=1.6, 8 Hz, 1H), 7.33 (dd, J=1.6, 8 Hz, 1H), 3.13 (m, 1H), 2.86 (t, J=7.6 Hz, 2H), 2.83 (t, J=7.6 Hz, 2H), 1.21 (d, J=7.6 Hz, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{24}H_{25}N_3O_2S$: 420.5 (M + H), Found 420.4.

Cpd	Name and Data
445	4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared by hydrogenation using Compound **444**. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.33 (d, J=8 Hz, 1H), 7.83 (dd, J=2, 8 Hz, 1H), 7.63 (d, J=8 Hz, 2H), 7.58-7.54 (m, 3H), 7.42 (d, J=8 Hz, 2H), 7.29 (dd, J=2, 8 Hz, 1H), 3.28-3.24 (m, 4H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{23}H_{17}F_6N_3O_2S$: 514.5 (M + H), Found 514.3.
447	4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared by hydrogenation using Compound **446**. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.42 (s, 1H), 7.94 (d, J=8 Hz, 1H), 7.63-7.56 (m, 5H), 7.42 (d, J=8 Hz, 2H), 7.29 (d, J=1.6, 8 Hz, 1H), 3.27-3.25 (m, 4H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{23}H_{17}F_6N_3O_2S$: 514.1 (M + H), Found 514.2.

Example 23

N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd **400**)

Using the procedure of Example 18, the title compound was prepared from Compound **18c** and 4-trifluoromethylphenyl propionic acid. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.04 (dd, 1H, J = 1.2 and 8.0 Hz) 7.66-7.53 (m, 6H) 7.42-7.38 (m, 3H) 7.29 (dd, 1H, J = 1.6 and 8.4 Hz) 3.27 (m, 4H) MS (ESI, pos. ion) *m/z*: 460.4 (M+1).

Example 24

N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd **350**)

Using the procedure of Example 18, the title compound was prepared from Compound **18c** and 3-trifluoromethylphenyl propionic acid. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 7.6 Hz) 7.64 (td, 1H, 1.2 and 8.2 Hz) 7.58-7.53 (m, 4H) 7.50-7.44 (m, 3H) 7.40 (dd, 1H, J = 1.2 and 7.2 Hz) 7.25 (dd, 1H, J = 1.6 and 8.0 Hz) 3.26-3.22 (m, 4H) MS (ESI, pos. ion) *m/z*: 460.4 (M+1).

Example 25

2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd **464**)

Using the procedure of Example 10, the title Compound **464** (0.013 g) was prepared from 5-bromo-2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazole Compound **25a** (0.048 g, 0.13 mmol) and Compound **10e** (0.032g, 0.20 mmol). ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 7.71 (dd, J=1.26,8.08Hz, 1H) 7.45 (d, J=7.8Hz, 2H) 7.37 (d, J=8.34Hz, 1H) 7.31 (d, J=8.08Hz, 2H) 7.20-7.26 (m, 2H) 7.10 (ddd, J=1.51, 7.33, 7.58Hz, 1H) 6.93-7.20 (m, 2H) 3.14 (m, 4H) 1.21 (s, 6H). MS (ESI, pos. ion) *m/z*: 425.1 (M+1).

Using the procedures described in Example 25 and Compound **25a**, and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:

Cpd	Name and Data
457	N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.50-7.60 (m, 5H) 7.32-7.44 (m, 5H) 7.22-7.26 (d, J=8.6Hz, 1H) 3.24-3.30 (s, 4H) 1.96 (s, 3H). MS (ESI, pos. ion) m/z: 424.2 (M+1).

Prophetic Example 26

Using the procedures of Examples 22, 23, 24 or 25, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared.

Cpd	Name and Data
133	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
134	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
135	1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

Cpd	Name and Data
136	1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
137	N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
138	2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
140	N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
141	1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
142	1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
143	N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
144	2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
146	C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
147	1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
148	1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
149	N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
150	2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
151	2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
152	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
153	1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
154	1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
155	N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

Cpd	Name and Data
156	2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
157	2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
158	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
159	1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
160	1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
161	N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
162	2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
163	2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
164	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
165	1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
166	1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
167	N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
168	2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
169	2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
170	N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
171	1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
172	1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
173	N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

Cpd	Name and Data
174	2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
176	C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
177	N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,
178	N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
179	N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
180	N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
181	2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
182	C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
183	N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
184	C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
185	C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,
186	C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
187	2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide, and
188	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide.

Example 27

2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd **190**)

Step A. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid methyl ester

To a solution of trimethylsulfonium iodide (0.53 g, 2.39 mmol) in 8 mL of DMSO was added sodium hydride (0.06 g, 2.39 mmol) at 25 °C. After stirring for

one hour, a solution of methyl 4-trifluoromethylcinnamate (0.50 g, 2.17 mmol) in 4 mL DMSO was added. The reaction mixture was stirred for six hours, when it was quenched by sat'd NH_4Cl solution. The resulting mixture was extracted with CH_2Cl_2, the organic layer was dried over Na_2SO_4, filtered and the filtrate was concentrated. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 2: 1) to provide the title Compound **27a** as a solid.

Step B. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid

A solution of Compound **27a** in 10 mL MeOH and 4 mL of 1N LiOH (aq) was heated at 70 °C for 4 h. The mixture was then acidified by 4N HCl (aq) and extracted with EtOAc. The organic layer was washed with brine, dried over Na_2SO_4, filtered, and filtrate was concentrated to provide the title Compound **27b**. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.56 (d, 2H) 7.25 (d, 2H) 2.39 (m, 1H) 1.80 (m, 1H) 1.47 (m, 1H) 1.18 (m, 1H).

Step C. 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide

To a solution of Compound **16c** (0.140 g, 0.438 mmol) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride Compound **27c** (0.060 g, 0.313 mmol) in 4 mL acetonitrile at rt was slowly added a solution of Compound **27b** (0.072 g, 0.313 mmol) in 2 mL of acetonitrile. After stirring for 2 hours, the mixture was passed through a short column (silica gel, hexanes: EtOAc, 2: 1). The collected eluent was concentrated, and the residue was dissolved in AcOH. The reaction was heated at 80 °C for 3 h. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 2: 1). This material was dissolved in TFA, and the mixture was heated at 60 °C for 2 h. The reaction was concentrated, and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 1:1) to provide the title Compound **190** as a solid. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.74-7.63 (m, 6H) 7.60-7.47 (m, 5H) 7.40 (dd, 1H, J = 1.6 and 7.2 Hz) 2.97-2.92 (m, 1H) 2.76-2.71 (m, 1H) 2.12-2.00 (m, 2H) MS (ESI, pos. ion) *m/z*: 458.3 (M+1).

Example 28

2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd **471**)

Step A. N-methoxy-N-methyl-3-(4-trifluoromethyl-phenyl)-acrylamide

To a solution of 4-trifluoromethyl cinnamic acid (3.6 g, 16.7 mmol) in anhydrous methylene chloride (40 mL) was slowly added oxalyl chloride (1.7 mL, 19.5 mmol). To the solution was added anhydrous dimethylformamide (10 μL) and the reaction was stirred at room temperature under an argon atmosphere. After 18 h, the reaction was concentrated. A solution of the residue Compound **10b** (16.7 mmol) in methylene chloride (40 mL) was added dropwise to a solution of N,N-dimethylhydroxylamine hydrochloride (1.6 g, 16.7 mmol) and triethylamine (5.8 mL, 41.7 mmol) in methylene chloride (40 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min, then warmed to room temperature. After 6 h, the reaction was successively washed with sodium carbonate (10 % in water), water and brine. The organic fraction was dried over magnesium sulfate, filtered and the filtrate was concentrated. The compound was purified by chromatography (silica, EtOAc: hexanes, 1: 1) to provide the title Compound **28a** (2.2 g, 50 % over two steps) ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 7.96 (d, J=8.3Hz, 2H) 7.78 (d, J=8.08Hz, 2H) 7.64 (d, J=15.9Hz, 1H) 7.24 (d, J=15.9Hz, 1H) 3.77 (s, 3H) 3.23 (s, 3H).

Step B. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid methoxy-methyl-amide

Anhydrous dimethylsulfoxide (8 mL) was added dropwise under an argon atmosphere to a mixture of sodium hydride (60 % suspension in oil, 0.369 g, 9.2 mmol) and trimethylsulfoxonium iodide (2 g, 9.1 mmol). To the solution was added dropwise Compound **28a** (1.2g, 4.6 mmol) in DMSO (8 mL). The reaction mixture was stirred at room temperature for 18 h. The reaction was poured into ethyl ether: water (1:1, 50 mL). The organic layer was separated and washed successively with water and brine. The organic fraction was dried over

magnesium sulfate, filtered and the filtrate was concentrated to provide the title Compound **28b** (1.9 g, 90 %). ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm) 7.55 (d, J=8.08Hz, 2H) 7.25 (d, J=8.3Hz, 2H) 3.72 (s, 3H) 3.26 (s, 3H) 2.54-2.59 (m, 1H) 2.43-2.52 (m, 1H) 1.68-1.74 (m, 1H) 1.33-1.38 (m, 1H).

Step C. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid

To a solution of Compound **28b** (3.6g, 13.2 mmol) in tetrahydrofuran (45 mL) was added a solution of potassium-t-butoxide (1M in tetrahydrofuran, 50 mL, 50 mmol). To the reaction was added water (1.5 mL, 83.3 mmol), and the reaction was stirred at room temperature under an argon atmosphere. After 18 h, ice was added to the reaction until it became homogeneous. To the solution was added ethyl ether, and the layers were separated. The aqueous layer was cooled and acidified with 1 M HCl until the pH was 4. The aqueous layer was extracted with ethyl acetate. The ethyl acetate layer was washed successively with water and brine. The organic layer was dried over magnesium sulfate, filtered and the filtrate was concentrated to provide the title Compound **28c** (2.2 g, 73 %). ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 12.4 (s, 1H) 7.62 (d, J=8.08Hz, 2H) 7.40 (d, J=8.08Hz, 2H) 2.46-2.54 (m, 1H) 1.88-1.96 (m, 1H) 1.46-1.52 (m, 1H) 1.38-1.44 (m, 1H).

Step D. 5-bromo-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazole

Using the procedure of Example 1, the title Compound **28d** was prepared from Compound **28c** and 4-bromobenzene-1,2-diamine. ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 7.96 (s, 1H) 7.68-7.75 (m, 3H) 7.60-7.64 (dd, J=1.5, 8.6Hz, 1H) 7.46-7.56 (m, 4H) 7.10-7.14 (d, J=8.4Hz, 2H) 2.96-3.02 (m, 1H) 2.70-2.78 (m, 1H) 2.10-2.16 (m, 1H) 2.00-2.08 (m, 1H).

Step E. 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol

Using the procedure of Example 10, the title Compound **471** was prepared from Compound **28d** and Compound **10e**. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm)

12.4 (s, 0.5H) 12.32 (s, 0.5H) 7.88 (m, 1H) 7.65 (d, 2H, J=8.084 Hz) 7.46 (m, 2H) 7.35 (m, 2H) 7.20 (m, 1H) 6.95 (m, 2H) 4.85 (s, 1H) 2.70 (m, 1H) 2.46 (m, 1H) 1.90 (m, 1H) 1.70 (m, 1H) 1.20 (d, 6H). MS (ESI, pos. ion) m/z: 437.2 (M+1).

Using the procedures described in Example 28 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:

Cpd	Name and Data
198	2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol, ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.83-7.86(m, 1H) 7.44-7.49 (bs, 1H) 7.31-7.36 (m, 4H) 7.21-7.26 (m, 3H) 7.055-7.13 (m, 2H) 2.60-2.65 (m, 1H) 2.40-2.44 (m, 1H) 1.84-1.90 (m, 1H) 1.62-1.70 (m, 1H) 1.32(s, 6H). MS (ESI, pos. ion) *m/z*: 403.2 (M+1).
234	2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol ^{1}H-NMR (400 MHz, CD3OD) δ (ppm) 7.71-7.74 (dd, J=1.01, 8.08Hz, 1H) 7.40-7.45 (m, 4H) 7.33-7.38 (d, J=8.34Hz) 7.21-7.26 (m, 2H) 7.08-7.13 (ddd, J=1.52, 7.58Hz, 1H) 6.99-7.02 (dd, J=1.52, 8.34Hz) 6.93-6.97 (dd, J=1.52, 7.58Hz, 1H) 2.60-2.66 (m, 1H) 2.37-2.42 (m, 1H) 1.78-1.84 (m, 1H) 1.59-1.65 (m, 1H) 1.22 (s, 6H). MS (ESI, pos. ion) m/z: 437.3 (M+1).
467	N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.52-7.62 (m, 5H) 7.33-7.41 (m, 4H) 7.24-7.32 (m, 2H) 2.70 (m, 4H) 2.48-2.53 (m, 1H) 1.90-1.96 (m, 1H) 1.69 - 1.75 (m, 1H). MS (ESI, pos. ion) m/z: 472.2 (M+1),
472	2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenol ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.70 (bs, 1H) 7.61 (d, 2H, J=8.34Hz) 7.51 (m, 3H) 7.42 (m, 3H) 7.30 (m, 1H) 7.15 (m, 1H) 6.93 (m, 2H) 2.72 (m,1H) 2.50 (m, 1H) 1.93 (m, 1H) 1.74 (m, 1H). MS (ESI, pos. ion) m/z: 395.2 (M+1),
474	(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanol ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.62 (m, 3H)7.50 (m, 4H) 7.35 (m, 3H) 7.20 (m, 1H) 4.50 (s, 2H) 2.73 (m, 1H) 2.52 (m, 1H) 1.95 (m, 1H) 1.78 (m, 1H). MS (ESI, pos. ion) m/z: 409.1 (M+1).

Cpd	Name and Data
494	2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.83-7.86(m, 1H) 7.44-7.49 (d, J=8.08Hz, 1H) 7.34-7.40 (m, 2H) 7.14-7.28 (m, 3H) 7.12-7.18 (m, 2H) 3.80 (s, 3H) 2.60-2.65 (m, 1H) 2.31-2.35 (m, 1H) 1.78-1.82 (m, 1H) 1.62-1.70 (m, 1H) 1.34(s, 6H). MS (ESI, pos. ion) *m/z*: 399.1 (M+1).
497	2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 12.30-12.40 (d, 1H) 7.84-7.87 (d, J=7.83Hz, 1H) 7.45-7.48 (d, J=7.83Hz, 1H) 7.29-7.40 (m, 6H) 7.17-7.23 (m, 1H) 6.96-7.10 (m, 2H) 2.60-2.67 (m, 1H) 2.38-2.43 (m, 1H) 1.81-1.86 (m, 1H) 1.62-1.68 (m, 1H) 1.20 (s, 6H). MS (ESI, pos. ion) m/z: 453.3 (M+1).
498	2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzamide ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 12.5 (bs, 1H) 7.68-7.72 (d, J=8.08Hz, 2H) 7.40-7.60 (m, 7H) 7.28 (s, 1H) 7.21-7.25 (dd, J=1.77, 8.34Hz, 1H) 2.70-2.78 (m, 1H) 2.44-2.53 (m, 1H) 1.90-1.99 (m, 1H) 1.70-1.80 (m, 1H). MS (ESI, pos. ion) m/z: 422.2 (M+1).
499	N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 12.40 (s, 1H) 8.2-8.3 (d, J=9.34Hz, 1H) 7.30-7.70 (m, 9H) 7.10-7.15 (m, 1H) 6.28-6.32 (m, 1H) 2.64-2.72 (m, 1H) 1.90-1.94 (m, 1H) 1.70-1.75 (m, 1H) 0.90 (s, 9H). MS (ESI, pos. ion) m/z: 514.2 (M+1).
500	5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazole ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 8.12-8.15 (dd, J=1.26, 7.83Hz, 1H) 7.70-7.83 (m, 6H) 7.53-7.57 (d, J=8.08Hz, 2H) 7.42-7.47 (ddd, J=1.26, 7.32Hz, 2H) 2.93-3.00 (m, 1H) 2.66-2.74 (m, 1H) 2.06-2.13 (m, 1H) 1.97-2.03 (m, 1H). MS (ESI, pos. ion) m/z: 457.1 (M+1).

Prophetic Example 29

Using the procedures of Examples 27 or 28, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared.

Cpd	Name and Data
189	2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name and Data
191	2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
192	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
193	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
194	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
195	1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
196	1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
197	N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
199	2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
200	N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
201	1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
202	1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
203	N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
204	2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
205	2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
206	C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
207	1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
208	1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
209	N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

Cpd	Name and Data
210	2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
211	2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)- benzenesulfonamide,
212	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
213	1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
214	1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
215	N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
216	2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
217	2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
218	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
219	1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]- ethanone,
220	1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]- ethanol,
221	N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
222	2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]- propan-2-ol,
223	2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
224	C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
225	1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
226	1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
227	N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

Cpd	Name and Data
228	2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
229	2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
230	N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
231	1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
232	1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
233	N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
235	2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
236	C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
237	N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,
238	N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,
239	N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
240	N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,
241	2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
242	C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
243	N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
244	C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,
245	C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,
246	C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,

Cpd	Name and Data
247	2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide, and
248	C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide.

Example 30

2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol (Cpd **489**)

Step A. (*E*)-5-bromo-2-(2-chloro-2-phenyl-vinyl)-1H-benzimidazole

A mixture of 4-bromo-benzene-1,2-diamine dihydrochloride (1.3 g, 5 mmol), phenylpropiolic acid (0.73 g, 5 mmol) in 4 mL of ethylene glycol was heated to reflux for 5 h. The mixture was cooled to rt and poured into water. The mixture was neutralized with 2N sodium hydroxide and filtered. The solid was suspended in water and extracted with ethyl acetate. The organic layers were combined, dried with anhydrous sodium sulfate, and filtered. The filtrate was concentrated to yield a red oil. The residue was purified using preparative TLC plates twice (silica gel, 20 X 20 cm, 2000 microns, EtOAc: hexanes 3: 7 and silica gel, 20 X 20 cm, 2000 microns, EtOAc: dichloromethane 3: 97) to provide a mixture of cis and trans isomers of the title Compound **30a** (0.345 g). ^{1}H NMR (400 MHz, DMSO-d_6) δ (ppm): 12.59 (m, 1H), 7.86-7.78 (m, 3H), 7.64-7.56 (m, 1H), 7.54-7.49 (m, 3H), 7.46 (s, 1H), 7.40-7.34 (m, 1H). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{15}H_{10}BrClN_2$: 333.0 (M + H), Found 333.1.

Step B. 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol

A mixture of Compound **30a** (25 mg, 0.075 mmol), Compound **10e** (18 mg, 0.113 mmol) and Pd(dppf)$Cl_2CH_2Cl_2$ (12 mg, 0.015 mmol) in 3 mL of DME and sodium carbonate solution (1.0 M, 0.6 mL) was heated at 150 °C for 1h in a Biotage Initiator™ microwave synthesizer. The mixture was filtered through a pad of silica gel. The reaction was repeated total three times. The residues were combined and purified using preparative TLC plates twice (silica gel, 20 X 20 cm, 2000 microns, EtOAc: hexanes 3: 7 and then silica gel, 20 X 20 cm, 2000 microns,

EtOAc: hexanes: methanol 2: 8: 1) to provide the title Compound **489** (8.4 mg). ^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.78 (dd, 1H, J= 8.1, 1.1 Hz, 1H), 7.62-7.60 (m, 2H), 7.52 (d, 1H, J= 8.3 Hz), 7.46-7.38 (m, 4H), 7.31 (dt, 1H, J= 1.5, 8.0 Hz), 7.21-7.17 (m, 2H), 7.02 (dd, J= 7.5, 1.3 Hz, 1H), 1.30 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{24}H_{20}N_2O$: 353.2 (M + H), Found 353.3.

Example 31

2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide (Cpd **490**)

Step A. N-tert-butyl-2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide

A mixture of Compound **30a** (25 mg, 0.075 mmol), 2-(tert-butylamino)sulfonylphenyl boronic acid (29 mg, 0.113 mmol), and $Pd(dppf)Cl_2 \cdot CH_2Cl_2$ (12 mg, 0.015 mmol) in 3 mL of DME and sodium carbonate solution (1.0 M, 0.6 mL) was heated at 150 °C for 1h in a Biotage Initiator™ microwave synthesizer. The mixture was filtered through a pad silica gel. The residue was purified by preparative TLC (silica gel, 20 X 20 cm, 2000 microns, EtOAc: hexanes 3: 7) to provide the title Compound **31a** (12.8 mg). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{25}H_{23}N_3O_2S$: 430.2 (M + H), Found 430.3.

Step B. 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide

A mixture of Compound **31a** (14.9 mg, 0.034 mmol) in trifluoroacetic acid and 1,2-dichloroethane (2 mL, 1: 1) was heated at 90 °C for 3 h. The reaction was cooled to rt, and concentrated under reduced pressure. The residue was dissolved in dichloromethane, and washed with saturated sodium bicarbonate solution. The aqueous layer was extracted twice with ethyl acetate. The organic layers were combined, dried with anhydrous magnesium sulfate, filtered, and the filtrate was removed under reduced pressure. The residue was purified using preparative TLC plates (silica gel, 20 X 20 cm, 2000 microns, EtOAc: hexanes: methanol 5: 5: 1) to provide the title Compound **490** (12.1 mg). ^{1}H NMR (400 MHz, CD_3OD) δ

(ppm): 8.11 (dd, 1H, J= 8.0, 1.2 Hz), 7.67-7.56 (m, 5H), 7.52 (ddd, 1H, J= 7.6, 6.4, 1.4 Hz), 7.48-7.33 (m, 5H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{21}H_{15}N_3O_2S$: 374.1 (M + H), Found 374.2.

Using the procedures described in Examples 30 and 31, and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:

Cpd	Name and Data
250	2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide ^{1}H NMR (400MHz, CD_3OD) δ (ppm): 8.04 (dd, 1H, J= 8.0, 1.2 Hz), 7.76 (d, J2H, = 8.2 Hz), 7.69 (d, 2H, J= 8.2 Hz), 7.58-7.53 (m, 2H), 7.54 (dt, 1H, J= 1.4, 7.5 Hz), 7.46 (dt, 1H, J= 1.4, 7.7 Hz), 7.31 (dd, 1H, J= 7.5, 1.3 Hz), 7.30 (dd, 1H, J= 8.4, 0.9 Hz). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{22}H_{14}F_3N_3O_2S$: 442.1 (M + H), Found 442.2.
294	2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol ^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.94 (s, 1H), 7.89 (d, 1H, J= 7.7 Hz), 7.80-7.74 (m, 2H), 7.66 (t, 1H, J= 7.8 Hz, 1H), 7.60-7.39 (m, 2H), 7.33 (m, 1H), 7.28-7.18 (m, 2H), 7.04 (dd, 1H, J= 7.5, 1.4 Hz, 1H), 1.32 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{25}H_{19}F_3N_2O$: 421.1 (M + H), Found 421.3.
295	2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide ^{1}H NMR (400 MHz, CD_3OD δ (ppm): 8.11 (dd, 1H, J = 8.0, 1.2 Hz), 7.94 (s, 1H), 7.89 (dm, 1H, J = 7.6 Hz), 7.77 (dm, 1H, J = 7.9 Hz), 7.67-7.58 (m, 4H), 7.52 (m, 1H), 7.38 (dd, J = 7.5, 1.3 Hz, 1H), 7.37 (br s, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{22}H_{14}F_3N_3O_2S$: 442.1 (M + H), Found 442.2

Cpd	Name and Data
492	2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol ^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.83 (d, 2H, J= 8.2 Hz), 7.79 (dd, 1H, J= 8.2 1.1 Hz, 1H), 7.76 (d, 2H, J= 8.3 Hz), 7.64-7.37 (m, 2H), 7.33 (m, 1H), 7.22 (br d, 1H, J= 7.2 Hz), 7.20 (dt, 1H, J= 1.3, 7.4 Hz), 7.04 (dd, 1H, J= 7.5, 1.4 Hz), 1.32 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{25}H_{19}F_3N_2O$: 421.1 (M + H), Found 421.3. Preparation of (4-trifluoromethylphenyl)propynoic acid. To a solution of 4-ethynyl-α,α,α-trifluorotoluene (5 g, 29 mmol) in anhydrous THF (25 mL), was slowly added n-butyllithium 2.6 M in hexanes (14.5 mL, 47 mmol). The mixture was stirred at –78 °C for 30 min and then at 0 °C for an additional 30 min. The mixture was cooled to –78 °C and transferred via a cannula to a saturated solution of carbon dioxide in anhydrous THF (25 mL) at -78 °C. The mixture was stirred and allowed to warm to rt over 18 h. The mixture was quenched with saturated sodium chloride solution, and the two layers were separated. The aqueous layer was washed with hexanes and then acidified with 2N hydrochloric acid. The aqueous layer was extracted twice with ethyl acetate. The organic layers were combined and dried with anhydrous sodium sulfate and magnesium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to yield the title Compound **31b** as a white solid (5.4 g, 87%). ^{1}H NMR (400MHz, DMSO-d_6) δ (ppm): 7.81 (s, 4H). Compound **31b** was carried forward using the procedure of Example 31 to provide the title Compound **492**.

Prophetic Example 32

Using the procedures of Examples 30 or 31, the corresponding bromobenzimidazole and, when not commercially available, the arylacetylenic acid precursors prepared as described in Reaction Scheme KK and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared. Alternatively, the following compounds may be prepared from their corresponding vinyl compounds by hydrogenation:

Cpd	Name and Data
249	2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
251	2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
252	C,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

Cpd	Name and Data
253	C,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
254	C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
255	1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
256	1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
257	N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
258	2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
259	2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
260	N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,
261	1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
262	1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
263	N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
264	2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
265	2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
266	C,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
267	1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
268	1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
269	N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
270	2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
271	2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

Cpd	Name and Data
272	C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
273	1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
274	1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
275	N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
276	2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
277	2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
278	C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
279	1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
280	1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
281	N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
282	2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
283	2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
284	C,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
285	1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
286	2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,
287	N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
288	1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
289	2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
290	N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,

Cpd	Name and Data
291	1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
292	1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
293	N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
296	C,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
297	N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,
298	N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,
299	N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
300	N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,
301	2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
302	C,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
303	N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,
304	C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,
305	C,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,
306	C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,
307	2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, and
308	C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide.

Example 33

(*E*)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol (Cpd. **449**)

Step A. 5-bromo-2-chloromethyl-1H-benzimidazole

A mixture of 4-bromo-benzene-1,2-diamine (200 mg, 1.07 mmol) and 2-chloroacetimidic acid ethyl ester hydrochloride salt (168 mg, 1.07 mmol; prepared according to the procedure described in *J. Med. Chem.* **1986**, *29*, 2280) in anhydrous ethanol (200 proof, 5 mL) was stirred at room temperature for 4 h. The reaction mixture was concentrated under reduced pressure and extracted with ethyl acetate and water. The organic layer was dried over Na_2SO_4, filtered, and the filtrate was concentrated in vacuo to provide the title Compound **33a** as an off-white solid (240 mg, 92 % yield). ^{1}H NMR (400MHz, $CDCl_3$) δ (ppm): 7.75 (d, 1H, J=1.4Hz), 7.47 (d, 1H, J=8.6Hz), 7.42 (dd, 1H, J=8.6Hz, J=1.3Hz), 4.84 (s, 2H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{18}H_{20}ClN_3O_2S$: 247.50 (M + H), Found 247.0.

Step B. (5-bromo-1H-benzimidazol-2-ylmethyl)-triphenyl-phosphonium chloride

A mixture of Compound **33a** (240 mg, 0.98 mmol) and triphenylphosphine (385 mg, 1.47 mmol), in 1,2-dichloroethane (10 mL) was heated at 140 ^{0}C for 1 h. The reaction mixture was concentrated under reduced pressure to provide the title Compound **33b**, which was used in the next step without further purification.

Step C. (*E*)-6-[2-(5-bromo-1H-benzimidazol-2-yl)-vinyl]-quinoline

A mixture of Compound **33b** (100 mg, 0.204 mmol), 6-quinolinecarboxaldehyde (32 mg, 0.29 mmol) and DBU (39.6 uL, 0.265 mmol) in ethanol: tetrahydrofuran (1:1, 2 mL) was stirred at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure, and the residue was purified by reverse phase preparative HPLC (10-100% gradient acetonitrile/water over 10 min) to provide the title Compound **33c** as an off-white solid (50 mg, 72 % yield). Calcd. For $C_{18}H_{12}BrN_3$: 350.21 (M + H), Found 350.2.

Step D. (*E*)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol

A mixture of Compound **33c** (50.0 mg, 0.143 mmol), Compound **10e** (46 mg, 0.29 mmol), $PdCl_2$(dppf) (23.4 mg, 0.029 mmol) and 1M sodium bicarbonate solution (1.15 mL, 1.15 mmol) in 1,2-dimethoxyethane (1 mL) was heated at reflux for 12 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography (silica, EtOAc) to provide the title Compound **449** as an off-white solid (11.8 mg, 20 % yield). ^{1}H NMR (400MHz, CD_3OD) δ (ppm): 9.01 (br s, 1H), 8.68 (d, 1H, J= 8.1 Hz), 8.35 (m, 2H), 8.12-8.21 (m, 2H), 7.76 (m, 3H), 7.67 (s, 1H), 7.53 (m, 2H), 7.38-7.43 (m, 1H), 7.28 (m, 1H), 7.09 (m, 1H), 1.42 (s, 6H). Calcd. For $C_{27}H_{23}N_3O$: 406.5 (M + H), Found 406.3.

Using the procedures described in Example 33 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
448	(*E*)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-ethanone The title compound was prepared from Compound **33b** (100 mg, 0.204 mmol) and 4-acetylbenzaldehyde (30.2 mg, 0.204 mmol) as an off-white solid (3.75 mg, 10% yield). ^{1}H NMR (400MHz, CD_3OD) δ (ppm): 8.06 (d, 1H, J = 8.8 Hz), 7.96 (m, 1H), 7.80 (m, 3H), 7.68 (m, 1H), 7.55 (m, 1H), 7.43 (m, 1H), 7.34 (m, 2H), 7.17-7.24 (m, 2H), 7.07 (m, 1H), 2.63 (s, 3H), 1.35 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{26}H_{24}N_2O_2$: 397.5 (M + H), Found 397.3.
450	(*E*)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-benzamide The title compound was prepared from [5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-ylmethyl]-triphenyl-phosphonium chloride Compound **33c** (90 mg, 0.15 mmol) and 4-carboxyaldehyde-N-isopropylbenzamide (24.3 mg, 0.15 mmol) as an off-white solid (10.5 mg, 15 % yield). ^{1}H NMR (400MHz, CD_3OD) δ (ppm): 8.06 (dd, 1H, J = 8.1, Hz, J=1.5Hz), 7.87 (m, 2H), 7.55-7.74 (m, 7H), 7.43 (dd, 1H, J=8.1Hz, J=1.5Hz), 7.29 (m, 2H), 4.22 (m, 1H), 2.37 (s, 3H), 1.26 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{26}H_{26}N_4O_3S$: 475.5 (M + H), Found 475.2.

Cpd	Name and Data
451	(*E*)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide The title compound was prepared from Compound **33c** (90 mg, 0.15 mmol) and 4-cyanobenzaldehyde (19.6 mg, 0.15 mmol) as an off-white solid (7.4 mg, 12 % yield). ^{1}H NMR (400MHz, CD_3OD) δ (ppm): 8.07 (dd, 1H, J=8.0Hz, J=1.0Hz), 7.49-7.69 (m. 8H), 7.37 (m, 2H), 7.20 (m, 2H), 2.32 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{23}H_{18}N_4O_2S$: 415.5 (M + H), Found 415.2.
452	(*E*)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-acetamide The title compound was prepared from Compound **33c** (90 mg, 0.15 mmol) and 4-acetamidobenzaldehyde (24.3 mg, 0.15 mmol) as an off-white solid (11.3 mg, 17 % yield). ^{1}H NMR (400MHz, CD_3OD) δ (ppm): 8.04 (dd, 1H, J=8.0Hz, J=1.3Hz), 7.63 (td, 1H, J= 7.4Hz, J=1.4Hz), 7.55 (m, 5H), 7.26-7.39 (m, 5H), 7.19 (dd, 1H, J=8.1Hz, J=1.5Hz), 2.22 (s, 3H), 2.03 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{24}H_{22}N_4O_3S$: 447.5 (M + H), Found 447.2.
453	(*E*)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-benzoic acid The title compound was prepared from Compound **33c** (90 mg, 0.15 mmol) and 4-carboxybenzaldehyde (22.4 mg, 0.15 mmol) as an off-white solid (3.4 mg, 5% yield). ^{1}H NMR (400MHz, CD_3OD) δ (ppm): 8.02 (m, 2H), 7.53-7.77 (m, 6H), 7.18-7.45 (m, 5H), 2.36 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{23}H_{19}N_3O_4S$: 434.5 (M + H), Found 434.2.
454	(*E*)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide The title compound was prepared from Compound **33c** (90 mg, 0.15 mmol) and indole-6-carboxaldehyde (21.6 mg, 0.15 mmol) as an off-white solid (6.5 mg, 10% yield). ^{1}H NMR (400MHz, CD_3OD) δ (ppm): 8.06 (m, 1H), 7.05-7.73 (m, 11H), 6.48 (m, 2H), 2.36 (m, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{24}H_{20}N_4O_2S$: 429.5 (M + H), Found 429.2.
455	(*E*)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide The title compound was prepared from Compound **33c** (90 mg, 0.15 mmol) and 2,4-bis(trifluoromethyl)benzaldehyde (24.4 uL, 0.15 mmol) as an off-white solid (8.62 mg, 11% yield). ^{1}H NMR (400MHz, CD_3OD) δ (ppm): 7.14-8.17 (m, 12H), 2.44 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{24}H_{17}F_6N_3O_2S$: 526.5 (M + H), Found 526.3.

Cpd	Name and Data
456	(*E*)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide The title compound was prepared from Compound **33c** (90 mg, 0.15 mmol) and 4-acetylbenzaldehyde (22.1 mg, 0.15 mmol) as an off-white solid (8.32 mg, 13% yield). ^{1}H NMR (400MHz, CD_3OD) δ (ppm): 8.06 (m, 3H), 7.56-7.79 (m, 9H), 7.44 (m, 1H), 2.62 (s, 3H), 2.37 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For $C_{24}H_{21}N_3O_3S$: 432.5 (M + H), Found 432.2.

Example 34

2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzylamine (Cpd **486**)

Step A. (*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzonitrile

A mixture of Compound **10c** (52 mg, 0.14 mmol), 2-cyanophenylboronic acid (38 mg, 0.26 mmol), $Pd(dppf)Cl_2CH_2Cl_2$ (36 mg, 0.044 mmol), tetrabutylammonium bromide (55 mg, 0.17 mmol), and sodium carbonate (1 mL, 1.0 M) in DME (5 mL) was heated at 90 °C for 18 h. The mixture was cooled to rt, filtered through a pad of Celite and concentrated under reduced pressure. The residue was purified using preparative TLC plates (silica gel, 20 X 20 cm, 2000 microns, EtOAc:hexanes 1:1 and hexanes: dichloromethane: methanol 6: 14: 1) to provide the title Compound **34a** (20 mg, 37 %). ^{1}H NMR (400 MHz, CD_3OD+$CDCl_3$) δ (ppm): 7.72-7.47 (m, 10H), 7.40-7.30 (m, 3H), 7.14 (d, 1H, *J*= 16.55 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{23}H_{14}F_3N_3$:.390.1 (M + H), Found 390.3.

Step B. 2-{2-[2-(4-Trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzylamine

A mixture of Compound **34a** (20 mg, 0.051 mmol), Raney®-Nickel, ammonium hydroxide (0.1 mL) in ethanol was hydrogenated under 50 psi for 18 h. The mixture was filtered through a pad of Celite and washed with ethanol. The filtrate was concentrated under reduced pressure. The residue was purified using preparative TLC plates (silica gel, 20 X 20 cm, 2000 microns, NH_3 in methanol:

EtOAc 1: 9) to provide the title Compound **486** (6.3 mg, 31 %). ^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.57-7.52 (m, 4H), 7.46-7.34 (m, 6H), 7.14 (dd, J= 8.2, 1.5 Hz, 1H), 4.05 (s, 2H), 3.24 (s, 4H). Mass Spectrum (LCMS, APCI pos.) Calcd. For $C_{23}H_{20}F_3N_3$: 396.2 (M + H), Found 396.2.

Example 35

(Z)-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd **469**)

A solution of Compound **18** (0.030 g, 0.07 mmol) in DMSO (5 mL) was stirred at room temperature for 5 days under a 60W light bulb. The reaction was then applied to a 2000 micron prep TLC plate (20 X 20 cm) and developed using ethyl acetate: hexanes 4: 6. The desired band was extracted with MeOH, filtered and concentrated to provide the title Compound **469** (0.001 g). ^{1}H-NMR (400 MHz, DMSO d6) δ (ppm) 7.71(dd, J=1.01, 8.34Hz, 1H) 7.53 (s, 4H) 7.37-7.41 (m, 1H) 7.21-7.28 (m, 2H) 7.11 (dt, J=1.26, 7.33Hz, 1H) 7.05 (dd, J=1.52, 8.34Hz, 1H), 6.94-7.10 (m, 4H) 6.67 (d, 12.6Hz, 1H) 1.23 (s, 6H). MS (ESI, pos. ion) *m/z*: 423.2 (M+1).

Example 36

(*E*)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-5-yl}-phenyl)-methanesulfonamide (Cpd **443**)

(*E*)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide (Cpd **477**)

Step A. (*E*)-5-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and (*E*)-6-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole

To a solution of sodium hydride (60% suspension in oil, 0.131 g, 3.2 mmol) in anhydrous tetrahydrofuran (10 mL) was added Compound **10c** (1 g, 2.7 mmol). The solution was stirred at room temperature under an argon atmosphere. After five minutes methyl iodide was added (0.205 mL, 3.2 mmol), and the solution was

stirred at room temperature for 3 h. The reaction mixture was partitioned between ethyl acetate (10 mL) and ice water (20 mL). The organic fraction was washed with brine, dried over magnesium sulfate, then filtered and concentrated to give a 1:1 mixture of the title Compound **36a** and **36b** (0.38g).

Step B. (*E*)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-5-yl}-phenyl)-methanesulfonamide and (*E*)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide

Using the procedure of Example 1, Step B, the title compounds were prepared from a mixture of (*E*)-5-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and (*E*)-6-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and 2-methylsulfonylaminophenyl boronic acid.

Cpd **443**: ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.82-7.80 (m, 3H) 7.75 (d, J=8.1Hz, 3H)7.52-7.62 (m, 3H) 7.34-7.42 (m, 4H) 4.00 (s, 3H) 2.76 (s, 3H). MS (ESI, pos. ion) m/z: 472.1 (M+1).

Cpd **477**: ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm) 7.88-7.95 (m, 3H) 7.72-7.77 (m, 3H) 7.56-7.67 (m, 4H) 7.40-7.44 (m, 3H) 4.10 (s, 3H) 2.73 (s, 3H). MS (ESI, pos. ion) m/z: 472.1 (M+1).

Example 37

(*E*)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone (Cpd **311**)

Step A. (*E*)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-5-[2-(1-trimethylsilanyloxy-vinyl)-phenyl]-1H-benzimidazole

To a solution of Compound **15** (0.20 g, 0.492 mmol) in 16 mL 1,2-dichloroethane was added TBSOTf (0.19 mL, 1.08 mmol) and Et_3N (0.27 mL, 1.97 mmol) at 0 °C. After 5 min., the mixture was warmed to 25 °C and stirred for 8 hours. The reaction was concentrated and the residue was purified by

chromatography (silica gel, hexanes: EtOAc, 4: 1) to provide the title Compound **37a** as a colorless oil.

Step B. (*E*)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-5-[2-(2-trimethylsilanyloxy-oxiranyl)-phenyl]-1H-benzimidazole

A mixture of Compound **37a** (0.124 g, 0.238 mmol) and mCPBA (0.053 g, 0.238 mmol) in 10 mL CH_2Cl_2 was stirred for two hours. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 4: 1) to provide the title Compound **37b** as a yellow oil.

Step C. (*E*)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone

A mixture of Compound **37b** (0.026 g, 0.048 mmol) and p-toluenesulfonic acid monohydrate (p-TsOHH_2O, 0.018 g, 0.0968 mmol) in 4 mL THF was stirred for four hours. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 1: 2) to provide the title Compound **311** as a brown solid. ^{1}H-NMR (400 MHz, CD_3OD) δ (ppm): 7.85 (d, 2H, J = 8.8 Hz) 7.74 (d, 2H, J = 7.6 Hz) 7.71 (d, 1H, J = 16.4 Hz) 7.63-7.47 (m, 6H) 7.33 (d, 1H, J = 16.0 Hz) 7.25 (dd, 1H, J = 1.6 and 8.4 Hz) 4.08 (s, 2H) MS (ESI, pos. ion) *m/z*: 423.3 (M+1).

Example 38

2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd **501**)

Step A. (1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester

To a suspension of copper(I)trifluoromethanesulfonate toluene complex (31.0 mg, 0.12 mmol) in anhydrous $CHCl_3$ (3.0 mL) was added a solution of 2,2-bis-[(4S)-(1,1-dimethylethyl)-1,3-oxazolin-2-yl]propane (35 mg, 0.12 mmol) in chloroform (1.2 mL). After stirring at ambient temperature for 1 h, the resulting green solution was filtered through glass wool under argon atmosphere into a flask

previously charged with a solution of 4-(trifluoromethyl)-styrene (0.887 mL, 6.00 mmol) in chloroform (0.9 mL). To this solution was added a solution of ethyl diazoacetate (1.56 mL, 15.0 mmol) in chloroform (12.0 mL) at ambient temperature through a dropping funnel over a period of 6 h. The resulting mixture was stirred for 24 h, concentrated to dryness, and purified by flash chromatography on a silica gel column (45 mm X 140 mm silica gel), eluting with ethyl acetate / hexane (1, 1.5, 2%) to provide the title Compound **38a** (892 mg, 58 % yield, 98% ee) as a colorless liquid, and cis isomer (1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester Compound **38b** (128 mg, 5% yield calculated based on 34 wt % contamination of ethyl fumarate as analyzed by 1NMR). The enantiomeric excess of the product was determined as described in Step E below.

^{1}H-NMR of Compound **38a** (400 MHz, $CDCl_3$) δ (ppm): 7.53 (d, 2H, J = 8.3 Hz), 7.23 (d, 2 H, J = 8.1 Hz), 4.18 (q, 2 H, J = 7.1 Hz), 2.55 (dd, 1 H, J = 2.6, 4.3, & 6.6 Hz), 1.94 (ddd, 1H, J = 4.3, 5.6, & 9.6 Hz), 1.68-1.53 (m, 1H), 1.34 (1H, ddd, 4.8, 6.7, & 1.1 Hz), 1.29 (t, 2H, J = 7.0 Hz).

1H-NMR of Compound **38b** (400 MHz, $CDCl_3$) δ (ppm): 7.51 (d, 2H, J = 7.9 Hz), 7.37 (d, 2H, J = 7.8 Hz), 3.92-3.86 (m, 2H), 2.62-2.56 (m, 1H), 2.14 (ddd, 1H, J = 5.8, 8.1 & 9.3 Hz), 1.73 (td, 1H, J = 5.3 & 7.6 Hz), 1.39 (ddd, 1H, J = 5.1, 7.8 & 8.6 Hz), 0.99 (t, 3H, J = 7.1 Hz).

Step B. (1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid

To a solution of Compound **38a** (750 mg, 2.91 mmol) in ethanol (7.27 mL) was added a 1M aqueous solution of NaOH (7.27 mL). The resulting mixture was stirred at ambient temperature for 16 h, concentrated to about 4 g, acidified with 2M HCl to pH 3, and extracted with ethyl acetate (15 mL x 2). The extracts were combined, washed with brine, dried over Na_2SO_4, concentrated to provide the title Compound **38c** (611 mg, 91% yield) as a white solid. ^{1}H-NMR (400 MHz, $CDCl_3$ with a drop of CD_3OD) δ (ppm): 7.51 (d, 2H, J = 8.3 Hz), 7.18 (d, 2H, J = 8.1 Hz),

2.57 (ddd, 1H, J = 4.2, 6.6, & 10.3 Hz), 1.90 (ddd, 1H, J = 4.0, 5.3, & 8.3 Hz), 1.65 (dt, 1H, J = 4.9 & 9.3 Hz), 1.35 (ddd, 1H, J = 4.9, 6.4, & 11.1 Hz).

Step C: 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol

Using the procedure of Example 10, Steps B and E, the title Compound **501** was prepared from Compound **38c**. ^{1}H-NMR (400 MHz, DMSO-d6) δ (ppm): 12.40 (s, 0.5 H), 12.32 (s, 0.5 H), 7.87-7.84 (m, 1H), 7.66 (d, 2H, J = 8.0 Hz), 7.49-7.17 (m, 6H), 7.00-6.96 (m, 2H), 4.84 (s, 1H), 2.72-2.67 (m, 1H), 2.50-2.46 (m, 1H), 1.92-1.86 (m, 1H), 1.74-1.68 (m, 1H), 1.19 (s, 3H), 1.18 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd for $C_{26}H_{24}F_3N_2O$: 437.2. Found 437.3.

Step D: (1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid methoxy-methyl-amide

To a mixture of Compound **38c** (50 mg, 0.216 mmol), N,O-dimethylhydroxylamine hydrochloride (30 mg, 0.30 mmol), BOP (134 mg, 0.30 mmol), and DMF (0.4 mL) was added DIEA (0.15 mL). The resulting mixture was stirred at ambient temperature for 48 h, concentrated to dryness, and partitioned between saturated $NaHCO_3$ (2 mL) and ethyl acetate (4 mL). The ethyl acetate layer was separated, and the aqueous layer was extracted with ethyl acetate (5 mL X 2). All ethyl acetate layers were combined, washed with brine, dried over Na_2SO_4, concentrated, and purified by prep-TLC, developed with 10% ethyl acetate / DCM to provide Compound **38d** (46 mg, 78% yield) as a white solid. ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm): 7.52 (d, 2H, J = 8.4 Hz), 7.23 (d, 2H, J = 8.1 Hz), 3.70 (s, 3H), 3.24 (s, 3H), 2.56-2.52 (m, 1H), 2.45 (bs, 1H), 2.17-1.67 (m, 1H), 1.34 (ddd, 1H, J = 4.6, 6.3, & 8.7 Hz).

Step E: Determination of ee:

To a solution of Compound **38d** (0.8 mg) in $CDCl_3$ (0.6 mL) was added (R)-(-)-2,2,2-trifluoro-1-(9-anthryl)ethanol portion-wise and the amount of addition was monitored by ^{1}HNMR until base line resolution of the resulting methoxy singlets

was achieved. Thus, the enantiomer methoxy singlets were around 3.47 and 3.45 ppm. The integration of these singlets was 99 and 1, respectively; thus providing an ee value of 99%.

Using the procedure described in Example 38 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:

Cpd	Name and Data
502	2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide Using the procedure of Example 38, the title compound was prepared from Compound **38c** and 2-(t-butylamino)sulfonylphenyl boronic acid. ^{1}H-NMR (400 MHz, $CDCl_3$) δ (ppm): 12.42 (s, 0.5H), 12.40 (s, 0.5H), 8.04 (dd, 1H, J = 1.3 & 7.8 Hz), 7.66 (d, 2H, J = 8.3 Hz), 7.63-7.34 (m, 7H), 7.17-7.11 (m, 1H), 7.06 (s, 1H), 7.03 (s, 1H), 2.71-2.65 (m, 1H), 2.50-2.46 (m, 1H), 1.92-1.87 (m, 1H), 1.75-1.70 (m, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd for $C_{23}H_{19}F_3N_3O_2S$: 458.1 (M +1). Found 458.2.

Cpd	Name and Data
503	2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol monosodium salt Using the procedure of Example 38, the title compound was prepared from 2,2-bis-[(4R)-(1,1-dimethylethyl)-1,3-oxazolin-2-yl]propane and 4-(trifluoromethyl)-styrene. To a suspension of N,N'-bis-[(2R)-3,3-dimethyl-1-hydroxybutyl]-2,2-dimethyl-1,3-propanediamide (83 mg, 0.25 mmol, prepared according to the procedure described in *J. Am. Chem. Soc.* **1991**, 113, 726) in DCM (2.5 mL) was added (diethylamino)sulfur trifluoride (0.066 mL, 0.50 mmol, as described in J. Org. Chem. 2002, 67, 8566 for the formation of oxazoline from hydroxyamide) dropwise at ambient temperature. The resulting mixture was stirred at ambient temperature for 16 h, and poured into saturated $NaHCO_3$ (4.0 mL). The mixture was extracted with DCM (3 x 5 mL). The extracts were combined and dried over Na_2SO_4, then concentrated and flash chromatographed with ethyl acetate / DCM (0, 5, 10, and 20 %) to provide 2,2-bis-[2-((4R)-(1,1-dimethylethyl)-1,3-oxazolinyl)]propane (53 mg, 72 % yield) as a white solid. ^{1}H-NMR was identical to the literature as reported by Evans. ^{1}H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.82 (dd, 1H, J = 1.5 & 8.1 Hz), 7.61 (d, 2H, J = 8.1 Hz), 7.37 (d, 2H, J = 8.1 Hz), 7.24 (dt, 1H, J = 1.8 & 7.3 Hz), 7.15-7.11 (m, 2H), 7.00 (d, 1H, J = 1.5 Hz), 6.98 (dd, 1H, J = 1.5 & 7.3 Hz), 6.52 (d, 1H, J = 7.8 Hz), 4.63 (bs, 1H), 2.52-2.47 (m, 1H), 2.33 (ddd, 1H, J = 4.1, 5.8 & 8.8 Hz), 1.75 (ddd, 1H, J = 3.7, 5.8, & 8.8 Hz), 1.45-1.40 (m, 1H), 1.22 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd for $C_{26}H_{24}F_3N_2O$: 437.2. Found 437.2. Analogous to Example 38, step A, both the trans isomer (1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester Compound **38e** and the cis isomer (1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester Compound **38f** were isolated.
504	2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide Using the procedure described for Compound **503**, the title compound was prepared from Compound **38e**, 4-(trifluoromethyl)-styrene and 2-(t-butylamino)sulfonylphenyl boronic acid. ^{1}H-NMR (400 MHz, DMSO-d6) δ (ppm): 12.41 (s, 0.5H), 12.40 (s, 0.5H), 8.04 (dd, 1H, J = 1.3 & 7.8 Hz), 7.66 (d, 2H, J = 8.3 Hz), 7.63-7.34 (m, 7H), 7.17-7.11 (m, 1H), 7.06 (s, 1H), 7.03 (s, 1H), 2.71-2.65 (m, 1H), 2.50-2.46 (m, 1H), 1.92-1.87 (m, 1H), 1.75-1.70 (m, 1H). MS (ESI, pos. ion) *m/z*: 458.2 (M+1). Mass Spectrum (LCMS, ESI pos.) Calcd for $C_{23}H_{19}F_3N_3O_2S$: 458.1 (M +1). Found 458.2.

Cpd	Name and Data
505	2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol Using the procedure described for Compound **503**, the title compound was prepared from Compound **38f**. 1H-NMR (400 MHz, CD_3OD) δ (ppm): 7.79 (dd, 1H, J = 1.0 & 8.1 Hz), 7.36-7.15 (m, 8H), 7.01 (t, 1H, J = 1.5 Hz), 6.99 (d, 1H, J = 1.5 Hz), 2.83-2.73 (m, 2H), 2.08-2.03 (m, 1H), 1.71 (td, 1H, J = 8.6 & 5.6 Hz), 1.23 (s, 3H), 1.22 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd for $C_{26}H_{24}F_3N_2O$: 437.2. Found 437.3. Determination of ee: To a mixture of (1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid (14 mg, 0.0.061 mmol), (S)-(-)-α-methylbenzylamine (10.0 mg, 0.0609 mmol), BOP (27 mg, 0.0609 mmol), and DMF (0.2 mL) was added DIEA (0.023 mL, 0.13 mmol). The resulting solution was stirred at room temperature for 48 h, concentrated to dryness, and partitioned between saturated $NaHCO_3$ (1 mL) and ethyl acetate (3 mL). Ethyl acetate layer was separated, and aqueous was extracted with ethyl acetate (5 mL X 2). All ethyl acetate layers were combined, washed with brine, dried over Na_2SO_4, concentrated, and purified by prep-TLC, developed with 10% ethyl acetate / DCM to give the title compound (10.1 mg, 70% yield) as a white solid. 1H-NMR (400 MHz, C_6D_6) δ (ppm): 7.26 (d, 2H, J = 8.1 Hz), 7.03-6.95 (m, 5H), 6.68-6.65 (m, 2H), 4.96-4.89 (m, 1H), 4.79 (bd, 1H, J = 7.6 Hz), 1.80-1.73 (m, 2H), 1.23-1.17 (m, 1H), 1.00 (d, 3H, J = 6.8 Hz), 0.82-0.79 (m, 1H).). In the 1H-NMR doublet of the Me in (1R, 2S, 1'S)-N-(1'-phenethyl)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxamide appeared at 0.85 ppm. Integration of this methyl doublet and that of the title compound was 2.5 and 97.5, respectively.
506	2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide Using the procedure of Example 38, the title compound was prepared from Compound **38b** and 2-(t-butylamino)sulfonylphenyl boronic acid. 1H-NMR (400 MHz, CD_3OD) δ (ppm): 8.09 (dd, 1H, J = 1.3 & 7.9 Hz), 7.59 (dt, 1H, J = 1.6 & 7.6 Hz), 7.51 (dt, 1H, J = 1.5 & 7.8 Hz), 7.47 (bs, 1H), 7.42-7.29 (m, 6H), 7.19 (dd, 1H, J = 1.7 & 8.3 Hz), 2.84-2.74 (m, 2H), 2.05 (q, 1H, J = 6.3 Hz), 1.72 (td, 1H, J = 8.5 & 5.7 Hz). Mass Spectrum (LCMS, ESI pos.) Calcd for $C_{23}H_{19}F_3N_3O_2S$: 458.1 (M +1). Found 458.2.

Cpd	Name and Data
507	2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol Using the procedure of Example 38, the title compound was prepared using Compound **38b**. 1H-NMR (400 MHz, CD_3OD) δ (ppm): 7.79 (dd, 1H, J = 1.0 & 8.1 Hz), 7.36-7.15 (m, 8H), 7.01 (t, 1H, J = 1.5 Hz), 6.99 (d, 1H, J = 1.5 Hz), 2.83-2.73 (m, 2H), 2.08-2.03 (m, 1H), 1.71 (td, 1H, J = 8.6 & 5.6 Hz), 1.23 (s, 3H), 1.22 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd for $C_{26}H_{24}F_3N_2O$: 437.2. Found 437.3. Determination of ee: Using the procedure described for Compound **506**, the amide intermediate of Compound **507** was prepared from (1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid Compound **38g** and (S)-(-)-α-methylbenzylamine. 1H-NMR (400 MHz, C_6D_6) δ (ppm): 7.37 (d, 2H, J = 8.1 Hz), 7.35-7.02 (m, 5H), 6.97-6.95 (m, 2H), 4.95-4.88 (m, 1H), 4.82 (bd, 1H, J = 7.8 Hz), 1.81-1.75 (m, 1H), 1.70 (ddd, 1H, J = 4.8, 5.8 & 7.3 Hz), 1.14 (ddd, 1H, J = 5.6, 7.8 & 9.0 Hz), 0.85 (d, 3H, J = 6.6 Hz), 0.80-0.75 (m, 1H). In the 1H-NMR doublet of the Me in (1S, 2R, 1'S)-N-(1'-phenethyl)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxamide appeared at 1.00 ppm. Integration of this methyl doublet and that of the title compound was 3 and 97, respectively.
508	2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide Using the procedure described for Compound **503**, the title compound was prepared from Compound **38f** and 2-(t-butylamino)sulfonylphenyl boronic acid. 1H-NMR (400 MHz, CD_3OD) δ (ppm): 8.09 (dd, 1H, J = 1.3 & 7.9 Hz), 7.59 (dt, 1H, J = 1.6 & 7.6 Hz), 7.51 (dt, 1H, J = 1.5 & 7.8 Hz), 7.47 (bs, 1H), 7.42-7.29 (m, 6H), 7.19 (dd, 1H, J = 1.7 & 8.3 Hz), 2.84-2.74 (m, 2H), 2.05 (q, 1H, J = 6.3 Hz), 1.72 (td, 1H, J = 8.5 & 5.7 Hz). Mass Spectrum (LCMS, ESI pos.) Calcd for $C_{23}H_{19}F_3N_3O_2S$: 458.1 (M +1). Found 458.2.

Biological Examples

Example 1

Human VR1 (hVR1) Binding Assay

Compounds of the present invention were tested for their ability to inhibit the binding of [^{3}H] RTX to hVR1 receptors in a [^{3}H] RTX binding assay as previously described (Zhang, Sui-Po. *Improved ligand binding assays for vanilloid receptors.* PCT Int. Appl. (2002), WO 0233411 A1 20020425 AN 2002:315209, and Elfrida G.R. et al., *J. Pharmacol. Exp. Ther.*, 2002, 300(1): 9-17.)

HEK293 cells were transfected with hVR1 vanilloid receptors and washed with Hank's balanced Salt Solution, dissociated with cell dissociation buffer (Sigma), and then centrifuged at 1000 x g for 5 min. Cell pellets were homogenized in cold 20 mM HEPES buffer (pH = 7.4), containing 5.8 mM NaCl, 320 mM sucrose, 2 mM $MgCl_2$, 0.75 $CaCl_2$ and 5 mM KCl and centrifuged at 1000 x g for 15 min. The resultant supernatant was then centrifuged at 40,000 x g for 15 min. The pelleted membranes were stored in a freezer at -80°C.

Approximately 120 µg protein/ ml from membranes were incubated with indicated concentrations of [^{3}H]RTX in 0.5 ml of the HEPES buffer (pH 7.4) containing 0.25 mg/mL fatty acid-free bovine serum albumin at 37°C for 60 min. The reaction mixture was then cooled to 4°C, and 0.1 mg of α_1-acid glycoprotein was added to each sample, which was then incubated at 4°C for 15 min. The samples were centrifuged at 18,500 x g for 15 min. The tip of the microcentrifuge tube containing the pellet was cut off. Bound radioactivity was quantified by scintillation counting. Non-specific binding was measured in the presence of 200 nM unlabeled RTX.

Data were calculated according to the equation:

% inhibition = 100% x [(total binding-binding)/(total binding-non specific binding)]

K_i values were calculated using a Prism program.

Table 1

Cpd	Ki (nM)	Cpd	Ki (nM)	Cpd	Ki (nM)
1	9.7	**27**	1800	**71**	22
3	20	**32**	100	**78**	6.4
4	31	**36**	820	**79**	18
5	17	**40**	81	**310**	10
9	0.9	**50**	16	**312**	19
14	380	**51**	6.4	**319**	6

Cpd	Ki (nM)	Cpd	Ki (nM)	Cpd	Ki (nM)
15	41	**56**	120	**407**	5.7
17	8.7	**69**	6	**434**	39
18	6.5	**70**	8.6		

Example 2

Human VR1 (hVR1) Functional Assay

The functional activity of the test compounds was determined by measuring changes in intracellular calcium concentration using a Ca^{++}-sensitive fluorescent dye and FLIPR™ technology. Increases in Ca^{++} concentration were readily detected upon challenge with capsaicin.

HEK293 cells expressing hVR1 were grown on poly-D-lysine coated 384 well black-walled plates (BD 354663) and 1 day later loaded with Calcium 3 Dye for 35 min at 37°C, 5% CO_2 and then for 25 min at room temperature, and subsequently tested for agonist-induced increases in intracellular Ca^{2+} levels using FLIPR™ technology. Cells were challenged with test compounds (at varying concentrations) and intracellular Ca^{2+} was measured for 5 min prior to the addition of capsaicin to all wells to achieve a final concentration of 0.030 μM eliciting about 80% maximal response. IC_{50} values were determined from concentration-response studies, which were generated using the average of quadruplicate wells for each data point.

For those compounds tested, an IC_{50} (nM) value and percent inhibition value is shown in Table 2. Except where indicated, the percent inhibition values were obtained at a test concentration of 1 μM; otherwise: [(1)]the test concentration was 5 μM. The percent inhibition value is provided for those compounds where an IC_{50} value was not obtained. The term "NA" means that the data is "not available" because it was not obtained for a particular compound.

Table 2

Cpd	% Inh	IC_{50}	Cpd	% Inh	IC_{50}
1	100	27	**360**	98	46
2	100	12	**361**	97	27
3	NA	140	**362**	99	8
4	78	400	**363**	98	12
5	100	71	**364**	97	65
6	12	NA	**365**	99	17
7	10	NA	**366**	99	35
8	10	NA	**367**	98	53
9	99	2	**368**	99	15
10	94	280	**369**	99	8
11	100	210	**370**	98	13
12	100	10	**371**	98	18
13	82	310	**372**	97	71
14	49	1000	**373**	99	20
15	100	120	**374**	99	34
16	100	45	**375**	97	139
17	100	8	**376**	100	28
18	100	4	**378**	100	12
19	32	NA	**379**	99	40
20	NA	320	**380**	99	12
22	NA	18	**383**	96	11
24	8	NA	**384**	98	7
25	4	NA	**385**	97	21
26	6	NA	**386**	96	43
27	100	260	**387**	98	41
28	96	250	**388**	99	54
29	6	NA	**389**	23	NA
30	10	NA	**390**	96	7
31	NA	13	**391**	95	8
32	77	380	**392**	97	10
33	NA	1700	**393**	98	10
34	[1]75	NA	**394**	98	6
35	100	41	**395**	99	15

Cpd	% Inh	IC_{50}	Cpd	% Inh	IC_{50}
36	44	NA	**396**	99	13
37	18	NA	**397**	99	23
38	89	270	**398**	97	3
39	98	200	**399**	97	3
40	99	54	**402**	93	38
41	90	280	**404**	94	47
42	100	22	**405**	95	20
43	58	890	**406**	97	170
44	95	300	**407**	96	9
45	100	16	**408**	64	NA
46	100	46	**409**	43	NA
47	100	20	**410**	91	156
48	33	NA	**411**	85	350
49	16	NA	**412**	86	190
50	100	100	**413**	82	240
51	100	66	**414**	98	140
52	28	NA	**415**	95	150
53	98	**47**	**416**	96	120
54	20	NA	**417**	100	11
55	14	NA	**418**	100	18
56	100	110	**419**	93	32
57	15	NA	**420**	93	15
58	87	95	**421**	95	10
59	80	440	**422**	98	7
60	7	NA	**423**	99	11
61	100	**75**	**424**	99	11
62	100	200	**425**	2	NA
63	97	260	**426**	99	22
64	41	NA	**427**	98	13
65	0	NA	**428**	100	7
66	98	48	**429**	98	6
67	98	130	**430**	100	9
68	NA	329	**431**	97	35
69	98	6	**432**	98	15

Cpd	% Inh	IC_{50}	Cpd	% Inh	IC_{50}
70	100	7	**433**	98	10
71	99	22	**434**	98	7
77	100	76	**435**	97	20
78	99	5	**436**	96	10
79	100	7	**437**	97	24
83	NA	>500	**438**	96	71
84	100	40	**439**	97	23
85	16	NA	**440**	98	40
95	81	301	**441**	40	NA
101	NA	>500	**442**	96	4
113	48	NA	**444**	98	28
114	99	3	**445**	96	20
129	96	34	**446**	97	76
130	100	6	**447**	98	44
131	96	31	**448**	99	17
139	98	31	**449**	100	9
145	19	NA	**450**	27	NA
175	100	16	**451**	101	28
190	94	38	**452**	5	NA
198	95	10	**453**	22	NA
234	7	NA	**454**	36	NA
250	98	19	**455**	100	17
294	101	9.1	**456**	100	45
295	100	16	**457**	22	NA
309	73	NA	**458**	15	NA
310	100	6	**459**	0	NA
311	99	54	**460**	21	NA
312	100	6	**461**	99	5
314	100	18	**462**	98	97
315	100	11	**463**	100	14
316	101	12	**464**	100	3
317	101	11	**465**	75	363
318	100	50	**466**	98	71
319	100	10	**467**	86	182

Cpd	% Inh	IC_{50}	Cpd	% Inh	IC_{50}
320	100	13	**468**	97	8
321	100	18	**469**	99	7
322	101	14	**470**	97	45
323	97	40	**471**	100	10
324	98	33	**472**	NA	>500
325	73	NA	**473**	NA	>500
326	89	157	**474**	NA	>500
327	77	343	**475**	NA	77
328	99	35	**476**	NA	68
329	98	27	**477**	44	NA
330	85	131	**478**	NA	>500
331	97	43	**479**	12	NA
332	98	49	**480**	NA	>500
333	98	27	**481**	42	NA
334	94	178	**482**	100	13
335	100	47	**483**	21	NA
336	89	240	**484**	NA	>500
337	96	14	**485**	NA	>500
338	96	104	**486**	NA	>500
339	99	27	**487**	20	NA
340	98	62	**488**	4	NA
341	99	6	**489**	96	2
342	98	24	**490**	99	26
343	82	243	**491**	NA	77
344	101	24	**492**	99	5
345	101	13	**494**	93	52
346	87	264	**497**	94	39
347	100	44	**498**	100	19
348	86	162	**499**	7	NA
349	99	59	**500**	97	19
350	100	33	**501**	99	85
351	NA	>500	**502**	82	190
357	100	8	**503**	93	10
358	99	9	**504**	95	22

Cpd	% Inh	IC_{50}	Cpd	% Inh	IC_{50}
359	98	24			

Example 3

Chemically-Induced Models Of Inflammatory Pain

Compounds of the present invention were tested in animal models of inflammation and inflammatory pain. To assess the ability of test compounds to reverse thermal hyperalgesia, baseline response latencies on a radiant heat (RH) paw stimulator were obtained before an intraplantar injection of 100 µL (1 µg/µL) CFA (1:1 CFA:saline) in male Sprague-Dawley rats. Only withdrawal responses that were quick hind paw movements (with or without licking of the hind paw) were recorded. Paw movements associated with locomotion or a shifting of weight were not considered a withdrawal response. The stimulus intensity that produced 10-15 sec baseline withdrawal latencies was used and a maximum cutoff of 20 sec was imposed. Hypersensitivity was evaluated 24 hr after CFA. Only rats that exhibited at least a 25 % reduction in response latency from baseline (i.e. hyperalgesia) were included in further analysis.

Following the post-inflammogen latency assessment, rats were orally dosed (2.5 mL/kg) with test compound (10 mg/kg) or vehicle (20 % hydroxypropyl beta cyclodextran). To determine the time of peak effect, latencies were redetermined 30, 60, 100, 180 and 300 min after compound administration.

Data are presented as the maximal percent reversal of hypersensitivity obtained during the 300 min test, which was calculated for each animal according to the formula:

% reversal = 100% x (treatment response – post-inflammogen response) / (pre-inflammogen response – post-inflammogen response)

Table 3

Cpd	% Reversal
17	104
18	133
22	18
23	31
31	72
47	58
70	76
78	19
114	56
310	23
464	65

Example 4

Incision-Induced Model Of Postoperative Surgery

Compounds of the present invention were tested in animal models of postoperative surgery, as previously described (Brennan, T.J. et al., *Pain*, 1996, 64: 493-501). Male Sprague-Dawley rats were anaesthetized with 2-3 % isoflurane and the plantar surface of the hindpaw was sterilized using three alternating betadine and alcohol scrubs. A 1 cm longitudinal incision through the skin of the plantar paw was made using a number 10 scalpel beginning 0.5 cm from the proximal heel and extending toward the toes. The plantaris muscle was excised using a forcep and incised longitudinally. The skin was then sutured in two locations using 5-0 silk. The wound site was then covered with antibiotic ointment and the animals were returned to their individual home cages. Changes in thermal sensitivity were evaluated before surgery and 24 hr after surgery. Vehicle (20 % HPβCD) or test compound was orally administered and thermal sensitivity was re-assessed 30, 60, 100, 180 and 300 min later.

Data are presented as the maximal percent reversal of hypersensitivity obtained during the 300 min test, which was calculated for each animal according to the formula:

% reversal = 100% (treatment response – post-inflammogen response) / (pre-inflammogen response – post-inflammogen response)

Table 4


Cpd	% Reversal
18	132

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.

All publications disclosed in the above specification are hereby incorporated by reference in full.

CLAIMS:

1. A compound of Formula (I):



(I)

or a salt, stereoisomer, tautomer or ester thereof, wherein:

the dashed lines between positions 1, 2 and 3 in Formula (I) indicate the positions of a tautomeric double bond,

wherein when a double bond is formed between positions 1 and 2, then R_{3b} is present, and

wherein, when a double bond is formed between positions 2 and 3, then R_{3a} is present;

p is 1 or 2;

q is 0 or 1;

r is 0, 1, 2 or 3;

L is C_{2-3}alkenyl, C_{2-3}alkynyl or cyclopropyl;

A_1 is selected from the group consisting of phenyl, biphenyl, naphthyl, pyridinyl, quinolinyl and indole;

R_1 is each selected from the group consisting of hydroxy, cyano, halogen, formyl, carboxy, C_{1-6}alkyl, haloC_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, C_{1-6}alkylcarbonyl, C_{1-6}alkoxycarbonyl, C_{1-6}alkylthio, C_{1-6}alkylsulfonyl, C_{3-8}cycloalkyl, C_{3-8}cycloalkyl-C_{1-4}alkyl, C_{3-8}cycloalkyl-C_{1-4}alkoxy, C_{3-8}cycloalkyl-oxy, amino, $(C_{1-6}alkyl)_{1-2}$amino, $(C_{3-8}cycloalkyl)_{1-2}$amino, $(C_{3-8}cycloalkyl\text{-}C_{1-4}alkyl)_{1-2}$amino, aminocarbonyl, $(C_{1-6}alkyl)_{1-2}$aminocarbonyl, C_{1-6}alkylcarbonylamino,

C_{1-6}alkoxycarbonylamino, aminocarbonylamino, $(C_{1-6}alkyl)_{1-2}$aminocarbonylamino, C_{1-6}alkylsulfonylamino, C_{1-6}alkylsulfinylamino, aminosulfonyl, $(C_{1-4}alkyl)_{1-2}$aminosulfonyl, aminosulfonylamino and $(C_{1-6}alkyl)_{1-2}$aminosulfonylamino,

wherein alkyl is optionally substituted with C_{1-8}alkoxy, amino, $(C_{1-4}alkyl)_{1-2}$amino, C_{1-6}alkylcarbonylamino, C_{1-6}alkoxycarbonylamino, aminocarbonylamino, $(C_{1-6}alkyl)_{1-2}$aminocarbonylamino, C_{1-6}alkylsulfonylamino, aminosulfonylamino, $(C_{1-6}alkyl)_{1-2}$aminosulfonylamino hydroxy and phenyl,

wherein phenyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, cyano, nitro, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-6}alkylthio and C_{1-6}alkylsulfonyl, and

wherein, each instance of alkyl and alkoxy is optionally perfluorinated;

R_2 is selected from the group consisting of halogen, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}alkylsulfonyl, nitro, amino, $(C_{1-4}alkyl)_{1-2}$amino and cyano,

wherein each instance of alkyl and alkoxy is optionally perfluorinated;

R_{3a} and R_{3b} are each selected from the group consisting of hydrogen and optionally perfluorinated C_{1-4}alkyl; and

R_4 is each selected from the group consisting of halogen, nitro, cyano, carboxy, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkyl, haloC_{1-6}alkoxy, C_{1-6}alkoxy-C_{1-6}alkyl, C_{1-6}alkylcarbonyl, C_{1-6}alkylthio, haloC_{1-6}alkylthio, C_{1-6}alkylsulfonyl, haloC_{1-6}alkylsulfonyl, C_{3-8}cycloalkyl, C_{3-8}cycloalkyl-C_{1-4}alkyl, C_{3-8}cycloalkyl-C_{1-4}alkoxy, C_{3-8}cycloalkyl-oxy, amino, $(C_{1-6}alkyl)_{1-2}$amino, $(C_{3-8}cycloalkyl)_{1-2}$amino, $(C_{3-8}cycloalkyl\text{-}C_{1-4}alkyl)_{1-2}$amino, aminocarbonyl, $(C_{1-6}alkyl)_{1-2}$aminocarbonyl, C_{1-6}alkylcarbonylamino, C_{1-6}alkoxycarbonylamino, aminocarbonylamino, $(C_{1-6}alkyl)_{1-2}$aminocarbonylamino, C_{1-6}alkylsulfonylamino, haloC_{1-6}alkylsulfonylamino, C_{1-6}alkylsulfinylamino, aminosulfonyl and $(C_{1-4}alkyl)_{1-2}$aminosulfonyl,

wherein each instance of alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C_{1-8}alkoxy, amino, $(C_{1-4}alkyl)_{1-2}$amino, C_{1-6}alkylcarbonylamino, C_{1-6}alkoxycarbonylamino, aminocarbonylamino, $(C_{1-6}alkyl)_{1-2}$aminocarbonylamino, C_{1-6}alkylsulfonylamino, oxo and hydroxy, and

wherein, each instance of alkyl and alkoxy is optionally perfluorinated.

2. The compound of claim 1, wherein q is 0.

3. The compound of claim 1, wherein A_1 is selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole.

4. The compound of claim 1, wherein

R_1 is each selected from the group consisting of hydroxy, halogen, formyl, C_{1-6}alkyl, haloC_{1-6}alkyl, haloC_{1-6}alkoxy, C_{1-6}alkylcarbonyl, C_{1-6}alkoxycarbonyl, C_{1-6}alkylthio, C_{1-6}alkylsulfonyl, amino, aminocarbonyl, C_{1-6}alkylcarbonylamino, C_{1-6}alkoxycarbonylamino, C_{1-6}alkylsulfonylamino, aminosulfonyl, $(C_{1-4}alkyl)_{1-2}$aminosulfonyl and aminosulfonylamino,

wherein alkyl is optionally substituted with amino, $(C_{1-4}alkyl)_{1-2}$amino, aminosulfonylamino or hydroxy, and wherein, alkyl is optionally perfluorinated.

5. The compound of claim 1, wherein R_2 is selected from the group consisting of halogen and C_{1-4}alkyl, wherein alkyl is optionally perfluorinated.

6. The compound of claim 1, wherein R_{3a} and R_{3b} are each selected from the group consisting of hydrogen and C_{1-4}alkyl.

7. The compound of claim 1, wherein R_4 is each selected from the group consisting of halogen, carboxy, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkyl, haloC_{1-6}alkoxy, C_{1-6}alkylcarbonyl, haloC_{1-6}alkylthio, C_{1-6}alkylsulfonyl, haloC_{1-6}alkylsulfonyl, $(C_{1-6}alkyl)_{1-2}$amino, $(C_{1-6}alkyl)_{1-2}$aminocarbonyl, C_{1-6}alkylcarbonylamino, C_{1-6}alkylsulfonylamino and haloC_{1-6}alkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.

8. The compound of claim 1, wherein

p is 1 or 2;

q is 0;

r is 0, 1, 2 or 3;

L is C_{2-3}alkenyl, C_{2-3}alkynyl or cyclopropyl;

A_1 is selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole;

R_1 is each selected from the group consisting of hydroxy, halogen, formyl, C_{1-6}alkyl, haloC_{1-6}alkyl, haloC_{1-6}alkoxy, C_{1-6}alkylcarbonyl, C_{1-6}alkoxycarbonyl, C_{1-6}alkylthio, C_{1-6}alkylsulfonyl, amino, aminocarbonyl, C_{1-6}alkylcarbonylamino, C_{1-6}alkoxycarbonylamino, C_{1-6}alkylsulfonylamino, aminosulfonyl, $(C_{1-4}alkyl)_{1-2}$aminosulfonyl and aminosulfonylamino,

wherein alkyl is optionally substituted with amino, $(C_{1-4}alkyl)_{1-2}$amino, aminosulfonylamino or hydroxy, and wherein, alkyl is optionally perfluorinated;

R_2 is selected from the group consisting of halogen and C_{1-4}alkyl, wherein alkyl is optionally perfluorinated;

R_{3a} and R_{3b} are each selected from the group consisting of hydrogen and C_{1-4}alkyl; and

R_4 is each selected from the group consisting of halogen, carboxy, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkyl, haloC_{1-6}alkoxy, C_{1-6}alkylcarbonyl, haloC_{1-6}alkylthio, C_{1-6}alkylsulfonyl, haloC_{1-6}alkylsulfonyl, $(C_{1-6}alkyl)_{1-2}$amino, $(C_{1-6}alkyl)_{1-2}$aminocarbonyl, C_{1-6}alkylcarbonylamino, C_{1-6}alkylsulfonylamino and haloC_{1-6}alkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.

9. A compound selected from the group consisting of:

(*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,

(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,

(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,

(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,

(*E*)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,

(*E*)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,

(*E*)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol,

(*E*)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol,

(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl-1H-benzimidazole,

(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-benzamide,

(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,

(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,

(*E*)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,

(*E*)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,

(*E*)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

(*E*)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,

(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,

(*E*)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

(*E*)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,

(*E*)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,

(*E*)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,.

(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,

(*E*)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

(*E*)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,

(*E*)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,

(*E*)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

(*E*)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,

(*E*)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,

(*E*)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

(*E*)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,

(*E*)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,

(*E*)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

(*E*)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

(*E*)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,

(*E*)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,

(*E*)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,

(*E*)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

(*E*)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,

(*E*)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,

(*E*)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,

(*E*)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,

2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,

1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,

N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,

2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)- benzenesulfonamide,

C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,

1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,

N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,

2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,

C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]- ethanone,

1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]- ethanol,

N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]- propan-2-ol,

2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,

C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,

N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,

N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,

2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,

C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,

C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,

2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

C,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

C,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,

1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,

N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,

2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,

1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,

1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,

N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,

2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

C,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,

2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,

N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,

2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,

1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,

1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,

N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,

2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

C,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,

N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,

N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,

2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

C,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,

C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,

C,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,

C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,

2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

(*E*)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

(*E*)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

(*E*)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

(*E*)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,

(*E*)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,

(*E*)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

(*E*)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

(*E*)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,

(*E*)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-benzamide,

(*E*)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-acetamide,

(*E*)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-benzoic acid,

(*E*)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,

(*E*)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propionamide,

(*E*)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,

(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid methyl ester,

(*E*)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,

(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester,

N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,

(*Z*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,

2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenol,

(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,

(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,

(*E*)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,

(*E*)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl-phenyl)-1H-benzimidazole,

(*E*)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzyl)-amine,

(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzaldehyde,

(*E*)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzyl)-amine,

(*E*)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,

(*E*)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,

2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,

2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,

(E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,

2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,

2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzamide,

N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazole,

2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol, and

2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide.

10. The compound of claim 9, wherein the compound is selected from the group consisting of:

(*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,

(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,

(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,

(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,

(*E*)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol,

(*E*)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,

(*E*)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,

(*E*)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol,

(*E*)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol,

(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl-1H-benzimidazole,

(*E*)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-benzamide,

(*E*)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,

(*E*)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,

(*E*)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,

(*E*)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,

(*E*)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,

(*E*)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

(*E*)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

(*E*)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,

2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

(*E*)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

(*E*)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-ınethyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

(*E*)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

(*E*)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,

(*E*)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,

(*E*)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

(*E*)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

(*E*)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-ethanone,

(*E*)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,

(*E*)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-benzamide,

(*E*)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-acetamide,

(*E*)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-benzoic acid,

(*E*)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,

(*E*)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,

(*E*)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propionamide,

(*E*)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,

(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid methyl ester,

(*E*)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,

(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester,

N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,

(*Z*)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,

2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenol,

(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,

(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,

(*E*)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,

(*E*)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,

(*E*)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,

(*E*)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl-phenyl)-1H-benzimidazole,

(*E*)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzyl)-amine,

(*E*)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzaldehyde,

(*E*)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzyl)-amine,

(*E*)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,

(*E*)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,

2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,

2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,

(E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,

2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,

2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzamide,

N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazole,

2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol, and

2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide.

11. The compound of claim 9, wherein the compound is selected from the group consisting of:

(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

(*E*)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,

(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,

(*E*)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

(*E*)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,

(*E*)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,

(*E*)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,

(*E*)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,

(*E*)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,

(*E*)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,

(*E*)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

(*E*)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,

(*E*)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,

(*E*)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,

(*E*)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,

(*E*)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

(*E*)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

(*E*)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

(*E*)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

(*E*)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

(*E*)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,

(*E*)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,

(*E*)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,

(*E*)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

(*E*)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

(*E*)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,

(*E*)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,

(*E*)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,

(*E*)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

(*E*)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,

2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,

1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,

N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,

2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)- benzenesulfonamide,

C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,

1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,

N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,

2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,

C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]- ethanone,

1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]- ethanol,

N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]- propan-2-ol,

2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,

C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,

1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,

N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,

N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,

2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,

C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,

C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,

C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,

2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

C,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

C,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,

1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,

N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,

2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,

1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,

1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,

N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,

2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

C,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,

1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,

N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,

2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,

C,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,

1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,

2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,

N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,

2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,

1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,

1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,

N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

C,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide;

N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,

N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,

2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,

C,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,

N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,

C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,

C,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,

C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,

2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, and

C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide.


12. A salt of the compound of Formula (I) as claimed in claim 1, wherein the salt is selected from the group consisting of acetate, adipate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate (or camphosulphonate), carbonate, chloride, choline, clavulanate, citrate, dihydrochloride, disodium, edetate, fumarate, gluconate, glutamate, hydrabamine, hydrobromine, hydrochloride, iodide, isothionate, lactate, malate, maleate, mandelate, mesylate, nitrate, oleate, pamoate, palmitate, phosphate/diphosphate, salicylate, sodium, stearate, sulfate, succinate, tartrate, tromethane, tosylate, trichloroacetate and trifluoroacetate.

13. The salt of claim 12, wherein the salt is selected from the group consisting of disodium, hydrochloride and sodium.

14. A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutically acceptable carriers, excipients or diluents.


15. A process for preparing the compound of claim 1 comprising the steps of:

Step A. reacting an aldehyde **QQ1** with malonic acid and a catalytic amount of piperidine in pyridine at elevated temperatures to provide an acid **QQ2**:




;

Step B. reacting the acid **QQ2** with oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride to provide an acid chloride **QQ3**:



;

Step C. reacting the acid chloride **QQ3** with a 4-bromobenzene-1,2-diamine **AA1** in acetic acid to provide a bromobenzimidazole **QQ4**:



; and

Step D. reacting the bromobenzimidazole **QQ4** with a suitably substituted phenyl boronic acid in the presence of a reagent and a catalytic amount of a palladium catalyst in a solvent to give an alcohol substituted benzimidazole **QQ5**, representative of a compound of Formula (I):

